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GenerAl introduCtion And outline of thesis 

1INTRODUCTION
InTroducTIon
definitions
Pelvic Organ Prolapse is defined as a descent of pelvic organs, including the bladder, 
uterus or post-hysterectomy vaginal vault, the small or large bowel, resulting in 
protrusion, bulging or herniation of one or more pelvic organs into or out of the 
vagina.1,2 In contrast with a rectal prolapse, in which the rectum protrudes through 
the anus, pelvic organ prolapse affects only women. 
Different types of pelvic organ prolapse exist: anterior compartment prolapse, 
apical compartment prolapse and posterior compartment prolapse, or a combination 
of prolapse of these different compartments. 
Prolapse of the anterior compartment is the most common type of prolapse and 
includes descent of the bladder (also called cystocele).3 The urethra may also bulge 
into the vagina.  Prolapse of the apical compartment includes descent of the uterus 
or vaginal vault (after hysterectomy). Prolapse of the vaginal vault may include the 
small intestine (enterocele), the bladder or the sigmoid (sigmoidocele). Prolapse of 
the posterior compartment concerns the rectum (rectocele), but can also include the 
small or large bowel. 
The anatomic degree of pelvic organ prolapse can be measured with the pelvic 
organ prolapse quantitation system (POP-Q).4 This scoring system describes precisely 
in centimeters the degree of anterior, apical and posterior vaginal wall descent, and 
classifies uterovaginal support in five stages from 0 (perfect support) to IV (total 
procidentia or complete vaginal eversion).
Prevalence
Although pelvic organ prolapse is one of the most common indications for 
gynaecological surgery, epidemiological studies on the incidence and prevalence are 
scarce and often not population-based. However, the cross-sectional study of Slieker 
et al. in a small Dutch city demonstrated a prevalence of symptomatic pelvic organ 
prolapse of 11.4% in women aged 45-85 years.5 The prevalence of observed pelvic 
organ prolapse during pelvic examination in women between the age of 50 and 79 
years (either asymptomatic or symptomatic) varies from 24-40%.3,6,7,8 In a multicenter 
study of 1006 women (age 18-83 years) presenting for routine gynaecological care, 
24% had normal support and 38% had stage I, 35% stage II, and 2% stage III pelvic 
organ prolapse.9 Thus, some loss of uterovaginal support is present in most adult 
women. The lifetime risk of undergoing surgical treatment for pelvic organ prolapse 
is 7-20%.10,11
Causes and risk factors
The aetiology of pelvic organ prolapse is likely to be multifactorial.12 Vaginal childbirth, 
advancing age, and obesity are the most consistently reported risk factors.2 Other 
potential risk factors are pregnancy (irrespective of mode of delivery), forceps delivery, 
young age at first delivery, prolonged second stage of labour, infant birth weight 
> 4500 g, shape or orientation of the bony pelvis, family history of pelvic organ 
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prolapse, race or ethnic origin, occupations entailing heavy lifting, constipation, 
connective tissue disorders and previous hysterectomy.1
Pathophysiology
Anatomical support of the pelvic organs is mainly provided by the levator ani muscle 
complex and the connective-tissue attachments of the pelvic organs (endopelvic 
fascia). Disruption or dysfunction of one or both of these components can lead to 
loss of support and, eventually to pelvic organ prolapse. Direct muscle trauma and 
neuropathic injury of the levator ani muscles can result from vaginal delivery.13 Chronic 
straining has also been associated with pelvic muscle denervation.14 Abnormalities 
of connective tissue and connective-tissue repair might predispose some women to 
pelvic organ prolapse.15,16,17
symptoms
Prolapse-related symptoms are a sensation of a bulge or protrusion, seeing or feeling 
a bulge or protrusion, pressure and heaviness.18 Lower urinary-tract symptoms such 
as a weak or prolonged urinary stream, a feeling of incomplete bladder emptying, 
urinary frequency or urgent desire to pass urine, urinary stress incontinence and 
position change to start or complete voiding are frequent complaints in women with 
pelvic organ prolapse. 18,19 Women with pelvic organ prolapse frequently complain of 
symptoms related to bowel dysfunction, including incontinence of flatus, or liquid 
or solid stool, feeling of incomplete emptying, straining during defaecation, urgency 
to defaecate, or digital evacuation.20 Some women complain of dyspareunia or they 
report that the prolapse is a mechanical obstruction for intercourse. A third of sexually 
active women with pelvic organ prolapse complain that their prolapse interferes with 
sexual function.21
Pelvic organ prolapse symptoms and the impact on quality of life are measured 
by questionnaires. The Urogenital Distress Inventory (UDI), Defaecatory Distress 
Inventory (DDI) and Incontinence Impact Questionnaire (IIQ) are questionnaires used 
in the Netherlands.22,23 In these questionnaires the patient records the presence or 
absence of various symptoms and, in case a symptom is present, the patient rates 
the amount of bother of the symptom on a four-point Likert scale ranging from 1 (no 
bother at all) to 4 (greatly bothered).
Therapy
non-surgical intervention
Some women with advanced prolapse have remarkably few symptoms and report little 
or no bother. Expectative management is often advised if there is no hydronephrosis 
from chronic ureteral kinking and if there are no chronic bladder infections due to 
obstructed urination. 
Pelvic floor muscle training is not proven effective in the management of pelvic 
organ prolapse, however, findings of one study do suggest that daily pelvic floor 
muscle training can slow progression of anterior prolapse in elderly women.24
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Pessary treatment is widely used for the treatment of pelvic organ prolapse. It can 
be considered a patient-friendly, minimally invasive treatment which appears to be 
safe. 50% to 80% of women who were initially successfully fitted continued to use 
pessary at one year.25 14% to 48% of the women continue the pessary treatment 
more than 5 year.25 Pessary use results in improvement of bulge and irritative bladder 
symptoms. Vaginal discharge, odour and vaginal erosion are the most common side-
effects of pessary use.
surgical intervention
Surgical treatment of pelvic organ prolapse can be categorized broadly into obliterative 
and reconstructive techniques.
obliterative techniques
In elderly women and those at high-risk for complications of surgery, who are not 
sexually active, vaginal pelvic organ prolapse can be treated with (partial) vaginal 
closure or colpocleisis.26 Due to vaginal closure, intercourse is not possible anymore 
and 7-11% of these patients develop urinary incontinence.27  Success rates of 91% 
to 100% are reported.27 Another partial obliterative procedure is the Labhardts high 
perineoplasty.28 This leaves only a minimal introitus.
reconstructive techniques
Reconstructive surgery aims to correct pelvic organ prolapse while maintaining (or 
improving) vaginal sexual function and relieving any associated pelvic symptoms. 
Surgery can be undertaken by either vaginal or abdominal route.
Anterior colporrhaphy is a vaginal surgical technique to repair anterior vaginal 
wall prolapse. The prolapse is reduced by central plication of the fibromuscular layer 
of the anterior vaginal wall. Success rate of this procedure in randomized controlled 
trials is 40-60%.29,30 Posterior colporrhaphy treats the posterior vaginal wall prolapse 
by means of plication of the fibromuscular layer of the posterior vaginal wall.  Success 
rate of a posterior colporrhaphy is 80-88%.31,32 Transvaginal apical suspension 
procedures include high uterosacral ligament suspension, McCall culdoplasty, 
sacrospinous ligament fixation/sacrospinous hysteropexy and Manchester Fothergill. 
The failure rate for the apical compartment of these techniques is 0-15%.33
The abdominal route for correction of an apical prolapse is a sacral hystero- or 
colpopexy. This technique is associated with a low recurrent prolapse rate (0-15%).34 
Downsides of this treatment are a long operating time, a long length of hospital 
admission, higher morbidity rates and costs when compared with vaginal surgery.35 
Laparoscopic sacral colpopexy provides the potential to combine the success rate of 
an abdominal approach with the faster recovery time associated with a minimally 
invasive technique.
Reoperations after surgery for pelvic organ prolapse or incontinence are reported 
in 29% of patients.10 The high failure rate after traditional vaginal prolapse surgery 
has led to the introduction of mesh materials in vaginal prolapse surgery to obtain 
improved support.  Anatomic results of prolapse repair with synthetic mesh seem 
11
CHAPTER 1
promising with success rates ranging from 71% to 100%.36 Currently a number of 
synthetic implant materials with surgical instrument kits are commercially available. 
One could use an anterior mesh, a posterior mesh or a total mesh (figure 1, 2, 3). 
The synthetic material is a pre-cut non-absorbable monofilament prolene mesh. The 
anterior part is inserted between the bladder and the vagina and secured bilaterally 
by two arms through each obturator foramen into the arcus tendinous fascia 
pelvis (figure 2). The posterior part is placed between the rectum and the vagina 
and is secured bilaterally by one arm passing through each ischiorectal fossa and 
sacrospinous ligament or musculus (ilio) coccygeus (figure 3). Every brand of mesh 
has its own instruments (for example cannula-equipped guides and retrieval devices), 
designed to facilitate proper implant placement. 
 
Figure 1. Anterior and posterior mesh and relation to bladder, vagina and rectum in 3 
different positions. 
(With permission of Ethicon Women’s Health & Urology, Amersfoort, the Netherlands)  
 
 
 
Figure 2.  
The anterior mesh is inserted between the bladder and the vagina and secured bilaterally by 
two arms through each obturator foramen into the arcus tendinous fascia pelvis (red 
arrows). 
(With permission of Ethicon Women’s Health & Urology, Amersfoort, the Netherlands)  
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figure 1. Anterior and posterior mesh 
and relation to bladder, vagina and 
rectum in 3 different positions. (With 
permission of Ethicon Women’s Health & 
Urology, Amersfoort, the Netherlands).
figure 2. The anterior mesh is inserted 
between the bladder and the vagina 
and secured bilaterally by two arms 
through each obturator foramen into 
the arcus tendinous fascia pelvis (red 
arrows). (With permission of Ethicon 
Women’s Health & Urology, Amersfoort, 
the Netherlands).
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ouTlIne of The ThesIs
This thesis studies two types of pelvic organ prolapse surgery with mesh as 
a possible solution for the high recurrence rates after pelvic organ prolapse surgery. 
The first type of surgery is trocar-guided tension free vaginal mesh (Prolift-system) 
placement. The second type of surgery is laparoscopic sacral colpopexy with bone-
anchor fixation. We investigated whether the use of these types of surgery improves 
anatomic and functional outcome of pelvic organ prolapse surgery. Furthermore, we 
wanted to evaluate the complications associated with the use of mesh in pelvic organ 
prolapse surgery.
The main research questions were:
1. Is the anatomic failure rate in each treated compartment in women with recurrent 
pelvic organ prolapse lower in patients with a tension-free vaginal mesh insertion 
(Prolift) compared to conventional vaginal prolapse surgery? (chapter 2)
2. Is the subjective improvement rate higher in patients treated with a tension-free 
vaginal mesh insertion (Prolift) compared to conventional vaginal prolapse surgery 
in women with recurrent pelvic organ prolapse? (chapter 2)
3. Does mesh treatment of only one vaginal compartment provoke development of 
pelvic organ prolapse in other initially unaffected and untreated compartments? 
(chapter 3 and 4)
4. Can we identify predictors of failure of trocar-guided tension-free vaginal mesh 
surgery? (chapter 5)
5. Can we identify risk factors for complications of trocar-guided tension-free vaginal 
mesh surgery? (chapter 6)
6. Is laparoscopic sacral colpopexy with bone anchor fixation an effective and safe 
treatment of pelvic organ prolapse? (chapter 7)
  
Figure 3. 
The posterior mesh is placed between the rectum and the vagina and is secured bilaterally 
by one arm passing through each ischiorectal fossa and sacrospinous ligament or musculus 
(ilio) coccygeus (red arrow). 
(With permission of Ethicon Women’s Health & Urology, Amersfoort, the Netherlands)  
figure 3. The posterior mesh is placed 
between the rectum and the vagina 
and is secured bilaterally by one arm 
passing through each ischiorectal 
fossa and sacrospinous ligament or 
musculus (ilio) coccygeus (red arrow). 
(With permission of Ethicon Women’s 
Health & Urology, Amersfoort, 
the Netherlands).
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7. Is trocar-guided tension-free vaginal mesh as effective as laparoscopic sacral 
colpopexy? (chapter 8)
8. How should we treat mesh-related complications? (chapter 9)
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troCAr-Guided Mesh CoMPAred With ConventionAl 
vAGinAl rePAir in reCurrent ProlAPse: 
A rAndoMized Controlled triAl
mariëlla i. withagen, alfredo l. milani, Jan den Boon, 
harry a. vervest, mark e. vierhout
Obstet Gynecol 2011;117:242–50
absTracT
objective 
To compare efficacy and safety of trocar-guided tension-free vaginal mesh insertion 
with conventional vaginal prolapse repair in patients with recurrent pelvic organ 
prolapse.
Methods
Patients with recurrent pelvic organ prolapse stage II or higher were randomly 
assigned to either conventional vaginal prolapse surgery or polypropylene mesh 
insertion. Primary outcome was anatomic failure (pelvic organ prolapse stage II or 
higher) in the treated vaginal compartments. Secondary outcomes were subjective 
improvement, effects on bother, quality of life, and adverse events. Questionnaires 
such as the Incontinence Impact Questionnaire and Urogenital Distress Inventory 
were administered at baseline, 6 months, and 12 months. Anatomic outcomes 
were assessed by an unblinded surgeon. Power calculation with α=0.05 and β=0.80 
indicated that 194 patients were needed.
results 
Ninety-seven women underwent conventional repair and 93 mesh repair. The follow-
up rate after 12 months was 186 of 190 patients (98%). Twelve months postsurgery, 
anatomic failure in the treated compartment was observed in 38 of 84 patients 
(45.2%) in the conventional group and in eight of 83 patients (9.6%) in the mesh 
group (P<.001; odds ratio, 7.7; 95% confidence interval, 3.3–18). Patients in either 
group reported less bulge and overactive bladder symptoms. Subjective improvement 
was reported by 64 of 80 patients (80%) in the conventional group compared with 
63 of 78 patients (81%) in the mesh group. Mesh exposure was detected in 14 of 83 
patients (16.9%).
Conclusion
At 12 months, the number of anatomic failures observed after tension-free vaginal 
mesh insertion was less than after conventional vaginal prolapse repair. Symptom 
decrease and improvement of quality of life were equal in both groups.
CLINICAL TRIAL REGISTRATION: 
ClinicalTrials.gov, www.clinicaltrials.gov, NCT00372190.
2RECURRENT POP: MESH OR CONVENTIONAL REPAIR
InTroducTIon
Conventional surgical repairs of pelvic organ prolapse are associated with high failure 
rates. Anterior vaginal wall prolapse may recur in 30–70% of patients after standard 
anterior colporrhaphy,1-3 whereas recurrence rates in the posterior compartment after 
posterior colporrhaphy are only 12–20%.4,5 In the perspective of these high failure 
rates, particularly in the anterior compartment, vaginal surgery with prosthetic mesh 
has been introduced. The use of these synthetic meshes and biologic grafts in pelvic 
reconstructive surgery has increased considerably in recent years. Anatomic results of 
prolapse repair with synthetic mesh seem promising with success rates ranging from 
71% to 100%.6 The first randomized controlled trials comparing mesh with standard 
colporrhaphy showed failure rates of 6.7–11% after anterior mesh repair.2,3,7 Two 
other recent trials showed substantially higher failure rates after mesh repair of 
either the anterior or the anterior and posterior compartment (19–28%).8,9 All the 
previous trials mainly focused on anatomic outcome in the anterior compartment 
and had heterogeneous patient populations with primary as well as recurrent pelvic 
organ prolapse. Because the longest documented follow-up time of mesh-reinforced 
prolapse surgery is 38 months in only one study, and therefore no solid evidence on 
the long-term safety of synthetic mesh in pelvic reconstructive surgery exists, we 
limited our study to patients with recurrent pelvic organ prolapse.10
The aim of this study was to compare anatomic and subjective failure rates in all 
treated vaginal compartments of women with recurrent pelvic organ prolapse after 
tension-free vaginal mesh insertion (Prolift) and after conventional vaginal prolapse 
surgery. We hypothesized that the anatomic failure rate in the mesh group compared 
with the conventional repair group would be lower.
MaTerIals and MeThods
This study was undertaken after obtaining approval from the Institutional Review 
Board of the St Elisabeth Hospital in Tilburg, The Netherlands, and the boards 
from all participating sites. All patients provided written informed consent before 
participation and were recruited in 13 centers in The Netherlands between June 2006 
and July 2008. Women with a recurrent pelvic organ prolapse stage II or higher of 
the anterior wall, posterior vaginal wall, or both requiring surgical correction were 
eligible for participation. Exclusion criteria were pregnancy or contemplating future 
pregnancy, prior vaginal prolapse repair with mesh, a compromised immune system 
or any other condition that would compromise healing, previous pelvic irradiation or 
cancer, blood coagulation disorders, renal failure, upper urinary tract obstruction, or 
presence of large ovarian cysts or myomas.
Baseline evaluation included medical history, a validated urogynecologic 
questionnaire, which among others, contains the Dutch validated Urogenital 
Distress Inventory, Defecatory Distress Inventory, Incontinence Impact Questionnaire, 
a gynecologic investigation, and pelvic organ prolapse quantification examinations.11-13
After obtaining the signature for the informed consent, patients were randomly 
assigned per center by a computer-generated schedule to either conventional vaginal 
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prolapse surgery or tension-free vaginal mesh. Patients and surgeons were not 
blinded.
All procedures were performed by 22 participating gynecologists with broad 
experience in pelvic floor reconstruction and were specifically trained for the Prolift 
procedure by an authorized Prolift instructor before enrollment of patients. The 
number of prolapse repairs performed per surgeon in this study varied from one to 72.
The mesh insertions were performed as described in the article by Fatton et al.14 
before enrollment of patients. To resemble daily gynecologic practice as close as 
possible, the type of conventional vaginal surgery was left at the discretion of the 
surgeon. Guidelines for conventional surgery were as follows. Anterior colporrhaphy 
was performed by a midline anterior vaginal incision, dissection of the vaginal 
epithelial layer from the fibromuscular layer, midline plication of the fibromuscular 
layer with delayed absorbable material, optional excision of excess vaginal mucosa, 
and incision closure with delayed absorbable material. Apical compartment prolapse 
(uterus, vaginal vault, or cervix) was treated according to the surgeon’s preference. 
Vaginal hysterectomy, modified Manchester-Fothergill procedure15 uterosacral vaginal 
suspension (McCall procedure), and sacrospinous ligament fixation techniques were 
all allowed. Posterior colporrhaphy was performed through a posterior midline 
vaginal incision, dissection of the vaginal epithelial layer from the fibromuscular layer, 
midline plication of the fibromuscular layer with delayed absorbable material, optional 
excision of excess vaginal mucosa, and incision closure with delayed absorbable 
material. Reconstruction of the perineum (perineoplasty) was left to each surgeon’s 
discretion. In the conventional group, the use of adjunct mesh was not allowed.
The tension-free vaginal mesh procedure was performed as described in the article 
by Fatton et al.14 As recommended by these authors, a midline incision was made, 
which included full thickness of the fibromuscular wall of the vagina. The vagina was 
closed without any resection of vaginal tissue. No simultaneous hysterectomy or T 
incisions were allowed to reduce the chance of mesh exposure and erosions.14 Other 
additional conventional surgery such as sacrospinous ligament fixation or modified 
Manchester-Fothergill was permitted.
Preoperatively a single dose of intravenous antibiotic prophylaxis (cefazolin-
Natrium and metronidazole or amoxicillin and clavulanic acid) was given to all patients. 
An indwelling urinary catheter and vaginal gauze pack were left after completion of 
surgery according to local protocol.
Postoperative evaluations were performed during the hospital stay, at 6 weeks, 
and 6 and 12 months, respectively. Pelvic organ prolapse quantification measurements 
were recorded and Urogenital Distress Inventory, Defecatory Distress Inventory, 
Incontinence Impact Questionnaire, and Patient Global Impression of Improvement 
questionnaires completed at 6 and 12 months.16
The primary end point was anatomic failure in any of the treated vaginal compartments, 
defined as pelvic organ prolapse stage II or higher. The treated compartment in the 
tension-free vaginal mesh group was defined as anterior in case a patient underwent 
an anterior tension-free vaginal mesh procedure; anterior, posterior, and apical in case 
of a total tension-free vaginal mesh procedure; and posterior and apical in case of 
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a posterior tension-free vaginal mesh procedure. Additional conventional surgery in 
any of the other vaginal compartments in the tension-free vaginal mesh group was 
allowed but not considered a treated compartment. 
Treated compartment in the conventional group was defined as anterior in case 
a patient underwent anterior colporrhaphy; posterior if a patient underwent a 
posterior colporrhaphy; and apical if a patient underwent sacrospinal fixation, vaginal 
hysterectomy with uterosacral vaginal suspension, or a modified Manchester-Fothergill.
Secondary outcomes were duration of surgery, blood loss, length of hospitalization, 
complications and subjective improvement (Patient Global Impression of Improvement), 
and change in bother and quality of life measured by Urogenital Distress Inventory, 
Defecatory Distress Inventory, and Incontinence Impact Questionnaire scores. Pain 
was a secondary outcome as well and considered significant if a patient responded 
“yes, moderately to quite a bit” to the question “Do you experience pain in the lower 
abdomen or genital region?” Dyspareunia was considered significant if a patient 
responded “yes; moderately to quite a bit” to the question “Do you experience 
pain during intercourse?” Stress urinary incontinence was considered significant 
if a patient responded “yes, moderately to quite a bit” to the question “Do you 
experience urinary leakage during physical activity, coughing, or sneezing?”
Sample size calculation was based on the assumption of an estimated overall 
failure rate of 30% in the conventional surgery group (cure rate of 70%) and a 13% 
failure rate in the tension-free vaginal mesh group (cure rate of 87%).1,4,14,17 Using a 
two-tailed hypothesis test with type I error of 5% and 80% power, 88 patients would 
be required in each group to detect a significant difference of at least 17% in pelvic 
organ prolapse stage II or higher. Anticipating a 10% dropout rate, we planned to 
enroll 194 patients.
Statistical analysis was performed using Statistical Package for the Social Sciences 
15.0. Continuous variables were compared using the independent-samples t test to 
compare means or Mann-Whitney U test to compare medians. Categorical variables 
were compared using the chi square test. Related samples were compared using the 
paired-samples t-test to compare means or the Wilcoxon signed rank test to compare 
medians. A P value of <0.05 was considered statistically significant.
resulTs
One hundred ninety-four patients were enrolled and assigned to either conventional 
vaginal prolapse repair or to trocar-guided tension-free vaginal mesh insertion 
(Fig. 1). Two patients in each arm did not undergo surgery. The follow-up rate after 
12 months was 186 of 190 patients (98%). Three patients in the tension-free vaginal 
mesh arm and one in the conventional arm did not return for follow-up nor completed 
the urogynecologic questionnaires that were sent to them.
Baseline characteristics did not differ between the two groups apart from 
a higher number of previous sacrocolpopexies in the tension-free vaginal mesh group 
(Table 1). Peri- and postoperative characteristics are shown in Table 2. The duration 
of surgery was a median 8.5 minutes longer in the tension-free vaginal mesh group. 
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seven cases at the 12-month follow-up visit. Nine of
these 14 patients were asymptomatic. The size of
these mesh exposures varied from 2 to 20 mm. Mesh
exposures were equally distributed over the anterior
and posterior compartments. The mesh exposure
rates per center varied from 0% to 100% (median 0%).
In five patients, these mesh exposures were excised
and the defects covered with vaginal mucosa in a
day-care procedure after patients were initially treated
with local estrogen. These exposures resolved. The
other nine patients were treated with local estrogen
only; two exposures resolved and the other seven
were still under observation at the 12 months fol-
low-up visit.
At 12 months, pain in the lower abdomen or in
the genital area was reported by 10 of 85 patients
(11.7%) in the conventional group and by eight of 79
patients (10%) in the tension-free vaginal mesh group
(Table 3). Because we missed data on pain in 23
patients in the conventional group and on 22 patients
in the tension-free vaginal mesh group, we performed
a missing data analysis. The nonresponders were a
mean 4.9 years older compared with the responders.
All other factors (body mass index, comorbidity,
preoperative pelvic organ prolapse stage, treatment
group, complication, failure) were equal.
Preoperatively, 49 of 97 (51%) patients in the
conventional and 52 of 93 (56%) in the mesh repair
Patients included
N=194
Completed 6-month follow-up:
n=89
Visit and questionnaire: 81
Visit only: 5
Questionnaire only: 3
Underwent conventional 
vaginal repair
n=97
Completed POP-Q
n=97
Completed questionnaire
n=85
Underwent trocar-guided 
repair with tension-free   
vaginal mesh insertion
n=93
Completed POP-Q
n=93
Completed questionnaire
n=85
Randomized to trocar-
guided tension-free 
vaginal mesh insertion
n=95
Randomized to 
conventional vaginal surgery
n=99
Completed 6-week follow-up
n=93
Completed 6-week follow-up
n=97
Completed 6-month follow-up:
n=94
Visit and questionnaire: 80
Visit only: 6
Questionnaire only: 8
Completed 12-month follow-
up: n=90
Visit and questionnaire: 77
Visit only: 6
Questionnaire only: 7
Completed 12-month follow-
up: n=96
Visit and questionnaire: 75
Visit only: 8
Questionnaire only: 13
Lost to follow-up
n=3
Lost to follow-up
n=1
Surgery not performed: n=2
Refused surgery due to
domestic problems: 2
Surgery not performed: n=2
Refused surgery after 
ablatio retinae: 1
Died before surgery: 1
Included in analysis
n=90
Included in anatomic analysis
n=83
Included in functional analysis
n=84
Included in analysis
n=96
Included in anatomic analysis
n=84
Included in functional analysis
n=88
Fig. 1. Patient enrollment and fol-
low-up. POP-Q, pelvic organ pro-
lapse quantification.
Withagen. Recurrent POP: Mesh or
Conventional Repair. Obstet Gynecol
2011.
VOL. 117, NO. 2, PART 1, FEBRUARY 2011 Withagen et al Recurrent POP: Mesh or Conventional Repair 245
fig. 1. Patient enrollment and follow-up. POP-Q= pelvic organ prolapse quantification.
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In none of the patients did blood loss exceed 500 mL. Hematomas were seen more 
frequently in the tension-free vaginal mesh group (Table 3). One patient in the 
conventional group needed surgical reintervention for postoperative hemorrhage. 
No major complications occurred during surgery or in the immediate postoperative 
period. Temporary urinary retention was the most common complication in both 
groups but occurred significantly more often in the tension-free vaginal mesh group. 
Normal micturition restored spontaneously in all patients within 14 days.
In 14 of 83 patients (16.9%) in the tension-free vaginal mesh group, mesh 
exposure was detected, in seven patients at the 6-month follow-up visit and in seven 
cases at the 12-month follow-up visit. Nine of these 14 patients were asymptomatic. 
The size of these mesh exposures varied from 2 to 20 mm. Mesh exposures were equally 
distributed over the anterior and posterior compartments. The mesh exposure rates per 
center varied from 0% to 100% (median 0%). In five patients, these mesh exposures 
were excised and the defects covered with vaginal mucosa in a day-care procedure 
after patients were initially treated with local estrogen. These exposures resolved. 
The other nine patients were treated with local estrogen only; two exposures resolved 
and the other seven were still under observation at the 12 months follow-up visit. 
table 1. Patient characteristics.
Conventional (n=97) Prolift (n=93) p-value
Age a 64 + 10.2 64 + 10.5 0.96
Parity b 2 (1-5) 2 (0-6) 0.74
BMI a 27 + 4 27 + 6 0.54
Comorbidity c 46 (47%) 40 (43%) 0.54
Previous  surgery c
Abdominal hysterectomy 14 (14%) 20 (22%) 0.20
Vaginal hysterectomy 69 (71%) 56 (60%) 0.11
Anterior colporraphy 69 (71%) 54 (58%) 0.06
Posterior colporrhaphy 61 (63%) 51 (55%) 0.26
Sacrospinous ligament fixation 0 3 (3%) 0.08
Sacrocolpopexy 6 (6%) 17 (18%) 0.01
One prolapse procedure 81 (84%) 81 (87%) 0.49
More than one 16 (16%) 12 (13%) 0.49
Previous incontinence surgery c 23 (24%) 19 (20%) 0.59
Overall POP-stage c 0.66
II 47 (49%) 42 (45%)
III 45 (46%) 46 (50%)
IV 5 (5%) 5 (5%)
Treatment anterior compartment 56 58 0.51
POP-stage I/II/III/IV 5/28/20/3 0/25/31/2 0.053
Treatment posterior compartment 64 56 0.41
POP-stage I/II/III/IV 6/29/28/1 5/33/17/1 0.33
Treatment apical compartment 45 56 0.056
POP-stage 0/I/II/III/IV 25/4/10/3/3 35/11/2/4/4 0.349
Data presented as mean (standard deviation)a , median (range)b or number of patients (%)c.
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table 2. Peri- and post operative data.
Conventional (n=97) Prolift (n=93) p-value
Anterior ProliftTM a 0 37 (40%)
Posterior ProliftTM a 0 35 (38%)
Anterior + posterior ProliftTM a 0 1 (1%)
Total ProliftTM a 0 20 (21%)
(Concomitant) surgery a 21 (23%)
Vaginal hysterectomy 4 (4%) 0
Anterior colporraphy 56 (58%) 3 (3%)
Posterior colporraphy 64 (66%) 3 (3%)
Perineoplasty 8 (8%) 1 (1%)
Manchester Fothergill 2 (2%) 2 (2%)
Enterocele repair 10 (10%) 0
Monarc/tvt/tvt-o 1 (1%) 4 (4%)
Sacrospinous ligament fixation 39 (40%) 5 (5%)
Uterosacral vaginal suspension 4 (4%) 0
Spinal analgesia a 63 (66%) 57 (61%) 0.47
General analgesia a 32 (34%) 36 (39%) 0.47
Operating time (min) b 45 (16-120) 53.5 (29-125) 0.001
Blood loss (ml) b 100 (0-400) 100 (0-400) 0.15
Duration urinary catheter (days) b 2 (1-6) 2 (1-10) 0.27
Hospital stay (days) b 3 (2-13) 3 (2-15) 0.97
Data presented as number of patients (%) a or median (range)b.
table 3. Complications.
Complications Conventional (n=97) Prolift (n=93) p-value
Bladder perforation 0 2 (2%) 0.15
Repeat surgery for postoperative hemorrhage 1 (1%) 0 0.33
Haematoma 1 (1%) 6 (6%) 0.047
Temporary urinary retention 5 (5%) 15 (16%) 0.008
Buttock pain 1 (1%) 0 0.33
Cumulative mesh exposure at 12 months  - 14 (16.9%) <0.001
Pain (lower abdomen/genital area)
Baseline 24/79 (30%) 18/81 (22%) 0.24
At 12 months 10/85 (11.7%) 8/79 (10%) 0.74
De novo pain 2/50 (4%) 4/53 (7.5%) 0.44
Dyspareunia
Baseline 16/49 (33%) 13/52 (25%) 0.39
At 12 months 12/51(24%) 9/53 (17%) 0.41
De novo dyspareunia 3/29 (10%) 3/37 (8%) 0.75
Stress urinary incontinence (SUI)
Baseline 11/84 (13%) 15/84 (18%) 0.39
At 12 months 8/87 (9%) 14/81 (17%) 0.12
De novo SUI 8/88 (9%) 8/81 (10%) 0.86
Data presented as numbers (%).
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At 12 months, pain in the lower abdomen or in the genital area was reported 
by 10 of 85 patients (11.7%) in the conventional group and by eight of 79 patients 
(10%) in the tension-free vaginal mesh group (Table 3). Because we missed data 
on pain in 23 patients in the conventional group and on 22 patients in the tension-
free vaginal mesh group, we performed a missing data analysis. The nonresponders 
were a mean 4.9 years older compared with the responders. All other factors (body 
mass index, comorbidity, preoperative pelvic organ prolapse stage, treatment group, 
complication, failure) were equal. 
Preoperatively, 49 of 97 (51%) patients in the conventional and 52 of 93 (56%) in 
the mesh repair group were sexually active (Table 3). At 12 months, 51 of 97 (53%) 
of the conventional and 53 of 93 (57%) of the tension-free vaginal mesh repair 
patients were sexually active. In both groups, rates of dyspareunia had decreased at 
12 months compared with baseline. The difference in reported dyspareunia between 
groups was not significant either at baseline or at 12 months. At 12 months, de novo 
dyspareunia was reported by three of 29 (10%) in the conventional and three of 37 
(8%) in the tension-free vaginal mesh repair group (Table 3).
At 12 months, de novo stress urinary incontinence was found in eight of 88 
(9%) in the conventional group and in eight of 81 (10%) in the tensionfree vaginal 
mesh group. If we look only at the treated anterior compartment, the rates of de 
novo stress urinary incontinence are 11% (six of 53) and 12% (six of 50) for the 
conventional group and the tension-free vaginal mesh group, respectively. 
Six and 12 months postsurgery, the pelvic organ prolapse quantification points Aa, 
Ba, C, GH, PB, Ap, Bp, and D improved significantly (P<0.05) in both groups (Table 
4), but results were better in the tension-free vaginal mesh group compared with the 
conventional group with respect to points Aa, Ba, PB, Ap, and Bp. Anatomic failures 
in the treated compartments were observed in 38 of 84 patients (45.2%) in the 
conventional group and eight of 83 patients (9.6%) in the tension-free vaginal mesh 
group (Table 5). The difference in failure rates remained highly significant even if the 
lost-to-follow-up patients in the tension-free vaginal mesh group were all considered 
failures and in the conventional group were all considered successes (38 of 97 [39%] 
compared with 18 of 93 [19%], P<0.003) (odds ratio, 2.7; 95% confidence interval, 
1.4 –5.2). In the conventional group, four patients underwent reoperation within 
12 months as a result of symptomatic recurrence in the treated compartment. Two 
anterior tension-free vaginal mesh repairs, one posterior tension-free vaginal mesh 
repair and one Labhardt procedure were performed. In the tension-free vaginal mesh 
group, no reinterventions resulting from symptomatic recurrence were reported. In 
the conventional group, failure rates were higher in both the anterior as well as in the 
posterior compartment compared with the tension-free vaginal mesh group (Table 5). 
No differences in the failure rate of the apical compartment were detected. Analysis 
of the apical compartment was conducted after exclusion of seven patients in the 
tension-free vaginal mesh group who underwent additional conventional apical 
repair (two underwent a Manchester-Fothergill and five underwent sacrospinous 
ligament fixation). The failure rate per center in the conventional group varied from 
0% to 100% (median 45%) and in the tension-free vaginal mesh group, the failure 
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CHAPTER 2
rate per center varied also from 0% to 100% (median 0%). If we would have defined 
failure as an overall pelvic organ prolapse stage II or more (ie, leading edge of any 
compartment and thus not limited to treated compartment) or repeat prolapse 
surgery, the “failure rate” in the conventional group would have been 66% (56 of 
84 patients) and 49% (41 of 83 patients) in the tension-free vaginal mesh group 
(P=0.03).
The Urogenital Distress Inventory, Defecatory Distress Inventory, and Incontinence 
Impact Questionnaire domain scores were similar at baseline in the two treatment arms, 
except for the domain “mobility” of the Incontinence Impact Questionnaire (Table 6). 
At 12 months, significant improvements in the Urogenital Distress Inventory domains 
“genital prolapse,” “pain” and “overactive bladder,” and “physical functioning” of 
the Incontinence Impact Questionnaire were noted in both groups. Defecatory Distress 
Inventory domains “pain” and “incontinence” scored significantly better in the 
tension-free vaginal mesh group compared with the conventional group at 12 months.
The Patient Global Impression of Improvement scores at 12 months showed no 
difference in patients’ perception of improvement between groups; 64 of 80 patients 
(80%) in the conventional group reported improvement compared with 63 of 78 
patients (81%) in the tension-free vaginal mesh group. 
dIscussIon
This randomized controlled trial of mesh insertion compared with conventional vaginal 
repair in women with recurrent pelvic organ prolapse demonstrated significant lower 
failure rates in the anterior as well as the posterior compartment after tension-free 
vaginal mesh insertion. At the end point, 12 months, most of the anatomic failures, 
however, were pelvic organ prolapse stage II and not bothersome enough to lead to 
the necessity of reintervention. The anatomic failure rates of anterior colporrhaphy 
and posterior colporrhaphy in this study were slightly higher when compared with 
other studies that describe heterogeneous populations of primary and recurrent 
pelvic organ prolapse.2-5,7 Our population, however, only consisted of women with 
recurrent pelvic organ prolapse and this might explain this slightly higher failure rate 
in the conventional group compared with data from the literature. Anatomic failure 
rates in the tension-free vaginal mesh group are consistent with or even lower than 
rates reported in previous studies.2,3,7-9,18
Although anatomic support at 12 months was superior in the tension-free vaginal 
mesh group, bulge and overactive bladder symptoms improved significantly in both 
treatment groups and the overall subjective improvement was equal among both 
groups. Our stringent definition of anatomic failure does explain the high number 
of asymptomatic patients with failed anatomic results at 12 months postsurgery. 
However, these asymptomatic patients with pelvic organ prolapse stage II could be 
forerunners and might develop complaints within a few years. Longer follow-up is 
therefore mandatory and will be conducted and documented in a following study.
The effects of long-term presence of nonabsorbable mesh in the vagina are 
unknown and a reason for concern. Vaginal mesh exposure was detected in 16.9% 
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of tension-free vaginal mesh patients, which is higher than most authors previously 
reported.2,3,8,9,18,19 In two other studies, however, exposure rates of 17.3–20% were 
reported.7,20 Known risk factors for exposure are concurrent vaginal hysterectomy, 
T-incisions, age older than 70 years, and smoking.20-22 In our study, the tension-free 
vaginal mesh procedure was not combined with hysterectomy nor with T-incisions. 
Two of 14 patients with mesh exposure were older than 70 years of age. Smoking 
was not a recorded variable. All participating centers were strictly instructed to search 
for any mesh exposure at each of the follow-up visits. This could have contributed 
to this higher rate of exposure. Another explanation for this fairly high rate of 
exposure could be the fact that in this multicenter trial of 13 participating centers, 22 
surgeons, although all with an adequate level of experience, had their own learning 
curve. Exposure rates per center varied from 0% to 100%. Furthermore, the patient 
population only consisted of patients with recurrent pelvic organ prolapse, so more 
scar tissue of previous surgeries was present, which could have led to faulty or delayed 
healing with subsequent exposure. Given the 45.2% failure rate after conventional 
vaginal prolapse surgery and 9.6% failure rate after tension-free vaginal mesh repair, 
the number needed to treat for benefit would be 2.8. Given the 16.9% vaginal mesh 
exposure rate, the number needed to harm would be six. 
De novo pain and de novo dyspareunia rates were low and equally distributed 
among both groups. Because de novo dyspareunia rates of 13–42% have been 
reported in the literature after conventional vaginal prolapse surgery and after mesh 
repair, our rates in either group compare favorably.8,23,24 Unlike the higher rate of de 
novo stress urinary incontinence after mesh surgery in a previous study, we found an 
equal rate of de novo stress incontinence (9% and 10%) in both groups.7 A possible 
explanation could be the high rate of previous surgery for urinary incontinence of 
20% and 24% and the 100% rate of previous prolapse surgery. 
The strength of this study was that it is a randomized controlled trial that used 
validated outcome measures. Another strength is the design of the study, in which 
a new surgical technique, ie, pelvic organ prolapse reconstruction with mesh, is 
compared with conventional day-to-day vaginal techniques of pelvic organ prolapse 
repair. Furthermore, because 13 centers with a total of 22 gynecologic surgeons 
participated in this study, we consider the outcomes applicable to a broader population.
However, this study was subject to several limitations as well. The relatively short 
follow-up period of 12 months may have limited the detection of potential small 
differences in quality-of-life outcome scores. Although the total lost to follow-up rate 
of 2% (four of 194) was low, of 42 of 194 patients (22%), some part of the follow-
up data was missing. This could certainly bias our findings; however, the anatomic 
results remain highly significant if all the lost-to-follow-up patients in the tension-free 
vaginal mesh group would be considered failures and the lost-to-follow-up patients 
in the conventional group would be considered successful. The postoperative pelvic 
organ prolapse quantification measurements were performed by the surgeon or 
an available experienced colleague of the surgeon working in the same hospital 
but, unfortunately, not by an independent clinical examiner. This could have led to 
lower recurrence rates, because surgeons might overrate the results of their own 
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procedures. However, because they judged both mesh and conventional repairs, it 
seems probable that this bias would then be equally distributed over both techniques.
Despite these limitations, this study is one of few randomized controlled trials 
comparing conventional vaginal prolapse repair with polypropylene-reinforced mesh 
repair only in women with recurrent pelvic organ prolapse. Our results demonstrate 
equal improvements in symptoms as well as in physical functioning at 12 months, 
but the tension-free vaginal mesh group was associated with a significantly lower 
anatomic failure rate. 
Moreover, this study not only demonstrates lower anatomic failure rates in the 
anterior compartment, but in the posterior compartment as well.25 Because the 
long-term effects and safety of mesh-reinforced repairs are not yet fully known, 
surgeons may consider these procedures primarily for recurrent vaginal prolapse after 
counseling patients on the risks and benefits. New innovations aiming at strong tissue 
support with lower exposure rates should be the subject for future research and need 
to be evaluated in the context of further prospective randomized trials.
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absTracT
introduction and hypothesis
The objective of this study was to assess the effect of the tension-free vaginal mesh 
(Prolift™) procedure on the non-treated and initially unaffected vaginal compartments. 
Methods  
This prospective observational cohort study involved 150 patients who underwent 
a Prolift™ procedure. Pelvic organ prolapse (POP) quantification and evaluation of 
prolapse symptoms with validated questionnaires was performed pre-operatively and 
6 and 12 months postoperatively. Primary outcome was the rate of POP stage ≥II in 
the non-treated vaginal compartments. 
results  
Twenty-three percent of all patients developed a de novo POP stage ≥II in the 
untreated compartment. This occurred in 46% and 25% of patients after an isolated 
anterior and isolated posterior Prolift™, respectively. 
Conclusion  
Tension-free vaginal mesh treatment of one vaginal compartment seems to provoke 
the development of vaginal prolapse in initially unaffected vaginal compartments, 
particularly after an isolated anterior Prolift™ procedure. 
3EFFECT MESH REPAIR ON UNTREATED VAGINAL COMPARTMENT
InTroducTIon
Pelvic organ prolapse (POP) has a high prevalence in parous women.1 A wide 
variety of abdominal and vaginal surgical techniques is available for the treatment 
of POP, indicating lack of consensus on the optimal treatment. The choice of the 
type of operation depends on multiple factors such as site and severity of prolapse, 
additional symptoms, and the surgeon’s preference and capability. In order to prevent 
recurrence, the use of synthetic meshes and biological grafts in pelvic reconstructive 
surgery has increased considerably in recent years. The results of prolapse repair with 
synthetic mesh are promising, with success rates ranging from 71-100%.2 Mesh 
exposure, infection, dyspareunia, constipation, urgency, urge urinary incontinence, 
and urinary retention are reported as adverse effects, as well as bladder and rectal 
injury and bleeding during surgery. 
Since 2005, we performed an ongoing prospective observational cohort study 
to evaluate the anatomical and functional efficacy as well as morbidity of POP 
repair with a tension-free Vaginal Mesh Kit (Prolift™ Ethicon, Somerville, NJ, USA). 
During the systematic follow-up of these patients, the clinical impression rose that 
mesh treatment of one vaginal compartment provoked the development of vaginal 
prolapse in other initially unaffected compartments. In a previous study, Raalte et 
al. reported prolapse in the non-mesh compartment after a Prolift™ procedure in 
15.5% of cases.3 In contrast, only 5.3% of patients who underwent conventional 
prolapse surgery without mesh needed repeat prolapse surgery within 5 years in the 
compartment that previously appeared well-supported.4 
The aim of this article, therefore, is to evaluate the anatomical effect of Prolift™ 
treatment and its impact on prolapse symptoms on the non-treated and initially 
unaffected vaginal compartments. 
MaTerIal and MeThods
In two Dutch centers (Radboud University Nijmegen Medical Centre and Reinier de 
Graaf Group Delft) specializing in pelvic organ dysfunction and surgery, prolapse 
repair with the Prolift™ system was performed since September 2005. After obtained 
informed consent, consecutive patients with a recurrent POP stage ≥II and those with 
a primary POP stage ≥III were enrolled in this prospective observational cohort study. 
Surgery was performed by four gynecologists who were trained for the Prolift™ 
procedure as described in the paper by Fatton et al. prior to enrolment of patients in 
this study.5 As recommended by these authors, a midline incision was made which 
included full thickness of the fibromuscular wall of the vagina. The vagina was closed 
without resection of any vaginal tissue with a continuous running Vicryl 2.0 suture. 
No simultaneous hysterectomy or T-incisions were made in order to reduce the chance 
of mesh exposure and erosions.5 
POP was quantified pre-operatively and during follow-up at 6 and 12 months 
postoperatively according to the pelvic organ prolapse quantification (POP-Q) system, 
as recommended by the International Continence Society.6 Subjective symptoms 
were obtained pre-operatively and during follow-up visits at 6 and 12 months 
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postoperatively with the standard urogynecological questionnaire of the Dutch Pelvic 
Floor Society (a disease-specific quality of life questionnaire which among others 
contains the Urogenital Distress Inventory (UDI). The questionnaire as a whole has 
been validated for the Dutch language.7 Since the aim of this study was to specifically 
evaluate the anatomic effect of Prolift™ treatment on the non-treated and initially 
unaffected vaginal compartments, we only used the domain score on genital prolapse 
of the UDI. We choose to include only this domain since vaginal bulging symptoms 
are the only symptoms that are consistently associated with vaginal prolapse.8 
Primary outcome of this study was the rate of POP stage ≥II in the non-treated 
and initially unaffected compartments. Secondary outcomes were UDI scores on the 
domain of genital prolapse, anatomical success in the mesh-treated compartments, 
defined as POP stage≤I, as well as morbidity. 
Data on patient and surgical characteristics are presented as numbers with 
corresponding percentages or medians with range. Comparison between proportions 
was performed using the Pearson’s chi-square test. Mean domain scores and standard 
deviations were calculated on the UDI domain genital prolapse. Differences in means 
between baseline and 12-month follow-up were tested with the paired sample t test 
and differences in means between different groups were tested with the independent 
sample t test. Data were analyzed with the Statistical Package for the Social Sciences, 
version 16.0. A p value of <0.05 was considered significant. 
resulTs
Since the start of our study, 297 patients underwent the Prolift™ procedure and 
were registered in our database. On January 1, 2009, 196 patients had completed a 
follow-up of at least 12 months. Patients with a total Prolift™ procedure (46 patients) 
for post-hysterectomy vaginal vault prolapse, in whom, by definition, all three 
compartments are restored, were excluded from this study, leaving 150 patients for 
analysis. At baseline, POPQ data of 147 patients were complete and these patients 
were eligible for anatomic analysis. Two patients could not visit the hospital for the 
12-month follow-up, leaving 145 patients for follow-up analysis. At follow-up, 127 
patients (88%) had completed the validated questionnaire. 
Patient and surgical characteristics are presented in Table 1. Median age was 64 
years (range 32–89). In those patients who underwent a primary repair, median age 
was 71 years (range 55–89). Ninety-five patients (63%) underwent prior POP surgery, 
28 (19%) of those underwent more than one prior prolapse repair. Thirty-five patients 
(23%) underwent an anterior Prolift™ repair, 80 (54%) a posterior Prolift™ repair, 
and 35 (23%) a combined anterior and posterior Prolift ™ repair. Three (2%) bladder 
perforations occurred, all during dissection for an anterior Prolift™ procedure. In 
two of these patients, the anterior mesh was not placed, but the procedure was 
converted into a conventional anterior colporrhaphy. One superficial serosa lesion 
of the rectum occurred, without a perforation. The mesh procedure was continued, 
since the rectum wall was intact. One patient (1%) had significant hemorrhage (>500 
ml) and five patients (3%) developed a postoperative hematoma. Ten patients (7%) 
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had temporary postoperative urinary retention, which resolved spontaneously in all 
cases within 11 days. In 15 patients (10%), a mesh exposure was detected, six cases 
at the 6-month follow-up visit and nine at the 12-month follow-up visit. Most of 
these patients were asymptomatic. Only one patient complained of pain and one 
other of de novo dyspareunia, but none of them had vaginal discharge or signs 
of infection. The size of these mesh exposures varied from 2 to 20 mm. All mesh 
exposures were easily excised and covered with vaginal mucosa in a minor day-care 
procedure after initial treatment with local estrogens.
POP stages per compartment are shown in Table 2, divided into three categories: 
those who underwent a solitary anterior Prolift™, a solitary posterior Prolift™, or a 
combined anterior and posterior Prolift™ procedure. In Table 2, the patients who 
table 1. Patient and surgical characteristics.
Anterior 
prolift (n= 35)
Posterior 
prolift (n= 80)
Anterior+ posterior 
prolift (n = 35)
All patients 
(n= 150)
Agea 64 (34–82) 60 (35–87) 68 (32–89) 64 (32–89)
Paritya 2 (1–5) 2 (0–6) 3 (1–7) 2 (0–7)
BMIa 26 (21–31) 25 (20–36) 26 (20–37) 26 (20–37)
Previous prolapse surgeryb 24 (69%) 61(76%) 10 (39%) 95 (63%)
Operating time (min)a 50 (32–120) 45 (29–135) 80 (40–150) 50 (29–150)
Bloodloss (ml)a 100 (50–300) 100 (50–300) 125 (50–1200) 100 (50–1200)
Concomitant surgeryb 12 (34%) 15 (19%) 4(11%) 32 (21%)
- Anterior colporraphy 0 8 0 8
- Posterior colporraphy 7 0 0 7
- Perineorrhaphy 3 2 3 8
- Cervical amputation 0 0 1 1
- Enterocele repair 0 3 0 3
- Monarc/tvt/tvt-o 0 2 1 3
- Sacrospinous fixation 2 0 0 2
Analgesia
- Spinalb 19 (54%) 37 (46%) 16 (46%) 72 (48%)
- Generalb 13 (37%) 34 (43%) 13 (37%) 60 (40%)
Duration urinary catheter (days)a 2 (1–11) 1 (1–10) 2(2–6) 2 (1–11)
Hospital stay (days)a 4 (2–11) 4 (2–6) 4 (3–11) 4 (2–11)
Complications
- Bladder perforationb 3 (8%) 0 0 3 (2%)
- Rectum serosalesionb 0 1 (1%) 0 1 (1%)
- Hemorrhage >500 mlb 0 0 1 (3%) 1 (1%)
Repeat surgery for postoperative 
hemorrhageb 
0 1 (1%) 1 (3%) 2 (1%)
Hematomab 2 (6%) 1 (1%) 0 3 (2%)
Urinary retentionb 5 (14%) 3 (4%) 2 (6%) 10 (7%)
Mesh exposureb 2 (6%) 9 (11%) 4 (11%) 15 (10%)
amedian (range) 
bnumber of patients (%)
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underwent concomitant, non-mesh surgery are included. Patients who underwent 
repeat surgery before 12 months follow-up were considered failures.
In Table 3, the effect on the non-operated compartment is shown in patients 
without concomitant surgery. UDI scores on the domain of genital prolapse are 
shown in Table 4.
ta
b
le
 3
 e
ff
ec
t 
o
n
 n
o
n
-t
re
at
ed
 c
o
m
p
ar
tm
en
t 
at
 1
2 
m
o
n
th
s.
A
n
te
ri
o
r 
Pr
o
lif
t™
 
(n
=
 2
6)
 
Po
st
er
io
r 
Pr
o
lif
t™
 
(n
=
 6
5)
 
A
n
te
ri
o
r+
 p
o
st
er
io
r 
Pr
o
lif
t™
 (
n
 =
 3
3)
 
A
ll 
p
at
ie
n
ts
 
(n
=
 1
24
) 
Ba
 im
pr
ov
em
en
t
13
 (
20
%
)
Ba
 e
qu
al
30
 (
46
%
)
Ba
 d
et
er
io
ra
ti
on
22
 (
34
%
)
D
e 
no
vo
 s
ta
ge
 ≥
II 
an
te
ri
or
 c
om
pa
rt
m
en
t
16
 (
25
%
)
C
 im
pr
ov
em
en
t
18
 (
69
%
)
45
 (
69
%
)
31
(9
4%
)
C
 e
qu
al
3 
(1
2%
)
11
 (
17
%
)
0
C
 d
et
er
io
ra
ti
on
5 
(1
9%
)
9 
(1
4%
)
2 
(6
%
)
D
e 
no
vo
 s
ta
ge
 ≥
II 
ap
ic
al
 c
om
pa
rt
m
en
t
3 
(1
2%
)
2 
(3
%
)
0
Bp
 im
pr
ov
em
en
t
3 
(1
2%
)
Bp
 e
qu
al
7 
(2
7%
)
Bp
 d
et
er
io
ra
ti
on
16
 (
62
%
)
D
e 
no
vo
 s
ta
ge
 ≥
II 
po
st
er
io
r 
co
m
pa
rt
m
en
t
12
 (
46
%
)
D
e 
no
vo
 s
ta
ge
 ≥
II 
no
n-
m
es
h 
co
m
pa
rt
m
en
t
12
 (
46
%
)*
16
 (
25
%
)*
0
28
 (
23
%
)
Ba
 m
os
t 
de
sc
en
da
nt
 p
oi
nt
 a
t 
an
te
ri
or
 v
ag
in
al
 w
al
l, 
C
 c
er
vi
x 
or
 v
ag
in
al
 a
pe
x,
 B
p 
m
os
t 
de
sc
en
da
nt
 p
oi
nt
 a
t 
po
st
er
io
r 
va
gi
na
l w
al
l 
*p
=
0.
04
, 
ch
i-
sq
ua
re
 t
es
t
39
CHAPTER 3
results after anterior Prolift™
Anatomical success at 1 year in the anterior compartment after anterior Prolift™ repair 
was 89% (Table 2). Sixteen patients (46%) had a post-operative POP stage II or III of 
the posterior compartment, of whom three patients had already undergone repeat 
surgery with a posterior Prolift™ before the 12 months follow-up visit, resulting in 
a 54% “success” rate. In Table 3, deterioration and improvement of the posterior 
vaginal wall (Bp) is shown. Twenty-six patients underwent an anterior Prolift™ 
without concomitant posterior colporrhaphy or sacrospinous fixation. In three patients 
(12%), point Bp improved with 1 cm. However, in 16 patients (62%), the posterior 
wall deteriorated (1-4 cm) and in 12 patients (46%), a de novo POP stage ≥II of the 
posterior compartment was diagnosed at the 12-month follow-up visit. 
Five patients (14%) had a post-operative POP stage II or III of the apical compartment 
resulting in 86% “success” rate (Table 2). In Table 3, it is demonstrated that in five 
patients (19%) the apical compartment deteriorated, and in three patients (12%) 
a de novo POP stage ≥II of the apical compartment was detected. These three patients 
also developed a de novo prolapse in the posterior compartment. Pre-operatively, 
there was one patient with an apical compartment POP stage III. Due to scar tissue, 
it was not possible to perform any other surgery then an isolated anterior Prolift™. 
At 12 months, the apical compartment of this patient was classified as POP stage 
II. In two patients, a pre-operative POP stage II of the apical compartment resolved 
without concomitant intervention. 
In conclusion, of the 26 patients who underwent an anterior Prolift™ without 
concomitant surgery, 12 (46%) developed a de novo POP stage ≥II in the non-mesh, 
non-treated compartment. 
Genital prolapse symptoms were evaluated with UDI domain genital prolapse 
(Table 4). In all patients that underwent an anterior Prolift™, this score improved 
significantly. However, patients that developed de novo prolapse had a significantly 
higher bother score at 12 months as compared to patients without de novo prolapse. 
results after posterior Prolift™
Anatomical success in the posterior compartment in patients who underwent an 
isolated posterior Prolift™ was 90% at 12 months (Table 2). Thirty-one patients 
(40%) had a post-operative POP stage II or III in the anterior compartment, of whom 
one patient was treated with an anterior Prolift™ before the 12-months follow-up 
visit resulting in a 60% “success” rate. 
In Table 3, deterioration and improvement of the anterior vaginal wall (Ba) is 
shown after a posterior Prolift™. Sixty-five patients underwent no concomitant 
surgery. Deterioration occurred in 35% of them. In 16 patients (25%), a de novo POP 
stage II or III of the anterior compartment was diagnosed at 12 months. 
Five patients (8%) had a POP stage ≥II of the apical compartment at 12 months. In 
only two patients (3%), this was a de novo apical prolapse. These two patients were 
also diagnosed with a de novo anterior compartment prolapse. 
In conclusion, of the 65 patients with a posterior Prolift™ without concomitant 
surgery, 16 (25%) developed a de novo POP stage ≥II in the non-mesh, non-treated 
compartment. 
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In all, patients that underwent a posterior Prolift™, the UDI score on the domain 
genital prolapse improved significantly (Table 4). Patients that developed de novo 
prolapse showed a higher bother score at 12 months as compared to patients without 
de novo prolapse. The difference, however, was not statistically significant (p=0.06). 
De novo POP after an isolated posterior Prolift™ was diagnosed less often 
compared to de novo POP after an isolated anterior Prolift™ (25% vs. 46%) (p=0.044). 
results after a combined anterior and posterior Prolift™
Anatomical success at 12 months in patients with a combined anterior and posterior 
Prolift™ procedure was 79% for the anterior compartment, 91% for the posterior 
compartment, and 76% for the apical compartment (Table 2). In Table 3, deterioration 
and improvement of the apical compartment is shown. In only two patients (6%), 
a deterioration of the apical compartment was detected, though these patients were 
still classified as having POP stage I, which, by definition, is not regarded as a failure. 
Despite an improvement in centimeters compared to baseline, however, eight patients 
(24%) were still diagnosed with POP stage ≥II of the apical compartment, of which 
table 4. UDI domain score genital prolapse at baseline and 12 months.
Baseline 12 months p value 
All prolift™ procedures
All patients (n= 127) 57.8 (32.7) 9.4 (21.2) <0.001
Patients without concomitant surgery (n= 114) 57.7 (33.4) 9.4 (21.3) <0.001
Without de novo prolapse (n= 86) 58.1 (33.8) 4.2 (14.5)* <0.001
With de novo prolapse (n= 28) 56.8 (33.7) 23.2 (31.9)* <0.001
Anterior Prolift™
Patients without concomitant surgery (n= 23) 58.7 (31.0) 18.1 (31.3) <0.001
Without de novo prolapse (n= 11) 55.6 (36.3) 0 (0)** <0.001
With de novo prolapse (n= 12) 61.1 (27.8) 32.1 (36.3)** 0.019
Posterior Prolift™
Patients without concomitant surgery (n= 59) 56.3 (34.9) 7.3 (18.4) <0.001
Without de novo prolapse (n= 43) 57.1 (34.4) 4.9 (14.6)*** <0.001
With de novo prolapse (n= 16) 53.3 (38.4) 15.6 (26.3)*** 0.001
Anterior + posterior Prolift™
Patients without concomitant surgery (n= 32) 59.4 (33.0) 7.1 (16.2) <0.001
With adequate improvement (n= 24) 52.8 (35.2) 4.2 (4.1)**** <0.001
Without adequate improvement (n= 8) 53.7 (28.8) 16.6 (19.9)**** 0.013
Scores range between 0 (least bother) to 100 (maximum bother).
Data presented as means (±standard deviation)
*p<0.001, independent sample t test 
** p=0.01, independent sample t test 
*** p=0.06, independent sample t test 
**** p=0.06, independent sample t test
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two had additional surgery within 1 year; one laparoscopic cervicosacropexy, and one 
vaginal hysterectomy with a high Mc Call procedure. In all these eight patients, it was 
the uterus that had descended, not a vaginal vault. 
In conclusion, none of the 35 patients with a combined anterior and posterior 
Prolift™ developed a de novo prolapse. However, in eight patients (24%), 
the improvement of the apical compartment prolapse was insufficient. 
In all patients that underwent an anterior+posterior Prolift™, the UDI score on 
the domain genital prolapse improved significantly (Table 4). Patients who were still 
diagnosed with POP ≥II showed a higher bother score as compared to patients with 
a POP <II. The difference, however, was not statistically significant (p=0.06). 
In summary, 28 patients (23%) who underwent a Prolift™ procedure (anterior, 
posterior or combined) were diagnosed with de novo POP stage ≥II in the untreated 
compartment, and they all had higher bother scores on the UDI domain genital 
prolapse compared to patients without de novo prolapse. Six patients (4%) had to 
undergo repeat surgery in the previously non-mesh-treated compartment within the 
first year of follow-up. 
dIscussIon
The symptomatic de novo POP rate in the non-mesh-treated compartment appeared 
to be alarmingly high, particularly after an isolated anterior Prolift™. Our de novo 
POP rate in the non-treated compartment (23%) appeared higher than previously 
reported by Raalte et al. (15.5%).3 One explanation for this difference could be that 
our study population consisted of a higher number of patients with prior prolapse 
surgery compared to the population described by Raalte et al. (63% vs. 45%).3 The 
study of Clark et al. on conventional vaginal prolapse surgery demonstrated a repeat 
surgery rate in the untreated compartment in only 5.3% of patients after 5 years, 
whereas in our study, this rate was already 4% within the first year.4 
De novo POP in the non-mesh-treated compartment was diagnosed less common 
after a posterior Prolift™ than after an anterior Prolift™ (25% vs. 46%). Previous 
studies demonstrated that restoration of DeLancey’s level I support diminishes the rate 
of anterior and posterior wall prolapse.9,10 The position of the arms of the posterior 
Prolift™ through the sacrospinous ligaments ensures level I support, which potentially 
results in less de novo POP after a posterior Prolift™ compared to an anterior Prolift™. 
A recent study, using three-dimensional models generated from magnetic resonance 
pelvic imaging in women with normal pelvic support, demonstrated that an anterior 
mesh mainly offers level II support and not enough level I support, since the upper 
part of the vagina lies well above and posterior to the distal suspension points of 
the anterior mesh.11 Since the posterior Prolift™ procedure does provide adequate 
level I support and the anterior Prolift™ mainly provides level II support, this could 
explain why we detected an almost twofold higher de novo POP rate after an isolated 
anterior compared to an isolated posterior Prolift™. 
We found no de novo POP in the apical compartment after a combined anterior 
and posterior Prolift™. However, if the uterus was left in situ, the improvement of 
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the apical compartment was still insufficient (POP stage II or III) in eight cases (24%). 
Our previously published results, after a total Prolift™ procedure with one continuous 
mesh for post-hysterectomy vaginal vault prolapse, were significantly better (failure 
rate 9%).12 In order to prevent possible descent of the uterus, the French Tension-free 
Vaginal Mesh group advised us, during the study, to remove a little part of the mesh 
at the level where this is fixated to the uterus to ensure a more adequate and, thus, 
higher suspension of the uterus. 
In the mesh-treated compartments, the success rates of 89% (95% CI 78–99) 
after an anterior mesh and 90% (95% CI 83–97) after a posterior mesh were 
comparable with other reports on Prolift™ with 1 year follow-up.3,13 In the present 
study, the number of complications was comparable as well with previous reports.3,5,13 
Although Raalte et al. reported no patients with mesh exposure, our incidence of 
mesh exposure (10%) was comparable with an exposure rate of 11% described by 
Elmer.3,13 Despite the fact that mesh exposures rarely caused severe complaints and 
could be easily excised and covered with vaginal mucosa, it remains an important 
concern for the future, since the follow-up in this study of 1 year is still relatively 
short, and the exposure rate might still rise. 
The high success rates in the mesh-treated compartments and the high rates of 
(de novo) symptomatic prolapse in the unaffected/untreated compartments could 
indicate that we have to change our surgical strategies. Urogynecologists have to 
realize that placing a mesh in one compartment can provoke or deteriorate a prolapse 
in any other compartment. It seems logical to be “more liberal” in using mesh, also, 
in none or minor affected compartments. Whether such a strategy will improve 
results without an increase in morbidity, such as mesh exposure, mesh retraction and 
dyspareunia remains to be seen. Providing adequate level I support without the use of 
more mesh is another surgical strategy, for example adding a sacrospinous hysteropexy 
or a sacrospinous fixation as a preventive measure of de novo POP to an anterior 
Prolift™ procedure. Other effective surgical alternatives are the modified Manchester 
procedure or vaginal hysterectomy with high Mc Call procedure to restore or prevent 
apical compartment prolapse and, thus, ensuring adequate level I support.14 
In our opinion, the strengths of this study are the high number of patients with 
adequate follow-up of 12 months, the prospective data collection, and the use 
of validated instruments of measurement, such as POP-Q and urogynecological 
questionnaires. A relative drawback is the lack of a control group. A control group 
with conventional non-mesh surgery might answer the question whether prolapse 
in the previously unaffected compartments is more often provoked by mesh surgery 
than by conventional surgery. 
conclusIon
Our data suggest that mesh treatment of only one vaginal compartment does provoke 
the development of POP in other initially unaffected compartments. The development 
of de novo POP stage ≥II in previously unaffected compartments is almost twice as 
high after an isolated anterior Prolift™ than after an isolated posterior Prolift™. In 
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case of a POP stage ≥II of the anterior compartment and a stage I of the posterior 
and/or apical compartment, we suggest to add level I support by a conventional 
sacrospinous hysteropexy. If there is no uterus in situ, we would suggest considering 
a total Prolift™ procedure since the results of this treatment are highly effective 
as reported earlier by us.12 We feel that patients should be counseled about this 
strategy and about the pros and cons of additional mesh surgery. They should also 
be made aware of the potential risk on secondary surgery if no additional treatment 
is performed initially. 
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absTracT
objective
To compare the de novo prolapse rate in the untreated vaginal compartments 
following conventional vaginal prolapse repair and tension free vaginal mesh repair.
design
Secondary analysis of a randomised controlled trial.
setting
13 centres in the Netherlands.
Population
Women with recurrent pelvic organ prolapse stage II or higher.
Methods
Random assignment to either conventional vaginal native tissue repair or vaginal 
mesh insertion.
Main outcome measures
Primary outcome: de novo pelvic organ prolapse stage II or higher in the untreated 
vaginal compartments at 12 months after surgery. Secondary outcomes: de novo 
pelvic organ prolapse at and beyond the hymen, de novo prolapse beyond the hymen 
and prolapse domain scores of the Urogenital Distress Inventory (UDI).
results
At 12 months ten of 59 patients (17%) in the conventional group versus 29 of 62 
patients (47%) in the mesh group were diagnosed with a de novo pelvic organ 
prolapse stage II or higher in the untreated compartment (p<0.001, odds ratio 4.3 
(95% confidence interval 1.9-10.0)). Additional apical support to a mesh-augmented 
anterior repair significantly reduced the de novo prolapse rate. Patients with a de 
novo prolapse in the mesh treated group demonstrated significantly higher mean 
bother scores on the domain genital prolapse of the UDI (13.1 ± 24.2) as compared 
to those without de novo prolapse (2.9 ± 13.9) (p=0.03).
Conclusion
Mesh-augmented prolapse repair in only one vaginal compartment is associated 
with a higher de novo prolapse rate in the untreated compartments compared to 
conventional vaginal native tissue repair in patients with recurrent pelvic organ 
prolapse. 
4PROLAPSE REPAIR AND EFFECT ON UNTREATED VAGINAL COMPARTMENTS
InTroducTIon
The rapid and widespread transition from traditional pelvic organ prolapse surgery 
using native tissue, to mesh-augmented prolapse repair aims to improve the often 
unsatisfactory outcomes after conventional pelvic organ prolapse surgery with 
native tissue.1 Several randomised controlled trials revealed improved anatomic 
outcomes and lower failure rates in the treated compartments after vaginal 
polypropylene mesh insertion when compared with traditional vaginal prolapse 
repairs.2-5 However, a previous cohort study demonstrated that treatment of only 
one vaginal compartment with mesh could provoke the development of pelvic 
organ prolapse in other initially unaffected compartments.6 The de novo pelvic 
organ prolapse rate in the non-mesh treated compartments at one year appeared 
to be high (23%), particularly after an isolated anterior mesh repair. Clark et al., 
however reported that within five years after the primary procedure only 5.3% of 
patients, who had undergone conventional prolapse surgery with native tissue, had 
undergone a prolapse repair of the compartment that appeared well-supported 
before the primary procedure.7
We conducted a secondary analysis of data from participants in a previously 
reported randomised controlled trial that compared conventional vaginal prolapse 
surgery with tension free vaginal mesh insertion in patients with recurrent pelvic 
organ prolapse in either the anterior or posterior compartment, with or without 
concomitant apical descent, to compare rates of de novo pelvic organ prolapse in 
untreated vaginal compartments.5 We hypothesised that the de novo prolapse rate 
in the non-treated vaginal compartments would be higher in the mesh treated arm 
compared to the conventional arm. Data on the anatomy of the non-treated and 
initially unaffected vaginal compartments are presented.
MeThods
This study is a secondary analysis of data from patients of a multicentre randomised 
controlled trial primarily designed to compare anatomic outcomes of the treated 
vaginal compartments in patients with recurrent pelvic organ prolapse, who were 
randomly assigned to either a conventional vaginal prolapse repair with native tissue 
or to a tension free vaginal mesh insertion with a commercially available mesh kit 
(Prolift, Ethicon, Somerville, NJ, USA).5 
Conventional vaginal prolapse repair was performed according to the guidelines 
described in that trial. The mesh procedure was performed as described by Fatton et 
al.8 Patients were included in the present analysis if they underwent treatment in the 
anterior or the posterior compartment. Additional apical compartment treatment with 
sacrospinous ligament fixation, Manchester Fothergill and vaginal hysterectomy with 
uterosacral ligament suspension was allowed. Patients who underwent simultaneous 
treatment of the anterior and posterior compartment were excluded from the present 
analysis.
Baseline evaluation consisted of a medical history and gynaecologic investigation, 
including Pelvic Organ Prolapse quantification (POP-Q) examination.9 Subjective 
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symptoms, such as bulge, were recorded with the standard urogynaecological 
questionnaire of the Dutch Pelvic Floor Society (a validated disease-specific quality 
of life questionnaire that among others contains the Urogenital Distress Inventory 
(UDI)).10 The follow-up evaluation at 12 months included POP-Q examination and the 
same validated questionnaires. 
Primary outcome of this study was the rate of de novo pelvic organ prolapse stage 
II or higher in the non-treated vaginal compartments. Secondary outcomes were de 
novo pelvic organ prolapse at and beyond the hymen, de novo prolapse beyond the 
hymen and furthermore scores in the domain of genital prolapse of the Urogenital 
Distress Inventory (UDI).
To test the present hypothesis on de novo prolapse, we performed a new power 
calculation to check whether we would have enough power to investigate this 
hypothesis. This calculation was based on the assumption of a de novo prolapse 
rate in the untreated compartment of 5% in the conventional surgery group7 and of 
23% in the Prolift group.6 Using a two-tailed hypothesis test with type I error of 5% 
and 80% power, 55 patients would be required in each group to detect a significant 
difference of at least 18% in de novo pelvic organ prolapse stage II or higher. 
Continuous variables were compared using the independent-samples t-test to 
compare means or Mann-Whitney U test to compare medians. Categorical variables 
were compared using the chi-square test and the Fisher exact test in case of small 
numbers. Related samples were compared using the paired-samples t-test to compare 
means. A p-value of <0.05 was considered statistically significant. Statistical analysis 
was performed using Statistical Package for the Social Sciences, version 15.0 (SPSS 
inc., Chicago, Ill., USA).
resulTs
In the original randomised controlled trial 194 patients were enrolled and assigned 
to either conventional vaginal prolapse repair or to trocar-guided tension free vaginal 
mesh insertion (Prolift) (Figure 1). Two patients in each arm did not undergo surgery. 
Twenty patients in the Prolift arm and 21 in the conventional arm received treatment 
in all compartments and therefore were excluded from this study. Seven and eight 
patients respectively received concomitant treatment of the anterior and posterior 
compartment and were excluded as well. Four patients in the Prolift group and nine 
patients in the conventional group did not return for follow-up at 12 months. In total 
121 patients, 59 in the conventional arm and 62 in the Prolift arm with complete 
anatomical data, were available for this analysis. 
Baseline characteristics did not differ between the two treatment arms, except 
for a higher number of previous anterior colporrhaphies in the conventional group 
(table 1). However, compared to the mesh arm, more patients of the conventional 
arm with a previous anterior colporrhaphy, received an anterior repair in this study 
once more. Therefore, there was no significant difference in the number of untreated 
anterior compartments with a previous anterior colporrhaphy between the groups 
(15 of 62 in the mesh group versus 23 of 59 in the conventional group; p=0.08). 
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figure 1. Patient enrollment and follow-up.
Perioperative and postoperative characteristics are shown in table 2. As 13 patients 
(10%) were lost to follow-up, a missing data analysis was also performed (table 3). No 
significant differences were found between responders and non-responders, except 
for the following. In the non-responder group the number of previous and present 
posterior colporrhaphies was lower (p=0.02). The number of vaginal hysterectomies 
was significantly higher in the non-responders (p<0.01) and the blood loss was 50 ml 
less in this group (p=0.03). 
the following. In the nonresponder group the number of
previous and present posterior colporrhaphies was lower
(P = 0.02). The number of vaginal hysterectomies was sig-
nificantly higher in the nonresponders (P < 0.01) and the
blood loss was 50 ml less in this group (P = 0.03).
Results after anterior repair
There were two women (13%) with de novo pelvic organ
prolapse stage II or higher in the posterior compartment
after conventional anterior prolapse repair and 13 (50%)
after an anterior Prolift repair (Table 3). Furthermore, no
incidents of de novo prolapse in the apical compartment
were seen in the conventional group and only two (8%) in
the Prolift group, of which one also had a de novo poster-
ior compartment prolapse. The total de novo pelvic organ
prolapse rate after an anterior repair in the conventional
group was 13% compared with 54% in the Prolift group
(P = 0.01). This difference remained statistically significant
when de novo prolapse was defined as ‘at or beyond the
hymen’. In case an anterior compartment repair was
combined with apical repair, there was one de novo
prolapse in the conventional group (9%) and none in the
Prolift group. In contrast with a solitary anterior Prolift
that resulted in 54% (14 of 26 women) de novo pelvic
organ prolapse, no de novo pelvic organ prolapse stage II
or higher was found in the Prolift group when this
procedure was combined with an apical repair (P = 0.02).
Results after posterior repair
The rate of de novo pelvic organ prolapse stage II or higher
was significantly lower in women who underwent a poster-
ior colporrhaphy (17%) compared with women who
underwent a posterior Prolift repair (53%) (P = 0.005).
This difference remained statistically significant when de
novo prolapse was defined as ‘at or beyond the hymen’ and
even when de novo prolapse was defined as ‘beyond the
hymen’. Nine women in the conventional group underwent
a posterior colporrhaphy combined with an apical repair of
which 3 (33%) developed a de novo prolapse in the ante-
rior compartment.
194 patients included
Prolift™
n = 95
Conventional vaginal surgery
n = 99
Underwent Prolift™ repair: n = 93
Refused surgery because of domestic problems: n = 2
Underwent conventional vaginal repair: n = 97
Died before surgery: n = 1
Refused surgery a�er ablatio retinae: n = 1
Completed 12 months POP-Q follow-up: n = 62
Completed 12 months POP-Q and questionnaire: n = 56
Lost to follow-up: n = 4
Completed 12 months POP-Q follow-up: n = 59
Completed 12 months POP-Q and questionnaire: n = 54
Lost to follow-up: n = 9
Treatment in all compartments
(total Proli�): n = 20
Treatment in all
compartments: n = 21
Completed POP-Q at baseline: n = 66
Completed questionnaire at baseline: n = 56
Completed POP-Q at baseline: n = 68
Completed questionnaire at baseline: n = 63
Treatment in anterior and
posterior compartment n = 7
Treatment in anterior and
posterior compartment n = 8
Figure 1. Enrolment and follow up of women in the study.
Withagen et al.
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results after anterior repair
There were two cases (13%) of de novo pelvic organ prolapse stage II or higher in the 
posterior compartment after conventional anterior prolapse repair and 13 (50%) after 
an anterior Prolift repair (table 4). Furthermore, no cases of de novo prolapse in the 
apical compartment were seen in the conventional group and two cases (8%) in the 
Prolift group, of which one also had a de novo posterior compartment prolapse. The 
total de novo pelvic organ prolapse rate after an anterior repair in the conventional 
table 1. Patient characteristics
Conventional 
(n=59) Prolift (n=62) p-value
Age, median (range), years 63 (37-87) 62 (36-84) 0.63
Parity, median (range) 2 (1-4) 2 (0-5) 0.82
BMI, median (range), kg/m2 27 (18-37) 26 (21-40) 0.75
Comorbidity, No. (%) 30 (51%) 27 (44%) 0.42
Previous  surgery, No. (%) 59 (100%) 62 (100%) 0.99
Abdominal hysterectomy 9 (15%) 15 (24%) 0.22
Vaginal hysterectomy 38 (64%) 34 (55%) 0.28
Anterior colporraphy 41 (69%) 32 (52%) 0.04
Posterior colporrhaphy 40 (68%) 35 (56%) 0.20
Sacrospinous ligament fixation 0 (0%) 3 (5%) 0.25*
Sacrocolpopexy 5 (8%) 12 (19%) 0.12*
One prolapse procedure 45 (76%) 53 (85%) 0.32
More than one 14 (24%) 9 (15%) 0.32
Previous incontinence surgery, No. (%) 10 (17%) 18 (29%) 0.12
Overall POP-stage, No. (%)
II 31 (53%) 32 (52%) 0.99
III 26 (44%) 28 (45%) 0.99
IV 2 (3%) 2 (3%) 0.38
POP stage in untreated anterior compartment, No.(%) (n=33) (n=30)
0 13 (39%) 14 (47%) 0.56
I 15 (46%) 11 (36%) 0.50
II 4 (12%) 5 (17%) 0.25*
III 1 (3%) 0 (0%) 0.52*
POP stage in untreated posterior compartment, No(%) (n=26) (n=32)
0 11 (42%) 17 (53%) 0.41
I 10 (39%) 14 (44%) 0.68
II 4 (15%) 1 (3%) 0.10*
III 1 (4%) 0 (0%) 0.44*
POP stage in untreated apical compartment, No(%) (n=39) (n=56)
0 38 (97%) 53 (95%) 0.34*
I 1 (3%) 3 (5%) 0.34*
* Fisher exact test
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table 2. Peri- and post-operative data.
Conventional (n=59) Prolift (n=62) p-value
Anterior Prolift, No. (%) 0 (0%) 32 (52%)
Posterior Prolift, No. (%) 0 (0%) 30 (48%)
(Concomitant) surgery, No. (%) - 7 (11%)
Vaginal hysterectomy +Mc Call 3 (5%) 0 (0%)
Anterior colporraphy 26 (44%) 0 (0%)
Posterior colporraphy 33 (56%) 0 (0%)
Manchester Fothergill 2 (3%) 1 (2%)
Enterocele repair 6 (10%) 0 (0%)
Monarc/tvt/tvt-o 1 (16%) 2 (3%)
Sacrospinous ligament fixation 13 (22%) 5 (8%)
Spinal analgesia, No. (%) 43 (74%) 41 (66%) 0.37
General analgesia, No. (%) 16 (26%) 21 (34%) 0.37
Operating time, median (range),minutes 40 (16-90) 50 (29-125) 0.002
Blood loss, median (range) (ml) 88 (0-400) 100 (0-400) 0.38
Hospital stay, median (range), days 3 (2-13) 3 (2-15) 0.94
Complications, No.(%)
- temporary urinary retention 3 (5%) 6 (10%) 0.49*
- cumulative mesh exposure at 12 months - 8 (13%) 0.004*
 * Fisher exact test
group was 13% compared to 54% in the Prolift group (p=0.01). This difference 
remained statistical significant when de novo prolapse was defined as “at or beyond 
the hymen”. In case an anterior compartment repair was combined with apical repair, 
there was one de novo prolapse in the conventional group (9%) and none in the 
Prolift group. In contrast with a solitary anterior Prolift that resulted in 54% (14 of 
26 patients) de novo pelvic organ prolapse, no de novo pelvic organ prolapse stage II 
or higher was found in the Prolift group when this procedure was combined with an 
apical repair (p=0.02).
results after posterior repair
The rate of de novo pelvic organ prolapse stage II or higher was significantly lower 
in women who underwent a posterior colporrhaphy (17%) compared to women 
who underwent a posterior Prolift repair (53%)(p=0.005). This difference remained 
statistically significant when de novo prolapse was defined as “at or beyond the 
hymen” and even when de novo prolapse was defined as “beyond the hymen”. Nine 
patients in the conventional group underwent a posterior colporrhaphy combined 
with an apical repair of which three (33%) developed a de novo prolapse in the 
anterior compartment.
In summary, ten of 59 patients (17%) who underwent conventional vaginal 
pelvic organ prolapse surgery with native tissue were diagnosed with a de novo 
pelvic organ prolapse stage II or more in the untreated compartment. Whereas, 29 
of 62 patients (47%) who underwent pelvic organ prolapse surgery with a Prolift 
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table 3. Missing data analysis.
responders 
(n=121)
non-responders 
(n=13) p-value
Age, mean (SD), years 62 (36-87) 63 (40-86) 0.79
Parity, median (range) 2 (0-5) 2 (0-3) 0.07
BMI, mean (SD), kg/m2 26 (18-40) 27 (21-34) 0.64
Comorbidity, No. (%) 57 (47%) 5 (39%) 0.77*
Previous surgery, No. (%)
Abdominal hysterectomy 24 (20%) 3 (23%) 0.73*
Vaginal hysterectomy 72 (59%) 8 (62%) 0.89
Anterior colporraphy 73 (60%) 11 (85%) 0.09
Posterior colporrhaphy 75 (62%) 3 (23%) 0.02*
Sacrospinous ligament fixation 3 (3%) 0 (0%) 0.99*
Sacrocolpopexy 17 (14%) 1 (8%) 0.99*
One prolapse procedure 98 (81%) 13 (100%) 0.23*
Previous incontinence surgery, No. (%) 27 (22%) 1 (8%) 0.16*
Overall POP-stage, No. (%) 0.70
II 63 (52%) 6 (46%)
III 54 (45%) 7 (54%)
IV 4 (3%) 0 (0%)
Anterior Prolift, No. (%) 32 (26%) 2 (15%) 0.20*
Posterior Prolift, No. (%) 30 (25%) 2 (15%) 0.10*
Prolift with concomitant surgery, No. (%) 7 (6%) 0 (0%) 0.48*
Anterior colporrhaphy, No. (%) 26 (21%) 3 (23%) 0.27*
Posterior colporrhaphy, No. (%) 33 (27%) 0 (0%) 0.02*
Manchester Fothergill, No. (%) 3 (2%) 0 (0%) 0.73*
Vaginal hysterectomy with uterosacral vaginal 
suspension, No. (%)
3 (2%) 4 (31%) <0.01*
Sacrospinous ligament fixation, No. (%) 18 (15%) 0 (0%) 0.14*
Operating time, median (range), minutes 45 (16-125) 40 (20-75) 0.21
Blood loss, median (range), ml 100 (0-400) 50 (50-100) 0.03
Hospital stay, median (range), days 3 (2-15) 3 (2-6) 0.14
Temporary urinary retention, No. (%) 9 (8%) 0 (0%) 0.60*
Conventional vaginal prolapse surgery, No.(%) 59 (49%) 9 (69%) 0.24*
* Fisher exact test
mesh kit were diagnosed with a de novo pelvic organ prolapse stage II or more 
in the untreated compartment (p=0.001, odds ratio 4.3 (95% confidence interval 
1.9-10.0), relative risk 2.8 (95% confidence interval 1.5-5.2) ). The difference in de 
novo pelvic organ prolapse rate remained significant even if all lost to follow-up-
patients were considered to have developed a de novo pelvic organ prolapse (19 
of 68 (28%) in the conventional group versus 33 of 66 (50%) in the Prolift group, 
p=0.009). When the definition “at or beyond the hymen” or “beyond the hymen” 
was used, de novo prolapse was still significantly more often diagnosed in patients 
who underwent pelvic organ prolapse surgery with a mesh kit. One patient in the 
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conventional group and six patients (10%) in the Prolift group underwent surgery in 
the initially unaffected and thus non-treated compartments within the first year of 
follow-up (p=0.06). 
In table 5 the UDI scores of the domain ‘genital prolapse’ are presented. In both 
groups there was a significant improvement in domain scores at 12 months follow-
up. There were no differences in domain scores between the conventional and the 
Prolift group at baseline nor at 12 months follow-up. The mean domain score in 
the conventional group with de novo prolapse was 0 at 12 months. All of these 
patients had a de novo prolapse with the most descendant point of prolapse at or 
1 cm proximal of the hymen (0 or- 1 cm). The mean domain score of patients in the 
Prolift group that had developed a de novo prolapse (13.1 (SD 24.2)) was significantly 
higher than the mean score of patients without de novo prolapse in the Prolift group 
(2.9 (SD 13.9)) (p=0.03). 
dIscussIon
The data of this study confirm our hypothesis that reinforcement of the vaginal wall 
with polypropylene mesh in a single vaginal compartment can provoke a symptomatic 
de novo pelvic organ prolapse in the non-treated compartment. Forty-seven percent 
of patients with a mesh-augmented repair in only one compartment developed a 
de novo pelvic organ prolapse stage II or higher in the untreated compartment, 
compared to only 17% of patients undergoing a conventional pelvic organ prolapse 
repair with native tissue. When the definition of de novo prolapse was changed into 
“prolapse at or beyond the hymen” or “prolapse beyond the hymen” this difference 
became smaller but remained statistically significant. 
The strengths of this study are its clinical relevance and the use of validated 
instruments of measurement, such as POPQ and the Urogenital Distress Inventory. 
However, this study was subject to several limitations as well. The study is a secondary 
analysis of a randomised controlled trial and therefore a lot of the original data were 
excluded, since treatment in both the anterior and posterior compartment would 
bias interpretation of the data. Therefore the analysis of subgroups is often on fairly 
small numbers. Furthermore, no attempt was undertaken to avoid the surgeons’ 
potential bias during follow-up visits. Ideally, these should have been performed by 
an investigator blinded to the procedure.
The overall de novo pelvic organ prolapse stage II or higher of 47% in the non-
treated compartments in women with mesh-augmented repair is high compared to 
the rates of de novo POP stage II or higher of 15.5% and 23% reported in previous 
studies.6,11 In the study of Raalte et al. women with primary as well as recurrent 
pelvic organ prolapse were included and the follow-up rate in this study was only 
64%, which may have caused a significant bias. In a recent study with dynamic 
MRI a much higher rate of de novo prolapse of 73% (11 of 15) was observed in the 
untreated compartments three months following pelvic organ prolapse repair with 
polypropylene mesh.12 
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The exact aetiology of the higher rate of de novo pelvic organ prolapse in women 
treated with vaginal mesh is not fully understood. We hypothesise that insertion 
of polypropylene mesh in one compartment of the vagina causes such a vigorous 
support that it may be responsible for a supraphysiological reduction of prolapse and 
causes elevation as seen after a colposuspension and after a sacrospinous fixation. 
As a result, the vaginal wall of the non-treated compartment becomes less supported 
by the opposite vaginal wall. Consequently the forces on the pelvic floor are then 
transmitted to the least consolidated vaginal compartment and we believe that 
the risk of a de novo prolapse or aggravation of an initially minor prolapse in the 
untreated compartment can thus be explained. Conventional vaginal prolapse repair 
with native tissue does cause a less pronounced reduction of prolapse in the treated 
compartments. When vaginal compartments are unequally supported, it is obvious 
that the least supported vaginal compartment will then be the compartment most 
susceptible for de novo or recurrent prolapse.
The high success rates in the mesh-treated compartments and the high rates 
of (de novo) symptomatic prolapse in the initially unaffected and thus untreated 
compartments indicate that we may have to reconsider our surgical strategies. 
Urogynaecologic surgeons should realize that insertion of mesh in one compartment 
may provoke or deteriorate a prolapse in the opposite compartment. To prevent the 
development of a de novo pelvic organ prolapse, adequate level I support13 seems 
crucial, since none of the patients that underwent an anterior Prolift combined with 
a sacrospinous ligament fixation or modified Manchester-Fothergill had developed 
a de novo pelvic organ prolapse. Previously Lowder et al. also demonstrated the 
critical role of level I vaginal support on the position of the anterior and posterior 
vagina.14 Simulating apical support during the preoperative evaluation could help 
in determining the indication for apical support during surgery and in this probably 
decreases the chance of prolapse recurrence and de novo prolapse. 
conclusIon
Mesh-augmented repair of pelvic organ prolapse in only one compartment leads 
to a significantly higher percentage of clinically relevant de novo prolapse of the 
untreated vaginal compartment, as compared to conventional vaginal prolapse 
surgery with native tissue in only one compartment. Clinicians should be aware of 
this phenomenon when planning and counselling a patient on surgical correction of 
pelvic organ prolapse. However, we strongly discourage any preventive use of mesh 
in unaffected compartments, since long-term effects and complications of vaginal 
mesh are not yet fully known.
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absTracT
objectives
To compare one-year conventional and composite outcomes of trocar-guided vaginal 
mesh surgery and identification of predictors of failure. 
study design
Prospective observational Cohort study. Failure outcome definitions were: I; prolapse 
stage > II in mesh treated compartments, II; overall prolapse stage > II, III; composite 
outcome of overall prolapse > hymen and presence of bulge symptoms or re-surgery. 
Logistic regression to identify predictors of failure.
results
One-year follow-up of 433 patients. Treated compartment failure (I): 15% (95% CI 
12-19). Overall prolapse failure(II): 41% (95% CI 36-45). Composite failure (III): 9% 
(95% CI 7-13). Predictor of failure in all outcomes: combined anterior/posterior mesh 
with the uterus in situ. 
Conclusion 
Outcome of prolapse surgery depends on outcome definition. The mesh treated 
compartment failure outcome (I) and the composite failure outcome (III) appeared 
not to be statistically different. Consistent factor for failure in all outcomes was the 
combined anterior/posterior mesh insertion with the uterus in situ.
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InTroducTIon
Pelvic Organ Prolapse (POP) may occur in up to 50% of parous women.1 The lifetime 
risk of undergoing surgery for POP in the general female population to the age 
of 85 has recently been reported to be as high as 19-20%.2, 3 This high likelihood 
of undergoing surgery for POP combined with the knowledge of anatomic failure 
rates for native tissue repairs that range between 30-70% for the anterior vaginal 
wall and around 20% for the posterior vaginal wall, have led to the increased 
use of prosthetic mesh in vaginal prolapse surgery with the main aim to reduce 
anatomic failure rates and increase the durability of repairs.4-9 Most studies have 
used strict anatomic outcome criteria as proposed by the National Institutes of Health 
(NIH) Workshop on Standardization of Terminology for Researchers in Pelvic Floor 
Disorders in 2001, and only used patient reported outcomes as a secondary outcome 
measure.10, 11 But recently Barber et al have demonstrated that the postoperative 
absence of vaginal bulge symptoms had a significant relationship with a patient’s 
assessment of  overall improvement, while anatomic success alone did not.12 The 
authors therefore suggested that any future definition of success of POP surgery 
should include the absence of bulge symptoms in addition to anatomic criteria and 
the absence of re-treatment. The authors agreed with Swift et al that the hymen 
should thereby be regarded as the threshold for anatomic success.12, 13
The primary objective of this study was to compare one-year outcomes of a large 
cohort of patients that underwent trocar-guided tension-free vaginal mesh surgery 
(ProliftTM, Ethicon, Somerville, NJ, USA) according to the conventional NIH Workshop 
criteria with the newly suggested composite outcome of Barber et al.12 The second 
objective was to identify possible predictors of failure for these outcomes. 
MaTerIals and MeThods
This prospective observational cohort study is part of an ongoing outcome quality 
registration project of Radboud University Medical Centre the Netherlands, which 
has been approved by CMO Arnhem-Nijmegen, April 2006. The present analysis 
includes 12-month follow-up data of consecutively performed trocar-guided tension-
-free vaginal mesh procedures (Prolift, Ethicon) between September 2005 and April 
2010. Details of 150 patients in this cohort have previously been reported in a study 
focusing on de novo prolapse in untreated vaginal compartments, and 93 were 
part of a randomized controlled trial, comparing mesh with native tissue repair in 
recurrent prolapse.8, 14
Inclusion criteria were increased risk of recurrence, which was considered recurrent 
pelvic organ prolapse stage II or higher or primary pelvic organ prolapse stage III or 
higher.8, 15, 16 Exclusion criteria were (contemplating) pregnancy or a compromised 
immune system.
Surgery was performed by17 gynecologists in 13 collaborating centers. The range 
of procedures varied from 1 to 209 (mean: 25, median: 3). Four performed more 
than 25 procedures. All gynecologists were trained for the tension-free vaginal mesh 
procedure as described by Fatton et al.17 Depending on the prolapsed compartment, 
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mesh insertion could be anterior, posterior, anterior and posterior (in case of uterus 
or cervix in situ), or total (in case of a prolapsed vaginal vault). 
Concomitant native tissue repairs were allowed for other less prolapsed 
compartments or compartments that were not at increased risk of recurrence. To 
reduce the risk of mesh exposure, simultaneous hysterectomy or T-incisions were 
avoided.18 For most of the participating centers it was policy not to simultaneously 
insert a mid urethral sling because of anticipated increased risk on postoperative 
urinary retention.19 Patients were counseled on this strategy and the possibility 
of a second procedure. In case the presence of stress urinary incontinence post-
surgery necessitated the insertion of a mid urethral sling, this was not considered 
a re-intervention for POP and thus not registered as failure; on the other hand the 
symptomatic recurrence of POP that necessitated re-surgery was a re-intervention for 
POP and thus counted as a failure.
All procedures were performed under peri-operative antibiotic prophylaxis. Patients 
received an indwelling catheter for 1to 2 days and a vaginal gauze pack for 24 hours.
Postoperative urinary retention was defined as repeated post-void residual volume 
> 100 mls measured with a bladder scanner. De novo stress urinary incontinence was 
considered significant if a patient responded yes; ‘moderately to quite a bit’ to the 
question: ‘do you experience urinary leakage during physical activity, coughing or 
sneezing?’ 
The mesh used in the original trocar-guided Mesh procedure is monofilament 
polypropylene mesh, weighing 45 gr/m2. In 2009 some centers started using a partially 
absorbable mesh, consisting of a fifty-fifty blend of monofilament non-absorbable 
polypropylene and absorbable polyglecaprone 25 (Prolift+M, Ethicon). The technique 
is identical, but the mesh weighs 57 gr/m2 before absorption and after full absorption 
after 90-120 days only 31 gr/m.2,20 
Baseline evaluation included medical history and assessment of POP by using the 
Pelvic organ Prolapse Quantification (POP-Q) System.11 Data on symptoms and bother 
were obtained by the standard Dutch urogynecological questionnaire, which among 
others contains the Dutch validated version of the Urogenital Distress Inventory (UDI).21 
Follow-up visits were scheduled at 6 weeks, 6 and 12 months. At 12 months a 
POP-Q examination was performed and patients were again requested to complete the 
standard urogynecological questionnaire.
Failure outcomes were defined as follows: 
1. NIH failure mesh treated compartment; POP stage > II of mesh treated vaginal 
compartment(s) or re-surgery for POP in mesh treated compartments within 12 
months.
2. NIH failure overall POP; leading edge of prolapse in any compartment stage > II 
or re-surgery for POP in any compartment within 12 months.
3. Composite outcome failure; leading edge of any compartment > hymen and 
presence of bulge symptoms or re-surgery for POP within 12 months.12
‘Presence of bulge symptoms’ was defined clinically significant if a patient responded 
yes; ‘moderately to quite a bit’ to either of two questions: ‘do you see or do you feel 
a vaginal bulge?’21 
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To determine the minimum sample size we anticipated on a 90% success rate 
for the mesh treated compartments.8, 22, 23 We considered treatment successful if the 
one-sided 95% confidence interval (CI) did not fall below 85%. This resulted in a 
minimum number of 282 patients that were necessary for inclusion in this study. 
Results are summarized as numbers with corresponding percentages or as medians 
with range. Primary outcomes were failure percentages with 95% confidence 
intervals per pre-defined outcome definition. Univariable logistic regression was used 
to identify possible risk factors of failure in each of the outcomes. Considered risk 
factors were patient’s age, menopause, previous POP repair(s), parity, pre-operative 
POP stage, Body Mass Index, location of mesh insertion, the use of the new partially 
absorbable mesh, mesh combined with native tissue repairs, mesh combined with 
sacrospinous fixation, the presence of the uterus, operating time, blood loss, 
complications and mesh exposure. 
Crude Odds ratios (OR) for the possible risk factors of failure for each outcome were 
calculated with corresponding 90% confidence intervals (CI). To optimize the validity of 
the logistic model, restriction of the number of test variables was necessary.24 To ensure 
that the number of events per variable (EPV) did not drop below 10, only the allowed 
number of the most significant variables was selected for entry in the multivariable 
model. Multivariable logistic regression with forward selection was used to identify 
those variables that were independently related to failure in each of the outcomes. 
Variables reaching statistical significance at the P<0.10 level in the univariable analysis 
were considered valid for entry in the forward selection model. The adjusted OR with 
95% CI are presented. A P value of <0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS 18.0 for Windows.
resulTs 
Four hundred and thirty-three women met the inclusion criteria for trocar-guided 
mesh surgery and were included. Four hundred and nineteen (97%) completed 
the 12-month follow up. Baseline characteristics and preoperative POP stage are 
presented in table 1. Median age of patients was 64 (range 16-93). Seventy-two 
percent of patients had a recurrent POP and 67% a POP stage ≥ Stage III.
Table 2 shows peri- and postoperative data. Eighteen percent of patients (77) 
underwent surgery with a partially absorbable mesh. According to the 12-month 
follow-up questionnaire 38 of 280 (13.6%) patients were classified having de novo 
stress urinary incontinence.
Table 3 shows failure rates per location of mesh insertion for all pre-defined 
outcomes. NIH failure of the mesh treated compartments POP stage ≥ II was 15% 
(95% CI 12-19). NIH failure overall POP stage ≥ II was 41% (95% CI 36-45) and 
composite failure was 9% (95% CI 7-13). Re-surgery was performed in 18 of 433 
(4%) patients, of which sixteen (89%) in the untreated vaginal compartments. 
Highest failure rates were observed for combined anterior/posterior mesh insertions.
Table 4 shows crude Odds ratios with 90% confidence intervals per outcome 
definition for each of the tested variables. Variables that reached statistical 
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table 1. Baseline characteristics.
total n (%) or median (range)
Age, years 433 64 (16-93)
BMI, kg/m2 320 25.6 (18.9-41.8)
Menopause 396 348 (88)
Parity (number) 367 2 (0-7)
Previous POP repair 425 307 (72)
Pelvic organ prolapse
 Stage 0 429 0 (0)
 Stage I 429 0 (0)
 Stage II 429 141 (33)
 Stage III 429 266 (62)
 Stage IV 429 22 (5)
POP = pelvic organ prolapse.
table 2. Peri- and post-operative data.
total n (%) or median (range)
Location tension-free vaginal mesh
 Anterior 433 116 (27)
 Posterior 433 152 (35)
 Anterior and posterior 433 64 (15)
 Total 433 100 (23)
Partially absorbable mesh 433 77 (18)
Mesh procedure combined with native tissue POP 
repair (‘Mesh combined’)
432 83 (19)
 Sacrospinous ligament fixation 432 26 (6)
 Modified Manchester procedure 432 3 (1)
 Anterior colporrhaphy 432 17 (4)
 Posterior colporrhaphy 432 18 (4)
 Perineal repair 432 9 (2)
 Enterocele repair 432 10 (2)
 Mid-urethral sling 432 5 (1)
Operating time (min) 417 60 (20-150)
Blood loss (ml) 412 100 (0-1300)
Complications*
 Rectal serosa lesion 423 2 (0)
 Bladder injury 423 10 (2)
 Urinary retention 423 34 (8)
 Blood loss > 500 ml 412 4 (1)
 Postoperative hematoma 432 22 (5)
 Any complication 432 66 (15)
Mesh exposure within 12 months 425 54 (13)
POP = pelvic organ prolapse. * Multiple diagnoses possible.
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significance at the P<0.10 level (shown in bold) were considered valid for entry in the 
multivariable logistic regression model. Since outcome I resulted in just 64 failures, 
we only selected 7 of the 9 most significant variables for entry in the multivariable 
regression model.24
Table 5 shows adjusted Odds ratios after multivariable logistic regression analysis. 
For NIH outcome II (overall POP ≥ stage II), stage of prolapse ≥ III and a solitary 
mesh, be it anterior or posterior, significantly increased the risk of failure. A combined 
anterior/posterior mesh with the uterus in situ appeared to be independently 
associated to failure in all outcomes. Of 35 patients that were diagnosed with a 
composite outcome failure, 9 had undergone a combined anterior/posterior mesh 
insertion. Seven of these 9 (78%) patients had a symptomatic descent of the cervix/
uterus at 12-months; 4 were operated before the 12-months and underwent vaginal 
hysterectomy with a McCall procedure, and one an abdominal sacrocolpopexy. One 
patient was operated beyond the one-year follow-up, but had point C diagnosed at 
+5 cm at 12-months. 
The use of the partially absorbable mesh appeared only to be independently 
related to NIH failure of the treated compartment.
table 3. Failure outcomes at 12 months.
total n Percentage 95% Ci
I. NIH failure of mesh treated compartment POP stage > 
II or re-surgery 
415 64 15 (12-19)
 Anterior mesh only 112 20 18 (11-26)
 Posterior mesh only 146 9 6 (3-11)
 Anterior and posterior mesh 62 21 34 (22-47)
 Total mesh 94 14 15 (8-24)
II. NIH failure: overall POP stage > II or re-surgery 419 170 41 (36-45)
 Anterior mesh only 113 60 53 (43-63)
 Posterior mesh only 148 66 45 (36-53)
 Anterior and posterior mesh 62 30 48 (36-61)
 Total mesh 94 14 15 (8-24)
III. Composite failure: overall POP > hymen and bulge 
symptoms or re-surgery 
380 35 9 (7-13)
 Anterior mesh only 106 11 10 (5-18)
 Posterior mesh only 127 13 10 (6-17)
 Anterior and posterior mesh 58 9 16 (7-27)
 Total mesh 87 2 2 (0-8)
Re-surgery 433 18 4 (2-6)
 Mesh treated compartment 18 2 11 (1-35)
 Untreated compartment 18 16 89 (65-99)
Vaginal bulge symptoms 370 43 12 (9-15)
Data in bold are overall percentages with 95% CI per predefined outcome variable.
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coMMenT 
Failure rates are highly dependent on outcome definition. The composite outcome 
showed the lowest failure rate, but appeared not to be significantly different from the 
NIH outcome of the mesh treated compartments (9%, 95% CI 7-13 vs. 15%, 95% CI 
12-19). With 41% (95% CI 36-45) the NIH outcome II (leading edge of any prolapsed 
compartment stage ≥ II) showed the highest failure rate. Stage of prolapse ≥ III was 
predictive for failure in NIH outcome II. Predictor of failure for all of the outcomes was 
the location of mesh insertion. Particularly a combined anterior/posterior mesh with 
the uterus or cervix in situ increased the risk of failure in all outcomes. 
One of the weaknesses of this study is that an examiner at the 12-month 
follow-up was not blinded. Use of unblinded POP-Q staging might underestimate 
overall recurrences.25 Another drawback is the relatively short follow-up period of 12 
months. Strengths on the other hand were the use of validated tools of measurement, 
such as POP-Q and validated questionnaires to objectify symptoms and bother.11, 21 
Further strengths are the study’s prospective data registry and large sample size. 
This study clearly demonstrates the importance of the outcome definition when 
reporting results of POP surgery. Although it seems logical to focus on the outcome 
in mesh treated vaginal compartment(s), this blurs overall anatomic outcomes as is 
demonstrated and by others.12, 26 Focusing on anatomic criteria only, easily verifiable 
to the physician, does ignore a patient’s perception of symptoms, for which she 
primarily had sought relief.  Chmielewski et al have reanalyzed data of a randomized 
trial of three techniques of anterior colporrhaphy and revealed considerably better 
success with the use of this clinically relevant composite outcome compared with 
strict anatomic criteria.26 These authors also stated that there is a considerable 
portion of women who receive routine gynecologic care that have a POP stage II on 
straining and would therefore not meet the NIH Workshop criteria of a ‘satisfactory’ 
treatment result.10, 27, 28 This is comparable with data from a large Dutch cross 
sectional study among community dwelling women, that revealed that of women 
aged between 45 and 85 years, 36,5% were diagnosed with a stage I and 33% with 
a stage II prolapse, of whom only 6,9% of women with stage I and 15,8% of those 
with stage II experienced vaginal bulge symptoms as opposed to 43,3% of women 
with stage III and 100% of those with stage IV prolapse.29 A large proportion of 
women with stage II prolapse is thus asymptomatic and should be considered to have 
‘physiological’ pelvic organ support. We therefore strongly agree with Barber et al 
that their suggested composite outcome of success, whereby the hymen is regarded 
as threshold for anatomic success and the absence of bulge symptoms as patients 
reported sign of symptom relief, is the most realistic outcome for prolapse surgery 
and should be the outcome of choice in future studies.12 In this analysis we have used 
a composite failure outcome. Since we were particularly interested in patients with 
prolapse beyond the hymen that was symptomatic, the inclusion of bulge symptoms 
in our definition of composite failure was obligatory. 
The large difference in outcome of the mesh treated compartments and overall 
POP, seems to be due to the effect that the treatment of only one vaginal compartment 
can have on the remaining non-treated compartments as was demonstrated in 
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earlier work of us and other studies.12, 14, 26 This finding is emphasized by the overall 
re-surgery rate of 4% (18 out of 433 patients), of which only 11% (2 out of 18 patients) 
were re-interventions in the mesh treated vaginal compartment, but the vast majority 
of 89% (16 out of 18 patients) in the non-treated vaginal compartments. These 
results are comparable with data of a recently published retrospective French study 
on 524 patients, of whom 3% underwent repeat surgery for prolapse recurrence, 
in particular of the untreated vaginal compartments.30 The odds ratios for overall 
failure stage ≥ II after solitary mesh insertions were high and significant (table 5). 
In an earlier study on 150 mesh treated patients we demonstrated that 46% of 
patients after solitary anterior mesh, and 25% after solitary posterior mesh insertion 
developed de novo prolapse stage II or more in the previously unaffected vaginal 
compartments.14 It was recently demonstrated that mesh insertion compared with a 
native tissue repair of only one vaginal compartment is responsible for a greater risk of 
de novo prolapse in other untreated vaginal compartments.31 This secondary analysis 
of a randomized controlled trial, that compared mesh with native tissue repair in 
patients with recurrent prolapse, revealed that 47% of women that underwent mesh 
insertion in only one vaginal compartment developed a de novo prolapse in untreated 
vaginal compartments, compared to only 17% of women after native tissue repair of 
only one vaginal compartment. These data indicate that we have to reconsider our 
surgical strategies when using mesh in only one vaginal compartment. 
In contrast with a solitary posterior mesh, a solitary anterior mesh was no risk 
factor for failure in the composite outcome. Apical suspension is considered crucial 
in prolapse surgery.32 A solitary posterior mesh has the advantage of additional apical 
support by its bilateral sacrospinous suspension. It is well known that sacrospinous 
ligament fixation facilitates anterior vaginal walls to descent.33 We hypothesize, 
that a solitary posterior mesh, by its strong reduction of prolapse enhances the 
effect that sacrospinous ligament fixations already have on the anterior vaginal 
wall. This may contribute to a greater and consequently symptomatic descent of 
the anterior vaginal wall. 
The combination of an anterior/posterior mesh with the uterus or cervix in situ 
appeared independently associated to failure in all outcomes. Multivariable regression 
analysis clearly showed that it was not the single fact of the uterus being in situ, 
but the combination of an anterior/posterior mesh with the presence of the uterus 
that appeared independently associated to failure. Alternative treatment for this 
simultaneous mesh insertion and fixation to the uterus could be a single anterior mesh 
combined with a sacrospinous hysteropexy. Concomitant midline fascial plication of 
the posterior vaginal will adequately treat any prolapsed posterior compartment, if 
necessary.9, 34 This strategy offers the advantage of reduced mesh usage, particularly 
since the evidence for the use of mesh in the posterior compartment is still limited.1 
Another approach to the combined anterior/posterior mesh insertion with pronounced 
uterine descent would be supracervical laparoscopic sacrocolpopexy.35 
The use of the partially absorbable mesh was only independently related to failure 
in the NIH treated compartment outcome, but to none of the others. The use of this 
lighter weight mesh has potential advantages over the heavier-weight original mesh 
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and might be responsible for lesser mesh contraction, less pelvic pain and de novo 
dyspareunia.20 However, the evidence that the use of this partially absorbable mesh 
is superior to native tissue repair surgery still has to be delivered by well-designed 
controlled clinical trials. 
Complication rates in this cohort were comparable with other large studies using 
this mesh.4, 36, 37 Mesh exposure rate in this series was 13%. It has recently been 
reported that most of these mesh exposures are asymptomatic and that two thirds of 
these resolve after minor surgery. It has also been demonstrated that the experience 
of the surgeon has a protective effect on the risk of mesh exposure.38
Recently a FDA Public Health Notification update informed the public in the 
United States on the potential serious complications of trans-vaginal mesh surgery 
and gave recommendations, among which, proper training of the surgeon was one.39 
We therefore believe that only experienced surgeons who are capable of treating an 
adequate volume of patients should be allowed to perform this vaginal mesh surgery. 
The finding that experience of the surgeon diminishes the risk of complications 
supports this statement.30, 38 Future research should focus on surgeons’ experience 
as a potential risk factor for failure; this might give insight into the learning curve 
aspects of vaginal mesh surgery.
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absTracT
objective
To identify possible risk factors for exposure, dyspareunia, and pain after insertion of 
tension-free vaginal mesh in pelvic organ prolapse surgery.
Methods
This was a prospective observational cohort study. Consecutive women who 
underwent surgery with a trocar-guided tension-free vaginal mesh kit were included 
and evaluated at 6 weeks and at 6 and 12 months after surgery with respect to 
anatomy and complications. Logistic regression analysis was performed to identify 
risk factors for exposure, dyspareunia, and pain.
results
Two hundred ninety-four patients were included. Exposure was found in 34 patients 
(12%). Smoking and total mesh were risk factors for exposure (odds ratio [OR] 3.1, 
95% confidence interval [CI] 1.1– 8.7 and OR 3.0, 95% CI 1.2–7.0, respectively). 
Clinical and surgical experience were inversely related to the risk of exposure (OR 0.5, 
95% CI 0.3– 0.8 per decade). Pain (OR 3.2, 95% CI 1.2– 8.4) and dyspareunia (OR 
4.7, 95% CI 1.7–12.8) before surgery were predictive for pain and dyspareunia after 
surgery, respectively. Pain after surgery was found in 35 out of 275 (13%) patients 
and dyspareunia was found in 77 out of 171 (45%) patients.
Conclusion
Smoking, total tension-free vaginal mesh, and  experience were predictive factors for 
mesh exposure.
 
InTroducTIon
Pelvic organ prolapse is a major health problem that ultimately affects up to 50% 
of parous women.1 A cross-sectional Dutch study2 demonstrated a prevalence of 
symptomatic pelvic organ prolapse of 11.4%. Conventional vaginal prolapse surgery 
has been associated with high anatomic failure rates.3 This has led to the introduction 
of graft materials. Randomized controlled trials revealed improved anatomic 
outcomes after vaginal polypropylene mesh when compared with traditional vaginal 
prolapse repairs.4,5 However, the use of synthetic mesh in the vagina introduced 
different types of complications. The International Urogynecology Association and 
International Continence Society developed a classification of complications related 
to the insertion of grafts.6
Mesh exposure is the most commonly reported complication associated with the 
use of mesh in prolapse surgery. Exposures have been reported as early as 6 weeks 
and late as 4 years after vaginal mesh surgery, but they usually occur during the 
first year after the intervention.7-9 Reported exposure rates vary between 0% and 
25%.4,5,10,11 In previous studies, various predictive factors for mesh exposure such as 
patient age, experience of the surgeon, cystocele stage II or lower, and concomitant 
hysterectomy have been reported.4,12-17
Mesh exposure and shrinkage of fibrous tissues around the mesh may result in 
pelvic pain and dyspareunia. Dyspareunia rates of up to 38% have been reported 
after vaginal mesh placement.7 De novo pain rates between 3% and 10% have been 
reported; however, risk factors have not been identified until now.5,18,19 The objective 
of this study was to identify possible risk factors for mesh exposure, dyspareunia, and 
pain at 12 months after tension-free vaginal mesh insertion in a large cohort study.
MaTerIals and MeThods
This prospective observational cohort study was performed in two Dutch centers 
specializing in pelvic organ dysfunction and surgery (Radboud University Nijmegen 
Medical Centre and Reinier de Graaf Group Delft, both in the Netherlands). The first 
pelvic organ prolapse repair with tension-free vaginal mesh (Prolift, Ethicon) was 
performed in September 2005 in both centers. This analysis includes all trocar-guided 
tension-free vaginal mesh procedures between September 2005 and December 2009. 
The choice for conventional pelvic organ prolapse surgery or tension-free vaginal mesh 
surgery was left to the discretion of the surgeon and the patient. Common practice 
was to counsel women at higher risk for recurrence for pelvic organ prolapse for 
tension-free vaginal mesh. In practice, these were patients with a recurrent pelvic organ 
prolapse stage II or higher and patients with a primary pelvic organ prolapse stage III 
or higher who opted for tension-free vaginal mesh. Exclusion criteria were pregnancy 
or contemplating future pregnancy or a compromised immune system. All data were 
collected as part of an ongoing outcome registration project, which was approved by 
CMO regio Arnhem-Nijmegen Human Research Committee on April 19, 2006.
Surgery was performed by four gynecologists who were formally trained for the 
tension-free vaginal mesh procedure as described by Fatton et al20 before the start of this 
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study. Operations were sometimes performed by a combination of two gynecologists 
or by residents under supervision of a gynecologist. With regard to the “factor” 
surgeon, these operations were categorized under the first surgeon or the supervisor, 
respectively. As recommended, a full-thickness midline incision was made through 
the fibromuscular wall of the vagina. No simultaneous hysterectomy or T-incisions 
were made to reduce the already known risk of mesh exposure.12 Other additional 
conventional surgical procedures such as sacrospinous ligament fixation, anterior and 
posterior colporrhaphy, or modified Manchester-Fothergill were permitted.
Perioperatively, all patients received antibiotic prophylaxis. An indwelling urinary 
catheter for 1 or 2 days and vaginal gauze pack for 1 day were inserted after 
completion of surgery.
Baseline evaluation included medical history and assessment of pelvic organ 
prolapse by the pelvic organ prolapse quantification system.21 Data on subjective 
symptoms, such as pain and dyspareunia, were obtained from the standardized and 
validated urogynecological questionnaire (Urogenital Distress Inventory).22 In this self-
completed questionnaire, patients were asked to state whether pain and dyspareunia 
were present or absent; and if it was present, the patient was asked for the amount of 
bother on a 4-point Likert scale with scores ranging from “no bother at all” to “quite a 
bit of bother.” In this study, pain and dyspareunia were considered present if a patient 
responded at least “yes, moderately bothered” to the questions “do you experience 
pain in the lower abdomen or genital region?” and “do you experience pain during 
intercourse?”, respectively. Quality of life was assessed using EuroQuol 5D.23 Health 
status was quantified using a visual analog scale in which zero denotes the worst 
imaginable health status and 100 denotes the best imaginable health status.
Follow-up visits were planned at 6 weeks and at 6 and 12 months and included 
pelvic organ prolapse quantification, symptom assessment (questionnaire), and 
complication assessment. Anatomic failure was defined as pelvic organ prolapse 
stage II or higher of the treated compartment. Mesh exposure was defined as any 
visible or palpable mesh identified during vaginal examination or visualized during 
cystoscopy or rectosigmoidoscopy in case of an indication for these examinations. 
Complications were prospectively collected on a case record form and included rectal 
lesion, bladder injury, blood loss more than 500 mL, infection, hematoma, urinary 
retention (defined as repeated postvoid residual volume more than 100 mL measured 
with a bladder scanner and needing an indwelling Foley catheter or intermittent 
catheterization), reintervention attributable to complication, granuloma, exposure, 
pelvic abscess, rectovaginal or vesicovaginal fistula, pain, and dyspareunia.
Data are presented as numbers with corresponding percentages or medians with 
range. The Wilcoxon signed rank test was used to test differences between related 
samples for statistical significance. The χ2 test was used to compare proportions. 
Primary outcomes of this study were mesh exposure, dyspareunia, and pain within 12 
months after the tension-free insertion of vaginal mesh.
Univariable logistic regression was used to study the influence of the possible risk 
factors on each of the outcomes, separately. Considered risk factors were patient 
age, menopause, diabetes, body mass index, parity, current smoking, pelvic organ 
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prolapse stage, previous pelvic organ prolapse surgery, anterior mesh, posterior 
mesh, total mesh, tension-free vaginal mesh combined with conventional prolapse 
surgery, operating time, amount of blood loss, any complication perioperatively 
or postoperatively, bladder injury, postoperative hematoma, surgeon, clinical and 
surgical experience of the surgeon (in every separate case, the number of years of 
experience of the particular surgeon was calculated at that moment), number of 
tension-free vaginal mesh procedures previously performed by that surgeon, failure 
(pelvic organ prolapse stage II or higher) in the mesh-treated compartment, and 
postoperative sexual activity. Postoperative sexual activity was defined as a positive 
response to the question regarding having sexual intercourse. The odds ratio (OR) 
with the 95% confidence interval (CI) are presented.
Multivariable logistic regression with forward selection procedure was used to 
identify those variables that were independently related to predict mesh exposure, 
dyspareunia, and pain, separately. Variables reaching statistical significance at the 
P<0.10 level in the univariable analysis were valid for entry model in the selection 
procedure. It is generally recommended to put this level not too low, because otherwise 
possible (adjusted) predictors remain unrevealed. The adjusted OR with 95% CI of the 
final model are presented. P<0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS 15.0 for Windows.
resulTs
Between September 2005 and December 2009, 1,894 patients underwent pelvic 
organ prolapse surgery in the two centers. Three hundred seventy-four women 
met the inclusion criteria and underwent a trocar-guided tension-free vaginal mesh 
procedure. The 12-month follow-up data were available for 294 patients (79%). 
Details of 116 patients have previously been described in a study that focused on 
de novo prolapse in the untreated compartment, and 46 patients were part of a 
randomized controlled trial on tension-free vaginal mesh.5,24 Baseline characteristics 
are presented in table 1. Median age was 64 years, with a range of 16–93 years. A 
16-year-old girl had spina bifida and a descending uterus 1 cm past the hymen.
Table 2 shows the surgical procedures that were performed and the perioperative 
and postoperative complications. Seven (2.1%) bladder perforations occurred, all 
during dissection for an anterior tension-free vaginal mesh procedure. In two of these 
patients, the anterior mesh has not been placed for that reason, and a conventional 
anterior colporrhaphy was performed in combination with a posterior mesh 
procedure. One superficial serosa lesion of the rectum occurred, without perforation, 
and the mesh was placed in this patient. Three patients underwent reintervention 
because of postoperative bleeding. One of these women had a large hematoma 
in the retroperitoneal space of Retzius attributable to a lesion of the left obturator 
artery. Laparotomy through a median incision was performed and the bleeding 
branch of the obturator artery was ligated. The total estimated blood loss of this 
second procedure was 5,200 mL. There were no pelvic abscesses or rectovaginal and 
vesicovaginal fistulas in this series.
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table 1. Baseline characteristics.
total n(%) or median (range)
Age, years 294 64 (16-93)
BMI, kg/m2 290 26 (16-42)
Menopause 269 248 (92)
Parity (number) 268 2 (0-7)
Previous POP repair 294 188 (64)
>1 previous POP repair 294 66 (22)
Previous hysterectomy 294 191 (65)
Current smoking 286 30 (10)
Diabetes Mellitus 294 9 (3)
Pelvic organ prolapse
stage 0 294 0 (0)
stage I 294 0 (0)
stage II 294 98 (33)
stage III 294 185 (63)
stage IV 294 11 (4)
Pre-operative health status 260 70 (16-100)
Pre-operative pain 252 62 (25)
Pre-operative sexual activity 238 140 (59)
Pre-operative dyspareunia 140 60 (43)
Pre-operative not sexually active due to dyspareunia 98 12 (12)
POP= pelvic organ prolapse
Health status measured on visual analog scale (VAS) according to the EQ-5D
In 34 patients (12%), a mesh exposure was present in six cases detected at 6 
weeks, in 17 at 6 months, and in 11 at 12 months. Most of these patients were 
asymptomatic, three patients reported dyspareunia, and two had vaginal bleeding 
or discharge. Fifteen (44%) of these exposures were localized in the anterior vaginal 
wall after an anterior or total mesh placement, 16 (47%) in the posterior wall after 
a posterior or total mesh placement and three (9%) in the apex of the vagina after 
a total or a posterior mesh placement. The size of the exposures ranged from 2 
to 60 mm (median 10 mm). Figure 1 shows the follow-up of these patients with 
exposure. Twenty-three exposures (68%) resolved after therapy. The percentage of 
mesh exposures per surgeon varied between 8% and 29%.
Pain in the lower abdomen or genital region was present in 62 out of 252 patients 
(25%) before surgery and in 35 out of 275 patients (13%) after surgery. De novo pain 
was noted in 5%.
Data regarding sexual activity and dyspareunia are presented in figure 2. De novo 
dyspareunia was noted in 20 out of 78 patients (26%) and resolved dyspareunia in 
19 of 60 patients (32%). Twenty of 98 patients (20%) returned to sexual activity, 
of which the majority (12) experienced dyspareunia and 7 out of 140 (5%) ceased 
sexual activity after their surgical repair.
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table 2. Peri- and post-operative data.
total 
n (%) or median 
(range)
Peri-operative
Location mesh
anterior 294 71 (24)
posterior 294 110 (37)
anterior and posterior 294 47 (16)
total 294 66 (22)
Mesh combined with conventional surgery 294 69 (23)
Operating time (min) 283 60 (20-150)
Blood loss (ml) 278 100 (0-1300)
Complications*
rectal serosa lesion 294 1 (0)
bladder injury 294 7 (2)
urinary retention 294 25 (9)
urinary tract infection 294 6 (2)
blood loss > 500 ml 294 4 (1)
postoperative hematoma 294 12 (4)
other 294 5 (2)
any complication 294 60 (20)
12 months post-operative
POP stage in mesh-treated compartment
stage 0 294 188 (64)
stage I 294 68 (23)
stage II 294 36 (12)
stage III 294 2 (1)
stage IV 294 0 (0)
Exposure within 12 months 294 34 (12)
Post-operative health status 247 80 (20-100)
Post-operative pain 275 35 (13)
Post-operative sexual activity 276 171 (62)
Post-operative dyspareunia 171 77 (45)
POP= pelvic organ prolapse 
* Multiple diagnoses possible
Health status measured on visual analog scale (VAS) according to the EQ-5D
Anatomic outcomes are shown in table 2. The failure rate in the mesh-treated 
compartments was 13% (38 patients), of which 32 (84%) were asymptomatic. Two 
patients (1%) had a pelvic organ prolapse stage III, both with bulge symptoms. One of 
these women underwent repeat pelvic organ prolapse surgery and the other patient 
abstained from further treatment. Four patients (2%) had a symptomatic pelvic organ 
prolapse stage II, of whom two underwent repeat pelvic organ prolapse surgery 
during the follow-up period. Overall quality of life measured on a visual analog scale 
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placement. The size of the exposures ranged from 2 to
60 mm (median 10 mm). Figure 1 shows the follow-up
of these patients with exposure. Twenty-three exposures
(68%) resolved after therapy. The percentage of mesh
exposures per surgeon varied between 8% and 29%.
Pain in the lower abdomen or genital region was
present in 62 out of 252 patients (25%) before surgery
and in 35 out of 275 patients (13%) after surgery. De
novo pain was noted in 5%.
Data regarding sexual activity and dyspareunia
are presented in Figure 2. De novo dyspareunia was
noted in 20 out of 78 patients (26%) and resolved
dyspareunia in 19 of 60 patients (32%). Twenty of 98
patients (20%) returned to sexual activity, of which the
majority (12) experienced dyspareunia and 7 out of
140 (5%) ceased sexual activity after their surgical
repair.
Anatomic outcomes are shown in Table 2. The
failure rate in the mesh-treated compartments was
13% (38 patients), of which 32 (84%) were asymptom-
atic. Two patients (1%) had a pelvic organ prolapse
stage III, both with bulge symptoms. One of these
women underwent repeat pelvic organ prolapse sur-
gery and the other patient abstained from further
treatment. Four patients (2%) had a symptomatic
pelvic organ prolapse stage II, of whom two under-
went repeat pelvic organ prolapse surgery during the
follow-up period. Overall quality of life measured on
a visual analog scale according to the EuroQuol 5D
improved significantly from a median of 70 (16–100)
to 80 (20–100) 1 year after pelvic organ prolapse
surgery (P.002, Wilcoxon).
Table 3 shows the crude OR with 95% CI for the
risk of exposure, the risk of pain, and the risk of
dyspareunia. We found that the type of surgeon and
years of experience of the surgeon were statistically
significant and related to the risk of exposure. How-
ever, only the years of experience was an indepen-
dent risk factor for exposure (Table 4). Each decade
increase in clinical and surgical experience decreased
the risk of exposure (OR 0.49, 95% CI 0.29–0.83).
Table 2. Perioperative and Postoperative Data
Total
n (%) or
Median
(Range)
Perioperative
Location of mesh
Anterior 294 71 (24)
Posterior 294 110 (37)
Anterior and posterior 294 47 (16)
Total 294 66 (22)
Mesh combined with
conventional surgery
294 69 (23)
Operating time (min) 283 60 (20–150)
Blood loss (mL) 278 100 (0–1,300)
Complications*
Rectal serosa lesion 294 1 (0)
Bladder injury 294 7 (2)
Urinary retention 294 25 (9)
Urinary tract infection 294 6 (2)
Blood loss more than 500 mL 294 4 (1)
Postoperative hematoma 294 12 (4)
Other 294 5 (2)
Any complication 294 60 (20)
12 mo postoperative
Pelvic organ prolapse stage in
mesh-treated compartment
Stage 0 294 188 (64)
Stage I 294 68 (23)
Stage II 294 36 (12)
Stage III 294 2 (1)
Stage IV 294 0 (0)
Exposure within 12 mo 294 34 (12)
Postoperative health status 247 80 (20–100)
Postoperative pain 275 35 (13)
Postoperative sexual activity 276 171 (62)
Postoperative dyspareunia 171 77 (45)
* Multiple diagnoses possible.
Health status measured on visual analog scale according to the
EuroQuol 5D.
Expectant management
n=6
Mesh exposures
N=34
Vaginal estrogen therapy
n=6
Vaginal estrogen therapy
and surgical excision
n=22
Did not return for follow-up
n=3
Persistent exposure;
expectant management
n=6
Persistent exposure;
expectant management
n=2
Resolved exposure
n=23
Second 
surgical excision
n=1
n=1
n=21
n=1
n=1
Fig. 1. Follow-up mesh exposures.
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figure 1. Follow-up mesh exposures.
according to the EuroQuol 5D improved significantly from a median of 70 (16–100) 
to 80 (20–100) 1 year after pelvic organ prolapse surgery (P=0.002, Wilcoxon).
Table 3 shows the crude OR with 95% CI for the risk of exposure, the risk of 
pain, and the risk of dyspareunia. We found that the type of surgeon and years 
of experience of the surgeon were statistically significant and related to the risk of 
exposure. However, only the years of experience was an independent risk factor for 
exposure (table 4). Each decade increase in clinical and surgical experience decreased 
the risk of exposure (OR 0.49, 95% CI 0.29–0.83).
Smoking, total tension-free vaginal mesh, and experience of the surgeon were 
independently associated with the presence of mesh exposures (table 4). Of the 30 
smoking women, nine (30%) had an exposure in contrast to only 25 out of the 264 
(9%) nonsmokers (P<0.001, χ2 test).
An independent association between surgeon and postoperative dyspareunia 
was detected that could not be explained by the number of previously performed 
tension-free vaginal mesh procedures or by the years of experience (table 4). Pain and 
dyspareunia before surgery were the independent risk factors for these symptoms 
after surgery, respectively (table 4), indicating that the symptoms persisted after 
surgery. Furthermore, preoperative health status was inversely related to pain and 
dyspareunia after surgery.
dIscussIon
This prospective observational cohort study demonstrated that smoking, total 
tension-free vaginal mesh, and less clinical and surgical experience were independent 
risk factors for mesh exposure after a tension-free vaginal mesh procedure. Lower 
abdominal or genital pain before surgery was independently associated with pain 
after surgery. Preoperative dyspareunia and the surgeon were both independent 
predictive factors for postoperative dyspareunia.
This study is about an actual and highly relevant topic in urogynecological practice. 
Vaginal meshes have been widely applied in recent years, but there is still little 
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table 3. Crude Odds ratio for the risk of mesh exposure, the risk of pain and the risk of dyspareunia 
within 12 months post-operatively using univariable logistic regression.
exposure Pain dyspareunia
n or (95% Ci) n or (95% Ci) n or (95% Ci)
Age (years) 294 0.97(0.94-0.99) 275 0.95(0.92-0.98) 171 0.92(0.86-0.96)
Menopause (p) 269 2.10(0.66-6.73) 252 0.23(0.08-0.66) 151 0.24(0.07-0.79)
Previous POP repair (p) 287 1.83(0.79-4.20) 268 1.50(0.68-3.38) 169 3.13(1.51-6.49)
Smoking (p) 286 4.1(1.71-10.06) 267 1.60(0.58-4.66) 167 1.16(0.44-3.08)
Diabetes (p) 294 0.96(0.12-7.88) 275 0.85(0.16-7.03) 171 1.20(0.74-19.42)
Parity (number) 268 1.01(0.74-1.39) 251 0.99(0.71-1.38) 154 0.71(0.50-0.99)
Pre-operative POP-stage 294 275 171
stage II 1.00(reference) 1.00(reference) 1.00(reference)
stage III/IV 0.59(0.29-1.23) 0.66(0.32-1.36) 0.65(0.35-1.21)
PO Sexual activity (p) 276 2.08(0.90-4.79) 272 0.87(0.42-1.80) - -
Body Mass Index (kg/m2) 290 1.03(0.93-1.14) 272 1.07(0.97-1.19) 169 0.95(0.86-1.04)
Location mesh 294 275 171
total 1.00(reference) 1.00(reference) 1.00(reference)
anterior 0.31(0.10-0.92) 0.47(0.15-1.48) 0.81(0.33-2.00)
posterior 0.50(0.21-1.17) 1.06(0.43-2.59) 1.27(0.55-2.93)
Ant+pos 0.38(0.12-1.25) 0.97(0.32-2.97) 0.77(0.26-2.28)
Mesh combined (p) 294 0.99(0.43-2.29) 275 2.44(1.16-5.14) 171 1.03(0.52-2.07)
Op. time (per 20 min) 283 1.22(0.91-1.65) 264 1.28(0.96-1.70) 167 0.99(0.77-1.28)
Blood loss (per 100 ml) 278 1.14(0.93-1.39) 259 1.02(0.80-1.29) 161 1.14(0.88-1.47)
Any complication (p) 294 1.47(0.65-3.35) 275 1.64(0.74-3.65) 171 0.85(0.39-1.84)
Failure (p) 294 0.18(0.02-1.38) 275 0.57(0.17-1.96) 171 0.68(0.28-1.65)
Bladder injury (p) 294 1.28(0.15-10.95) 275 1.38(0.16-12.19) 171 0.23(0.03-1.99)
PO hematoma (p) 294 1.56(0.33-7.45) 275 0.68(0.08-5.45) 171 0.29(0.03-2.64)
Surgeon 294 275 171
surgeon A 1.00(reference) 1.00(reference) 1.00(reference)
surgeon B 0.87(0.34-2.25) 1.75(0.74-4.11) 6.20(2.87-13.39)
surgeon C 3.89(1.30-11.62) 1.79(0.46-6.93) 8.27(1.99-34.18)
surgeon D 2.19(0.82-5.89) 3.01(1.14-7.96) 4.51(1.80-11.29)
Experience (per 10 years) 294 0.55(0.34-.89) 275 0.77(0.48-1.25) 171 1.31(0.88-1.95)
Number of mesh procedures 
(per 10)
294 0.95(0.87-1.03) 275 0.88(0.79-.97) 171 0.94(0.87-1.01)
Pain pre-operative (p) 252 0.84(0.34-2.05) 240 6.00(2.68-13.42) 149 3.69(1.69-8.11)
Dyspareunia pre-operative (p) 160 0.85(0.35-2.08) 151 3.70(1.36-10.08) 134 5.01(2.39-10.49)
Health score pre-operative 260 1.01(0.99-1.04) 245 0.95(0.93-0.97) 152 0.96(0.94-0.98)
OR= odds ratio
CI= confidence interval 
(p) = absent coded as 0, present coded as 1
PO= post operative
POP= pelvic organ prolapse, 
Ant+pos= anterior and posterior
Op. time = operating time, 
Failure = failure in treated compartment (POP stage >II)
Bold numbers: Variables reaching statistical significance at the p<0.10 level, valid for entry in the 
selection procedure. 
Stage III/IV: stage III and stage IV are put in one category due to small numbers with prolapse stage IV
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table 4. Adjusted Odds Ratio for the risk of mesh exposure, the risk of pain and the risk of dyspareunia 
within 12 months post-operatively, using multivariable logistic regression with selection procedure.
factor
exposure 
(n=268)
Pain 
(n=205)
dyspareunia 
(n=111)
or (95% Ci) or (95% Ci) or (95% Ci)
Age (years) 0.97(0.93-1.01) 0.95(0.91-0.99)             -
Menopause (p)     -            - 0.29(0.06-1.43)
Smoking (p) 3.08(1.09-8.72)            -             -
PO Sexual activity (p) 2.15(0.79-5.79)            -             -
Total mesh (p)* 2.95(1.24-7.01)            -             -
Failure (p) 0.20(0.03-1.54)            -             -
Surgeon      -            -
surgeon A 1.00 (reference)
surgeon B 3.13(0.98-9.98)
surgeon C 11.37(1.75-74.02)
surgeon D 2.58(0.64-10.31)
Experience (per 10 years) 0.49(0.29-0.83)            -            -
Pain pre-operative (p)       - 3.21(1.23-8.40)            -
Dyspareunia pre-operative (p)       -            - 4.66(1.69-12.81)
Health status pre-operative (p)       - 0.95(0.91-0.98) 0.96(0.93-0.99)
OR= odds ratio, CI= confidence interval
(p) = absent coded as 0, present coded as 1.
PO= post operative
POP= pelvic organ prolapse
Op. time = operating time
Failure = failure in treated compartment (POP stage >II)
- = not selected 
Bold indicates variables reaching statistical significance at the P<0.05 level.
Note that 32/268 had exposure, 26/205 had pain and 46/111 had dyspareunia.
*To calculate the OR of location of mesh, the ‘anterior’, ‘posterior’ and ‘anterior and posterior’ are 
combined because their OR compared to ‘total’ are similar.
scientific evidence on the pros and cons, as well as the risk factors for postoperative 
problems. Further strengths are the prospective design of the study, the large sample 
size, and the use of standardized and validated instruments of measurement.
A drawback could be the relatively short follow-up period of 12 months. However, 
it has been reported previously that most complications and, particularly, mesh 
exposures occur during this first year after surgery.9 Furthermore, an independent 
clinical investigator who was not involved in and blinded to the procedures would 
ideally have performed the postoperative examinations.
This study identified tobacco smoking as an independent risk factor for mesh 
exposure after the tension-free vaginal insertion. Previously, Cundiff et al25 had 
demonstrated that smoking was a risk factor for vaginal mesh exposure after 
abdominal sacrocolpopexy in univariable analysis. Other authors12,16,17,26 have not 
reported on smoking as a potential risk factor or have failed to demonstrate an 
association with exposure.15 Nicotine is a vasoconstrictor that reduces nutritional 
blood flow to the epithelium, resulting in tissue ischemia and impaired healing, which 
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eventually might lead to vaginal mesh exposure.27 Slower wound healing clinically has 
been observed in smokers.27 Four weeks of abstinence from smoking already reduced 
smoking-associated complications.28
We have identified the total tension-free vaginal mesh as a risk factor for exposure. 
Apart from the fact that a total mesh contains a larger amount of mesh, the technique 
to insert a total mesh probably is more complex. The special technique that leaves a 
small bridge of vaginal vault intact29 may jeopardize the vascularization of the vaginal 
tissue and could be responsible for poor wound healing and, thus, mesh exposure.
The years of experience in prolapse repair, and not necessarily the number of 
previously performed tension-free vaginal mesh procedures, appeared to be protective 
for mesh exposure. One previous article26 also suggested an association, although not 
statistically significant, between surgical experience and exposure.
In contrast with a previous study of 52 sexually active patients, we could not 
demonstrate that “postoperative sexual activity” was independently associated with 
mesh exposure.16 This study, however, did not consider smoking as a risk factor.
In literature, data on age as an independent risk factor for mesh exposure are 
conflicting.16,17,26 We could not demonstrate any association between age and 
exposure in the present study.
A de novo pain rate of 5% is consistent with earlier reports.5,18 We found an 
increased risk for pain after surgery in patients with pain in the lower abdomen 
or genital region before surgery. This was to be expected because this pain is not 
necessarily related to prolapse and, in such cases, is not likely to resolve with pelvic 
organ prolapse surgery.
The rates of dyspareunia after surgery (45%) and de novo dyspareunia (26%) 
were similar to the rates reported by Carey et al30 (40% and 28%, respectively). 
However, other authors4,16,19 reported lower (7.6–20%) dyspareunia rates after 
surgery with vaginal mesh and lower de novo dyspareunia rates (2–12.3%). This 
study clearly demonstrates that preoperative dyspareunia increases the odds of 
postoperative dyspareunia, probably persistent dyspareunia. We were surprised by 
the differences in dyspareunia rates between surgeons. We have no good explanation 
for this. One has to realize that because not all patients were sexually active, the 
number of operations per surgeon was relatively small, illustrated by the high 95% 
CI. Furthermore, dyspareunia is a complicated topic and more detailed questions 
about sexuality might explain more.
When counseling a woman with pelvic organ prolapse for conventional compared 
with vaginal mesh repair, the potential complications such as mesh exposure, pain, 
and dyspareunia should be mentioned along with the differences in anatomic success 
rates. The present study may aid in a more individualized counseling, and we do 
suggest advising patients to quit smoking before mesh surgery. Furthermore, pain or 
dyspareunia may not necessarily disappear after pelvic organ prolapse surgery.
This study indicates that tension-free vaginal mesh surgery was safer if performed 
by more experienced urogynecological surgeons. The number of previous years 
of surgical and clinical experience seemed to be relevant. In the Netherlands, 
the Pelvic Floor Society of the Dutch Society of Obstetrics and Gynecology is working 
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on standards for vaginal mesh surgery. Centralization of mesh procedures performed 
by surgeons with proven experience would imply a major shift in referrals. The results 
of the present study, however, indicate that this discussion on the future organization 
of vaginal mesh surgery is mandatory.
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absTracT
introduction and hypothesis
The aim of this study was to evaluate short-term anatomic and functional outcomes 
and safety of laparoscopic sacrocolpopexy with bone anchor fixation.
Methods
A prospective cohort study of women undergoing laparoscopic sacrocolpopexy 
between 2004 and 2009. Anatomic outcome was assessed using the pelvic organ 
prolapse quantification score (POP-Q). Functional outcomes were assessed using the 
Urogenital Distress Inventory, Defecatory Distress Inventory and the Incontinence 
Impact Questionnaire preoperatively and at 6 months postoperatively. The Wilcoxon 
signed rank test was used to test differences between related samples.
results
Forty-nine women underwent laparoscopic sacrocolpopexy. The objective success rate 
in the apical compartment was 98%, subjective success rate was 79%. One mesh 
exposure (2%) was found. One conversion was necessary due to  injury to the ileum.
Conclusions
Laparoscopic sacrocolpopexy with bone anchor fixation is a safe and efficacious 
treatment for apical compartment prolapse. It provides excellent apical support and 
good functional outcome 6 months postoperatively.
InTroducTIon
A challenging aspect in the treatment of pelvic organ prolapse is the prolapsed 
apical compartment. The incidence of post-hysterectomy vault prolapse that requires 
surgery has been estimated at 1.3 per 1,000 women-years.1 The risk of prolapse 
surgery was 4.7 times higher in women whose initial hysterectomy was indicated by 
prolapse and 8.0 times higher if preoperative prolapse stage II or more was present.1
Numerous surgical procedures have been described for the management of vault 
prolapse but few have been subject to rigorous assessment of their anatomical and 
functional outcome. The abdominal sacrocolpopexy is regarded the best procedure 
compared to vaginal sacrospinous colpopexy in terms of a lower rate of recurrent 
vault prolapse and less dyspareunia.2 However, the vaginal sacrospinous colpopexy 
is quicker and cheaper to perform and women return earlier to activities of daily 
living. Laparoscopic sacrocolpopexy provides the potential to combine the success 
rate of an abdominal approach with the faster recovery time associated with a 
minimally invasive technique. Tissue dissection and mesh placement are facilitated by 
magnification of the operating field. The success rate of laparoscopic sacrocolpopexy 
has been reported to be 77–100%.3-9 
To reduce the risk of injuries to the presacral venous and nervous plexus and to 
make the procedure more feasible, a modified laparoscopic sacrocolpopexy operation 
using bone anchor fixation and synthetic mesh was developed.10 
The aim of this study was to evaluate the clinical outcomes, surgical morbidity 
and functional outcomes of laparoscopic sacrocolpopexy with bone anchor fixation.
MaTerIal and MeThods
This study was undertaken after obtaining approval from the Central Medical 
Ethics committee ‘Toetsing Wetenschappelijk Onderzoek Rijnmond’ (TWOR), the 
Netherlands.  All patients provided written informed consent before participation and 
were recruited between July 2004 and November 2009. Consecutive women with a 
symptomatic apical compartment prolapse requiring surgical correction were eligible 
for participation. Exclusion criteria were inability to understand Dutch, pregnancy 
or contemplating future pregnancy, former rectosigmoid resection, extensive 
intra-abdominal / pelvic adhesions, body mass index > 40 kg/m2 and treatment for 
malignancy in the past.
Baseline evaluation included medical history, a gynecologic investigation 
including a  pelvic organ prolapse quantification (POP-Q)examination11 and  validated 
urogynecologic questionnaire, which contains the Dutch validated Urogenital Distress 
Inventory (UDI), Defecatory Distress Inventory (DDI) and the Incontinence Impact 
Questionnaire (IIQ).12,13
All procedures were performed by the two last authors with the technique as 
previously described by van der Weiden et al.10 The operative procedure can be 
summarized as follows: at the lowest point of the pouch of Douglas, the right 
peritoneal fold is opened medially of the rectosigmoid by unipolar diathermy. 
Next, the presacral avascular plane is developed. The cortical bone of the sacral 
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segment 3 is penetrated in the midline with the laparoscopic bone anchor inserter 
(SFG prototype, van der Weiden TM or KS 02158-1-LAP TM prototype, Karl Storz, 
Tuttlingen, Germany). Fixation to the sacrum is performed with a selftapping titanium 
Corkscrew Suture Anchor (AR-1925S, Arthrex, Naples, Florida, USA) with 2 attached 
non-absorbable braided polyester-2 sutures (cases with the SFG prototype, van der 
Weiden TM) or with flat headed titanium screws (cases with the KS 02158-1-LAP TM 
prototype, Karl Storz, Tuttlingen, Germany). A 4.0 x 3.0 cm piece of monofilament 
knitted polypropylene mesh (Gynemesh Soft, Ethicon, Norderstedt, Germany) 
sutured to the apical part of the posterior vaginal wall with 4 Mersilene 1-0 sutures 
(Ethicon, Norderstedt, Germany) is subsequently sutured to the polyester-2 ligatures 
attached to the bone anchor. The mesh is covered with peritoneum placing it in 
a retroperitoneal position. Since the rate of vaginal mesh exposure is significantly 
higher when abdominal surgery is combined with vaginal surgery,14 additional 
prolapse or incontinence procedures such as posterior colpoperineorrhaphy, anterior 
colporrhaphy, paravaginal repair, surgery for stress urinary incontinence or ventral 
rectopexy, were not performed concomitantly. Patients received a single prophylactic 
dose of antibiotics.
Postoperative evaluations were performed during the hospital stay, at 6 weeks and 
6 months post-operatively. POP-Q measurements were recorded and questionnaires 
completed at 6 months.
The primary end point was anatomic failure in any of the vaginal compartments, 
defined as pelvic organ prolapse stage II or higher. Secondary outcomes were 
anatomic failure in the apical compartment and subjective failure. Subjective failure 
was considered significant if a patient responded at least:  ‘yes, a bit bothered’ to 
the questions “Do you feel bulging or protrusion in the vaginal area?” or “Do you 
see a bulge or protrusion in the vaginal area?”. Other secondary outcomes were 
duration of surgery, blood loss, length of hospitalization, and change in bother and 
quality of life measured by UDI, DDI and IIQ. Pain was a secondary outcome as well 
and considered significant if a patient responded “yes, moderately to quite a bit” 
to the question “Do you experience pain in the lower abdomen or genital region?” 
Dyspareunia was considered significant if a patient responded “yes; moderately to 
quite a bit” to the question “Do you experience pain during intercourse?”
Data are presented as numbers with corresponding percentages or medians with 
range. The Wilcoxon signed rank test was used to test differences between related 
samples for statistical significance. A p-value below 0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS 18.0 for Windows (SPSS 
inc., Chicago, Ill., USA).
resulTs
Forty-nine women were included in the study, 45 cases of laparoscopic sacrocolpopexy 
(including  2 cases of cervicopexy after a previous  supracervical  abdominal 
hysterectomy) and 4 cases of laparoscopic hysteropexy.  All patients returned for 
follow-up and a POP-Q measurement was taken, however only 47 patients completed 
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the questionnaires. Baseline characteristics are shown in table 1. Two patients had 
a bothersome stage I prolapse with the most descending point at hymen minus 2 
cm and underwent surgery. All other patients had a stage II or III prolapse. Twenty 
patients were sexually active and 3 (15%) had dyspareunia. 
Peri- and postoperative data are presented in table 2. In one patient conversion 
was necessary due to injury to the ileum. The lesion was sutured and subsequently 
healed without any long-term sequelae. One patient had neurologic complaints 
post-operatively, caused by irritation of the left sacral plexus. These complaints, 
although diminishing gradually, persisted to some extent at the 6 months follow-up 
and resolved spontaneously in the following 6 months. One patient developed a 
mesh exposure, which was successfully excised and the defects covered with vaginal 
mucosa in a day-care procedure.  There were no patients that developed de novo pain 
in the abdomen or genital area and 3 patients (15%) reported de novo dyspareunia. 
In 2 patients (10%) dyspareunia disappeared.
The POP-Q measurements are shown in table 3. At 6 months follow-up a significant 
improvement was seen in the apical (point C) and posterior (point Bp) compartments. 
Anatomical failure per compartment is presented in table 4. The apical compartment 
had only 2% failures, in contrast with the anterior compartment with 31% failures. 
table 1. Baseline characteristics.
data available  
for number of patients
 n (%) or 
median (range)
Age 49 66 (45-86)
Parity 47 2 (0-6)
BMI 29 24 (21-32)
Comorbidity 49 5 (10%)
Previous  surgery *
Abdominal hysterectomy 49 18 (37%)
Vaginal hysterectomy 49 27 (55%)
Anterior colporraphy 49 28 (57%)
Anterior mesh procedure 49 1 (2%)
Posterior colporrhaphy 49 27 (55%)
One POP procedure 49 28 (57%)
More than one POP procedure 49 5 (10%)
Previous incontinence surgery 49 9 (18%)
Overall POP-stage 49
I 2 (4%)
II 33 (67%)
III 14 (29%)
IV 0 (0%)
Point C 49 -1 (-3 to 4)
Pain (lower abdomen/genital area) 47 11 (23%)
Dyspareunia 20 3 (15%)
*multiple surgeries possible
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table 2. Peri- and post operative data.
data available 
for number of 
patients
n (%) or 
median (range)
Sacrocolpopexy 49 43 (88%)
Cervicopexy 49 2 (4%)
Hysteropexy 49 4 (8%)
Operating time (min) 49 120 (60-240)
Blood loss (ml) 49 50 (10-100)
Duration urinary catheter (days) 49 1 (1)
Hospital stay (days) 49 1 (0-5)
Complications (intra-operative)
conversion laparotomy due to injury ileum 49 1 (2%)
Complications at 6 months
neurologic complaints caused by irritation left sacral plexus 49 1 (2%)
cumulative mesh exposure 49 1 (2%)
pain (lower abdomen/genital area) 47 3 (6%)
de novo pain 47 0 (0%)
dyspareunia 20 4 (20%)
de novo dyspareunia 20 3 (15%)
table 3. POP-Q measurements at baseline and 6 months post surgery.
PoPQ 
point
data available 
for number of 
patients
Baseline 6 months
p-value Median (range) Mean (sd) Median (range) Mean (sd)
Aa 49 -2 (-3 to 1) -1.3(1.0) -2 (-3 to 0) -1.7(0.7) 0.007
Ba 49  -2 (-3 to 3) -0.9(1.6) -2 (-3 to 2) -1.4(1.2) 0.003
C 49 -1 (-3 to 4) -0.1(1.8) -8 (-8 to -3) -7.7(0.9) <0.001
GH 49 3 (2 to 5) 3.0(0.7) 3 (2 to 5) 3.0(0.7) 0.99
PB 49 3 (2 to 3) 2.7(0.5) 3 (2 to 3) 3.0(0.5) 0.16
TVL 49 8 (7 to 9) 8.0(0.2) 8 (7 to 9) 8.0(0.2) 0.99
Ap 49 -2 (-3 to 2) -1.4(0.9) -2 (-3 to 0) -1.9(0.5) <0.001
Bp 49 -1 (-3 to 2) -0.9(1.4) -2 (-3 to 2) -1.6(0.9) <0.001
D 4 -2.5 (-4 to 0) -2.3(1.7) -8 (-8 to -5) -7.3(1.5) 0.07
Subjective failure was demonstrated in 10 out of 47 (21%) patients. Of the 26 
patients with an overall anatomic failure, only 7 patients (27%) had bothersome 
prolapse complaints (subjective failure). Of the 23 patients with an overall POP stage 
0 or I, three patients (13%) had bothersome prolapse complaints (subjective failure). 
Changes in anterior ( point Ba), apical (point C) and posterior (point Bp) compartments 
are shown in table 5. Improvement in the apical compartment ranged from 5 to 12 
centimeters and was present in all cases but one. The majority of patients had no 
change in the anterior and posterior compartment.
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At 6 months the bother scores of genital prolapse, obstructive micturition, 
overactive bladder, pain and obstructed defecation were significant improved (table 
6). Bother scores were higher when the POP stage increased, although this was not 
statistically significant.
table 4. Anatomic failure.
PoP-
stage
Anterior 
compartment Apical compartment
Posterior 
compartment overall
baseline 6 months baseline 6 months baseline 6 months baseline 6 months
Stage 0 2 (4%)  3 (6%) 2 (4%) 49 (100%)* 1 (2%) 3 (6%) 0(0%) 2 (4%)
Stage I 25 (51%) 31 (63%) 9(19%) 0 (0%) 23 (47%) 34 (69%) 2 (4%) 21 (43%)
Stage II 17 (35%) 12 (24%) 30 (61%) 0(0%) 21 (43%) 11 (22%) 33 (67%) 22 (45%)
Stage III 5 (10%) 3 (6%) 8 (16%) 0(0%) 4 (8%) 1 (2%) 14 (29%) 4 (8%)
Stage IV 0 (0%) 0 (0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
Failure 15 (31%) 1 (2%) 12 (24%) 26 (53%)
Data presented as numbers (%)
*including 1 repeat sacrocolpopexy within 6 months 
Failure= POP > stage II or POP< stage II with repeat surgery
table 5. Change in POPQ point Ba, C and Bp 6 months post surgery.
Ba C Bp
Improvement
  1cm 9 (19%) 10 (21%)
  2cm 3 (6%) 3 (6%)
  3cm 4 (8%) 8 (16%)
  4cm 1 (2%)
  5cm 4 (8%)
  6cm 10 (20%)
  7cm 13 (27%)
  8cm 11 (23%)
  9cm 5 (10%)
  10cm 1 (2%)
  11cm 2 (4%)
  12cm 2 (4%)
No change 28 (57%) 0 27 (55%)
Deterioration
  1cm 2 (4%) 0
  2cm 2 (4%) 0 1 (2%)
Repeat surgery 1 (2%)
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table 6. Effect of surgery on symptoms and health related quality of life scores.
domain Baseline 6 months P value
Bother score in relation  
to PoP stage at 6 months
PoP stage 0+i
(n=21)
PoP stage ii
(n=20)
PoP stage iii
(n=4)
udi
Genital prolapse 67.8 (28.8) 13.3 (24.5) <0.001 10.3 (23.3) 13.3 (24.5) 33.3 (33.3)
OAB 33.3 (25.7) 17.3 (18.9) <0.001 12.7 (14.2) 16.1 (17.8) 47.2 (22.9)
Incontinence 15.6 (20.1) 10.0 (16.8) 0.09 7.9 (17.2) 10.0 (16.6) 20.8 (16.0)
Obstructive micturition 33.0 (24.7) 14.8 (21.3) <0.001 11.9 (16.8) 13.3 (20.7) 44.4 (38.5)
Pain 26.8 (25.2) 15.2 (19.3) 0.002 11.1 (16.1) 18.3 (22.2) 22.2 (19.2)
ddi
Constipation 13.0 (19.5) 12.4 (20.4) 0.56 5.6 (13.3) 17.5 (23.9) 27.8 (25.5)
Obstructed defecation 13.5 (14.4) 7.7 (11.1) 0.002 6.3 (12.3) 7.9 (9.4) 20.8 (5.9)
Pain 6.7 (15.8) 7.0 (15.5) 0.84 4.8 (15.0) 8.8 (16.1) 11.1 (19.3)
Incontinence 4.0 (11.2) 4.5 (9.8) 1.00 5.6 (12.2) 2.5 (6.1) 11.1 (9.6)
iiQ
Physical functioning 19.8 (26.3) 13.6 (23.4) 0.14 15.0 (23.5) 11.4 (24.9) 16.7 (19.3)
Mobility 25.5 (20.5) 23.5 (24.8) 0.53 23.9 (23.7) 21.1 (26.7) 33.3 (24.0)
Social functioning 12.8 (11.6) 7.9 (13.6) 0.08 8.8 (16.0) 7.1 (11.7) 5.6 (7.9)
Embarrassment 11.5 (20.0) 6.5 (13.4) 0.15 6.7 (13.7) 4.6 (9.6) 16.7 (28.9)
Emotional health 22.2 (19.8) 16.1 (21.9) 0.17 17.8 (22.9) 14.2 (22.5) 16.7 (7.9)
UDI, DDI, IIQ data presented as mean (standard deviation); 
Scores range between 0 (least bother) to 100 (maximum bother).
dIscussIon 
The data in this study show that that laparoscopic sacrocolpopexy with bone anchor 
fixation is a safe and effective surgical treatment for apical compartment prolapse. 
The procedure provided excellent vault support in 48 out of 49 women (98%). This 
high success rate for the apical compartment is comparable with other studies.4-9 
Subjective success was 79%, comparable with numbers reported by Higgs et al.,8 
and just below the previously reported subjective success rates of 86% to 97%.4,9 
This lower rate of subjective success was probably due to the persistent prolapse 
of the anterior or posterior vaginal wall that was found in 26 women (53%). This 
results in a high number of overall failures. A cause for this high overall failure rate 
could be the fact that we did not combine the apical compartment repair with 
anterior or posterior repairs (either with laparoscopic mesh placement or with vaginal 
colporrhaphia). In order to decrease the risk for mesh exposure14 and to avoid irritable 
bladder symptoms, such as de novo urgency of 18%,15 and to avoid rectal or bladder 
lesions we did not perform  combined repairs. Theoretically the fixation of the mesh 
to sacral segment 2 to 4, instead of the promontorium, could prevent the occurrence 
or recurrence of prolapse, since the axis of the vagina is more natural and further 
support is provided by the levator plate against which the upper vagina is compressed 
by intra-abdominal pressure.16 Furthermore adequate level I support has a critical role 
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on the position of the anterior and posterior vagina.17,18 However, this adequate level 
I support has not prevented the occurrence of anterior and posterior wall prolapse 
in all cases. 
For the definition of failure we used the National Institutes of Health (NIH) 
criteria.11,19  However, according to Barber the presence of ‘bulge’-symptoms 
together with a pelvic organ prolapse beyond the hymen or re-treatment would be 
more appropriate. If we look at our data in this way, we have a failure rate of 6 out 
of 49 (12%).20 
Intraoperative complications were rare.  Suspending the vault to the sacral 
segment 2-4 with a bone anchor avoids large difficult promontory dissection, 
declining the risk of presacral hemorrhage which can be difficult to control resulting 
in conversion to laparotomy.21 Blood loss during surgery was lower (median 50 ml 
(10-100ml), compared to 100 ml (range 20-300ml) in a previous study.3 Furthermore 
no bloodtransfusion peri-operatively was given, in contrast with 2% transfusions in 
the study of Maher.3 Neither bladder lesions nor rectum lesions were described, due 
to the minimum dissection at the bladder and rectum site, since mesh was only used 
at the apex of the posterior vaginal wall. Other studies described 2% bladder lesions 
and 1% rectum lesions.7,9 However, one conversion to laparotomy was necessary due 
to  injury to the ileum in a patient with extensive adhesion formation. 
Medium-term complications included one case (2%) of mesh exposure. This 
finding is low to consistent with the 1–9% rate of mesh exposure previously reported 
for sacrocolpopexy by either the open or the laparoscopic route.3,4,6-9 De novo pain 
was not found, compared to 4% in a group with vaginal native tissue repair and 7.5% 
in a group with vaginal mesh repair previously described.22 De novo dyspareunia rate 
of 15% is comparable to rates of 8–42% that have been reported in the literature 
after conventional vaginal prolapse surgery and after mesh repair.22-25
The short follow-up of 6 months was an important limitation of this study. 
Furthermore, an independent clinical investigator who was not involved in 
the procedures would ideally have performed the postoperative examinations. 
The strengths of this study are the prospective design of the study, the uniform 
surgical technique performed by the same gynecologist and laparoscopic surgeon, 
and the use of standardized and validated instruments of measurement.
conclusIons
Laparoscopic sacrocolpopexy with bone anchor fixation is a safe surgical treatment 
and has a high short-term success rate  for apical compartment prolapse. For anterior 
and/or posterior compartment prolapse in the same patient, additional surgery (with 
laparoscopic mesh or vaginal colporrhaphy) should be considered.
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absTracT
introduction and hypothesis
The surgical treatment of vaginal vault prolapse can either be performed by the 
vaginal or the abdominal (laparoscopic) route.  The objective of this study was to 
compare the laparoscopic sacral colpopexy (LSC) and total vaginal mesh (TVM) for 
vaginal vault prolapse.
Methods
This study compared a prospective cohort of LSC with bone-anchor fixation and 
mesh limited to the apex to a prospective cohort of TVM with a symptomatic vault 
prolapse in 3 centers. Women in each cohort with point C> -3 who underwent either 
operation were included in this comparison. Primary outcome was failure in the apical 
compartment after 6 month follow up, defined as pelvic organ prolapse (POP) stage 
>II with prolapse complaints or re-treatment in apical compartment.
results
97 women were included, 45 LSC and 52 TVM. The failure rate of symptomatic 
vault prolapse was 1(2%) in each group (p=0.99). The failure rate (POP stage > II) in 
any compartment was 23 (51%) in the LSC group and 11 (21%) in the TVM group 
(p=0.002). Each technique had its own type of complications. 
Conclusion(s)
Short-term failure rates in the apical compartment after TVM and LSC were similar. In 
case of anterior or posterior prolapse additional mesh insertion or additional vaginal 
colporrhaphy is indicated in LSC surgery. 
InTroducTIon
The incidence of post-hysterectomy vaginal vault prolapse that requires surgery has 
been estimated at 1.3 per 1000 women-years.1 The risk of pelvic organ prolapse 
surgery was 4.7 times higher in women whose initial hysterectomy was indicated by 
prolapse.1 The surgical treatment of vaginal vault prolapse can either be performed 
by the vaginal (e.g. vaginal sacrospinous colpopexy and total vaginal mesh (TVM)) 
or the abdominal route (e.g. sacral colpopexy). A Cochrane systematic review and 
meta-analysis on the topic has shown that for the treatment of vaginal vault prolapse 
the abdominal sacral colpopexy was the superior procedure compared to vaginal 
sacrospinous colpopexy in terms of a lower rate of recurrent vault prolapse and less 
dyspareunia.2 Vaginal sacrospinous colpopexy was, however, quicker and cheaper to 
perform and women returned earlier to activities of daily living. Laparoscopic sacral 
colpopexy (LSC) provides the potential to combine the success rate of an abdominal 
approach with the faster recovery associated with a minimally invasive technique. The 
success rate of LSC has been reported to be 90–100% for the apical compartment.3-9 
TVM aims at suspension of the apical compartment by means of a bilateral 
sacrospinous ligament fixation.  The success rate of a TVM has been reported to be 
96% for the apical compartment and 91% for all the compartments.10 
Both abdominal and vaginal techniques treat the apical compartment, but the 
techniques are very different, and not many gynecologists perform both procedures. 
As a result only limited data are available that compare these two techniques. In a 
recent randomized controlled trial success rate in all vaginal compartments was 77% 
for LSC as compared with 43% in the TVM group.11 
The aim of this study was to compare LSC and TVM with regard to the management 
of vaginal vault prolapse in centers with special expertise in either LSC or TVM.
MaTerIal and MeThods
This study compared two prospective observational cohorts of consecutive women 
with symptomatic vault prolapse referred to 3 including centers:  Sint Franciscus 
Gasthuis (SFG), Rotterdam, Radboud University Nijmegen Medical Centre (RUNMC) 
and Reinier de Graaf Group (RdGG) Delft, the Netherlands.  SFG is specialized in LSC 
with bone-anchor fixation. Both RdGG and RUNMC are specialized in pelvic organ 
prolapse surgery, including TVM technique. 
Inclusion criterion for this study was patients with a symptomatic vault prolapse 
with point C of the Pelvic Organ Prolapse Quantification (POP-Q) examination > -3.12 
Exclusion criteria were inability to understand Dutch, pregnancy or contemplating 
future pregnancy, a compromised immune system and treatment for malignancy in 
the past. Additional exclusion criteria for the LSC were former rectosigmoid resection, 
extensive intra-abdominal / pelvic adhesions and body mass index > 40 kg/m2. 
Approval from the Central Medical Ethics committee ‘Toetsing Wetenschappelijk 
Onderzoek Rijnmond’ (TWOR), the Netherlands for the LSC cohort study was 
obtained on 22 of December 2004. The data concerning the TVM patients were 
collected as part of an ongoing outcome registration project, which was approved by 
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the CME/IRB on April 19th, 2006. All patients provided written informed consent 
before participation and were recruited between July 2004 and November 2009.
Baseline as well as post-operative evaluation after 6 weeks and 6 months 
included medical history, a gynecologic investigation including a POP-Q examination 
and validated urogynecologic questionnaire, which contains the Dutch validated 
Urogenital Distress Inventory (UDI), Defecatory Distress Inventory (DDI) and the 
Incontinence Impact Questionnaire (IIQ).13,14
In both groups patients received a single prophylactic dose of antibiotics. All 
LSC were performed by two of the authors together (RW and GM) with a bone 
anchor fixation, a technique previously described by van der Weiden et al.15 The 
operative procedure can be summarized as follows:  after developing the presacral 
avascular plane, the cortical bone of the sacral segment 3 is penetrated in the 
midline with the laparoscopic bone anchor. Fixation to the sacrum is performed 
with a selftapping titanium Corkscrew Suture or with flat headed titanium screws. 
A 4.0 x 3.0 cm piece of monofilament knitted polypropylene mesh (Gynemesh Soft, 
Ethicon, Norderstedt, Germany) was sutured to the apical part of the posterior 
vaginal wall with 4 Mersilene 1-0 sutures (Ethicon, Norderstedt, Germany) and was 
subsequently sutured to the polyester-2 ligatures attached to the bone anchor. The 
mesh was covered with peritoneum placing it in a retroperitoneal position. Since 
the rate of vaginal mesh exposure is significantly higher when abdominal surgery is 
combined with vaginal surgery,16 and placement of a posterior mesh increased the 
risk of postoperative complications and appeared unnecessary in the absence of an 
associated Burch procedure or a patent posterior prolapse17 additional prolapse or 
incontinence procedures were not performed concomitantly. 
All TVM procedures were performed by four gynecologists, who were formally 
trained for the tension-free vaginal mesh procedure as described in the paper by 
Fatton et al. prior to the start of this study.18 As recommended, a full thickness midline 
incision was made through the fibromuscular wall of the vagina in order to reduce 
the known risk of mesh exposure.
Primary outcome was failure in the apical compartment, defined as apical POP 
> II with prolapse complaints or re-treatment in the apical compartment (failure 
outcome I). For secondary outcomes 6 different definitions for failure were tested: 
• Failure outcome II: POP stage > II in one or more compartment(s) or re-treatment
• Failure outcome III: POP stage > II in one or more compartment(s) with prolapse 
complaints or re-treatment
• Failure outcome IV: POP at or beyond hymen in one or more compartment(s) with 
prolapse complaints or re-treatment
• Failure outcome V: Point C>-3 or apical re-treatment
• Failure outcome VI: Point C>-3 with prolapse complaints or apical re-treatment
• Failure outcome VII: prolapse complaints or re-treatment
Prolapse complaints were considered present if patients responded affirmative to the 
questions of the UDI referring to seeing or feeling a vaginal bulge and the experience 
of at least a little bother from either of these symptoms.13 Data on symptom-scores 
of the UDI, DDI and IIQ questionnaires, duration of surgery, blood loss, length of 
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hospitalization and complications were collected. Pain was a secondary outcome 
as well and considered significant in case a patient responded “yes, moderately 
to quite a bit” to the question “Do you experience pain in the lower abdomen or 
genital region?”  Dyspareunia was considered significant in case a patient responded 
“yes; moderately to quite a bit” to the question “Do you experience pain during 
intercourse?” Stress urinary incontinence was considered significant in case a patient 
responded “yes, moderately to quite a bit” to the UDI question “Do you experience 
urinary leakage during physical activity, coughing, or sneezing?”
Sample size calculation prior to this comparison study was performed as follows: 
given the success rates for the apical compartment in literature of 90-100%3-8  after 
LSC and 96% after TVM,10  we hypothesized that we would not find a significant 
difference in primary outcome. Based on an overall failure in all compartments of 
23% in the LSC group11  and 57% in the TVM group,11  29 patients would be needed 
in each group to detect a difference of 34% in failure rate with a power of 80% and 
alpha 0.05. 
Continuous variables were analyzed using the independent-samples t-test to 
compare means or Mann-Whitney U test to compare independent medians and 
Wilcoxon signed rank test to compare related medians. Categorical variables were 
compared using the chi-square test and the Fisher exact test in case of small numbers. 
Related samples were compared using the paired-samples t-test to compare means. 
A p-value of <0.05 was considered statistically significant.  Statistical analysis was 
performed using Statistical Package for the Social Sciences, version 18.0 (SPSS inc., 
Chicago, Ill., USA).
resulTs
Forty-five women were included in the LSC group and 52 women were included in 
the TVM group. A flowchart of the two groups is presented in figure 1. All women 
undergoing LSC and 20 out of 52 (38%) undergoing TVM have previously been 
described.10,19  Baseline characteristics are shown in table 1. The TVM group had 
significantly more patients with overall a higher stage of POP, however the apical 
compartment prolapse was similar in the two groups (point C, table 1). One patient in 
the TVM group underwent an anterior repair with mesh (anterior avaulta) 2 years prior 
to the TVM. The total mesh was placed over the previous mesh without complications. 
Peri- and post-operative data are shown in table 2. Operating time was shorter 
(median 50 minutes) in the TVM group, but amount of blood loss, hospital stay and 
duration of indwelling urinary catheter was in favor of the LSC group. The frequency 
of temporary urinary retention was significantly different between the two groups. 
The other complications differed in character, but were similar in frequency (table 3). 
POP-Q measurements are shown in table 4. Improvement is seen in each 
compartment in both groups. No difference was found in the improvement of the 
apical compartment. In the TVM group, however, we found significantly lower 
prolapse stages in the anterior and posterior compartment after 6 months, despite 
the higher prolapse stages at baseline.
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Figure 1. Patient enrollment and follow-up. 
 
 
49 eligible for LSC 91 eligible for TVM 
45 underwent LSC 52 underwent TVM 
45 Completed 6 months follow-up 
 -45 completed POPQ 
 -40 completed questionnnaires 
52 completed 6 months follow-up 
 -52 completed POPQ 
 -49 completed questionnaires 
33 excluded (point C<-3) 
6 excluded (would not be 
able to return for follow-up 
due to dementia) 
4 excluded (uterus in situ) 
figure 1. Patient enrollment and follow-up.
table 1. Patient characteristics.
Characteristics lsC (n=45) tvM (n=52) p-value
Age(years)a 65.6 (9.7) 69.1 (11.6) 0.12
Parity (number)b 2 (0-6) 3 (0-6) 0.12
BMI (kg/m2) a 25.6 (3.1) 26.2 (3.6) 0.33
Comorbidity c 5 (11%) 25 (48%) <0.001
Previous  surgery c
Abdominal hysterectomy 18 (40%) 13 (25%) 0.15
Vaginal hysterectomy 27 (60%) 39 (75%) 0.11
Anterior colporraphy 24 (53%) 23(44%) 0.54
Anterior Mesh procedure 0 (0%) 1 (2%) 0.54
Posterior colporrhaphy 24 (53%) 18 (35%) 0.11
Sacrospinous ligament fixation 0 (0%) 2 (4%) 0.12
Sacrocolpopexy 0 (0%) 2 (4%) 0.17
Colpocleisis 0 (0%) 2 (4%) 0.17
Previous POP procedure 29 (64%) 28 (54%) 0.29
More than one POP procedure 2 (4%) 6 (12%) 0.14
Previous incontinence surgery c 9 (20%) 4 (8%) 0.08
Overall POP-stage c
I 2 (4%) 0 (0%) 0.21
II 31 (69%) 5 (10%) <0.001
III 12 (27%) 43 (83%) <0.001
IV 0 (0%) 4 (7%) 0.08
Point Cb 0 (-3 to 4) 1 (-3 to 9) 0.41
Data presented as mean (standard deviation)a and p-value calculated with independent-sample 
t-test , data presented as median (range)b and p-value calculated with Mann-Whitney U test or data 
presented as number of patients (%)c and p-value calculated with chi-square test and the Fisher 
exact test in case of small numbers. 
LSC= laparoscopic sacral colpopexy. TVM= total vaginal mesh.
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table 2. Peri- and post operative data.
variable lsC (n=45) tvM (n=52) p-value
Concomitant surgery a 2 (4%) 1 (2%) 0.35
TVT-O 0 1 (2%) 0.54
laparoscopic adhesiolysis 1 (2%) 0 0.46
laparoscopic aspiration pseudocysts 1 (2%) 0 0.46
Spinal analgesia a 0 33 (63%) <0.001
Operating time (min) b 120 (60-240) 70 (44-110) <0.001
Blood loss (ml) b 50 (10-100) 100 (50-1300) <0.001
Duration urinary catheter (days) b 1 (1) 2 (1-10) <0.001
Hospital stay (days) b 2 (0-5) 3 (0-8) <0.001
Data presented as number of patients (%) a and p-value calculated with chi-square test and the Fisher 
exact test in case of small numbers or data presented as median (range)b and p-value calculated with 
Mann-Whitney U test.
LSC= laparoscopic sacral colpopexy. TVM= total vaginal mesh.
table 3. Complications.
Complications (peri-operative) lsC (n=45) tvM (n=52) p-value$
Blood loss > 500 ml 0 (0%) 1 (2%) 0.54
Bladder perforation 0 (0%) 1 (2%) 0.54
Repeat surgery for postoperative hemorrhage 0 (0%) 1 (2%) 0.54
Haematoma 0 (0%) 2 (4%) 0.28
Temporary urinary retention 0 (0%) 10 (19%) 0.001
Conversion laparotomy due to injury ileum 1 (2%) 0 (0%) 0.46
Temporary neurologic complaints caused by irritation 
left lumbar plexus
1 (2%) 0 (0%) 0.46
outcome at follow-up 6 months
Cumulative mesh exposure 1 (2%) 4 (8%) 0.19
Re-treatment for POP 2 (4%) 0 (0%) 0.21
Pain (lower abdomen/genital area)
      Baseline 9/43 (21%) 11/44(25%) 0.65
      At 6 months 1/40 (3%) 1/45(2%) 0.50
      De novo pain 0 (0%) 0 (0%) 0.99
Dyspareunia
      Baseline 3/18 (17%) 4/17 (24%) 0.29
      At 6 months 3/21 (14%) 3/18 (17%) 0.33
      De novo dyspareunia 2/18 (11%) 1/17 (6%) 0.40
Stress urinary incontinence
      Baseline 3/43 (7%) 11/45 (24%) 0.02
      At 6 months 3/41 (7%) 5/46 (11%) 0.25
      De novo stress urinary incontinence 2/41 (5%) 2/41 (5%) 0.38
Data presented as numbers (%).LSC= laparoscopic sacral colpopexy. TVM= total vaginal mesh.
$ chi-square test and the Fisher exact test in case of small numbers
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In table 5 failure rates for various failure definitions are shown. The failure rate 
of symptomatic vault prolapse (failure I:  apical compartment POP stage > II with 
prolapse complaints or apical re-treatment) was 2% in de LSC group and 2% in 
de TVM group (p=0.99).  All definitions considering the apical compartment with 
or without prolapse complaints (I, V, VI) showed similar failure rates between the 
groups. However, in case a definition of failure included other compartments or 
prolapse complaints alone (II, III, IV, VII) the LSC group had a significant higher failure 
rate compared with the TVM group. 
Effect of surgery on symptom bother and health related quality of life scores is 
shown in table 6. UDI domain score of genital prolapse, overactive bladder, obstructive 
micturition and pain improved significantly after surgery in both groups. The domain 
score of genital prolapse 6 months after TVM was significantly lower (less bother) 
compared to the score of de the LSC group.
coMMenT
Comparison between LSC and TVM in women with symptomatic vaginal vault prolapse 
revealed comparable short-term failure rates in the apical compartment. However, 
the overall POP failure rate (symptomatic failure in any of the compartments) was 
significantly higher in the LSC compared with the TVM group. Different types of 
complications were seen in the two groups. Scores in the UDI domain genital prolapse 
table 4. POPQ measurements at baseline and 6 months post surgery.
PoPQ point
Baseline P-valueβ 6 months P-valueβ
p-valueα 
within group
lsC
(n=45)
tvM
(n=52)
lsC versus 
tvM
lsC
(n=45)
tvM
(n=52)
lsC versus 
tvM lsC/tvM
Aa -2 (-3 to 1) 3 (-3 to 3) <0.001 -2 (-3 to 0) -3(-3 to 0) <0.001 0.002/<0.001
Ba  -2 (-3 to 3) 3 (-2 to 9) <0.001 -2 (-3 to 2) -3 (-3 to 4) <0.001 0.005/<0.001
C 0 (-3 to 4) 1 (-3 to 9) 0.41 -8 (-8 to -3) -8 (-10 to 4) 0.074 <0.001/<0.001
GH 3 (2 to 5) 5 (2 to 7) <0.001 3 (2 to 5) 3 (2 to 6) 0.21 1.00/<0.001
PB 3 (2 to 3) 3 (1 to 7) 0.13 3 (2 to 3) 3 (1 to 6) <0.001 0.16/0.23
TVL 8 (7 to 9) 9 (5 to 10) <0.001 8 (7 to 9) 9 (6 to 10) <0.001 1.00/0.009
Ap -2 (-3 to 2) 1 (-3 to 3) <0.001 -2 (-3 to 0) -3 (-3 to 0) <0.001 <0.001/<0.001
Bp -2 (-3 to 2) 2 (-3 to 9) <0.001 -2 (-3 to 2) -3 (-3 to 4) <0.001 0.001/<0.001
POP stage anterior 1 (0 to 3) 3 (1 to 4) <0.001 1 (0 to 3) 0 (0 to 3) <0.001 <0.001/<0.001
POP stage apical 2 (0 to 3) 3 (0 to 4) 0.357 0 (0 to 1) 0 (0 to 3) 0.31 0.016/<0.001
POP stage 
posterior
1 (0 to 3) 3 (0 to 4) <0.001 1 (0 to 3) 0 (0 to 3) <0.001 0.001/<0.001
Total POP stage 2 (1 to 3) 3 (2 to 4) <0.001 1 (0 to 3) 1 (0 to 3) <0.001 <0.001/<0.001
Change C - - - 7 (5 to 12) 7 (3-19) 0.97 -
Data presented as median (range). POP= pelvic organ prolapse. LSC= laparoscopic sacral colpopexy. TVM= total 
vaginal mesh.
β Mann-Whitney U test. α Wilcoxon signed rank test
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improved significantly in both groups, but the post-operative genital prolapse score 
was lower (less complaints) in the TVM group.
The strengths of this study are the prospective design of the study and the use 
of standardized and validated instruments of measurement. Furthermore, since 
comparative data on these two main techniques for vaginal vault prolapse are 
limited, this is an actual and highly relevant topic in urogynecological practice. The 
short follow-up of 6 months and the non-randomized selection of intervention were 
important limitations of this study. Furthermore, an independent clinical investigator 
who was not involved in the management of the patients would ideally have 
performed the postoperative examinations. 
Although POPQ point C=-3 is not a common cutoff point for the treatment 
evaluation of POP, we have decided to use this cutoff in the present study. We 
have noticed patients with a vault prolapse with vaginal bulge symptoms in women 
despite an overall POP < stage II. In all those cases with symptoms of a vaginal bulge 
the POPQ point C was > -3 cm. Therefore we choose to introduce this new cutoff 
point. Furthermore we noticed that definitions on failure/success in studies on vault 
prolapse are very different. They vary from “point C being higher than one half of the 
total vaginal length and no need for re-operation or pessary use for a symptomatic 
apical failure”8 to “POP-Q points Aa, Ba, C, Bp, and Ap < -1 cm individually and 
as a total”.11 To facilitate comparison of our results with the available literature, 
we included various definitions of failure. Two of the definitions include the cutoff 
point C >-3, since patient inclusion was allowed with point C> -3 with complaints. 
If we only use the common POP stage > II for failure (or even “at or beyond the 
hymen”) a part of the patients would have already achieved success even before they 
underwent surgery. The various definitions in the literature demonstrate the search 
for a suitable definition of successful treatment of vault prolapse.  Sometimes the 
vault may be prolapsed clinically to a significant extent and yet be measured as POP 
stage I, demonstrating a limitation of the POP-Q scoring system with respect to the 
apical compartment.   We suggest using this new cutoff point in the evaluation of 
vaginal vault prolapse studies to avoid an overestimation of outcomes.
The high success rates of the LSC and TVM in the apical compartment were 
comparable to the rates available in literature.3-10,21 However, the overall failure rate 
of 51% in the LSC group was higher compared to 23% failure rate after two years 
follow-up as reported in a recent randomized controlled trial on LSC versus TVM 
for vaginal vault prolapse.11 This may be explained by the fact that mesh was only 
applied to the apex without combining LSC with anterior or posterior repairs (either 
laparoscopically applied mesh or with vaginal colporrhaphia) in the present study. 
In a cohort study on 22 LSC an overall failure rate of 73% after2 years was found 
when a mesh was attached to the apex and the posterior wall only.9 Anterior mesh 
application during LSC therefore seems important.  Adequate level I support has a 
critical role on the position of the anterior and posterior vagina.21,22 However, this 
adequate level I support has not prevented the occurrence of anterior and posterior 
wall prolapse in many cases in the LSC group. Combining the LSC with anterior or 
posterior repairs, either performed laparoscopically or vaginally, might have resulted 
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table 5. Failure at 6 months for different definitions.
failure definition
lsC
n=45
tvM
n=52 p-value$
or  
(95%Ci)
rr  
(95%Ci)
(I) Apical compartment POP 
stage > II with prolapse 
complaints or apical 
re-treatment
1(2%) 1(2%) 0.99 1.1(0.07-18.7) 1.0(0.9-1.1)
(II) POP stage > II in one or 
more compartment
23*(51%) 11(21%) 0.002 3.9(1.6-9.4) 2.4(1.3-4.4)
POP in every separate 
compartment
Anterior 14^(31%) 9(17%) 0.11 2.2(0.8-5.6) 1.8(1.0-2.2)
Posterior 10(22%) 4(8%) 0.04 2.2(1.0-11.8) 2.9(1.0-8.6)
Apical 1#(2%) 2(4%) 0.39 0.6(0.1-5.9) 0.5(0.1-5.7)
(III) Overall POP stage > II 
with prolapse complaints or 
re-treatment
7/42(17%) 1/52(2%) 0.02 10.2(1.2-86.6) 1.2(1.0-1.4)
(IV) POP at or beyond hymen 
with prolapse complaints or 
re-treatment
6/44(14%) 1/52(2%) 0.04 8.1(0.9-69.7) 1.1(1.0-1.3)
(V) Point C>-3 or apical 
re-treatment 
2(4%) 2(4%) 0.99 1.2(0.2-8.6) 1.0(0.9-1.1)
(VI) Point C>-3 with prolapse 
complaints or apical 
re-treatment
1(2%) 1(2%) 0.99 1.1(0.07-18.7) 1.0(0.9-1.1)
(VII) Prolapse complaints or 
re-treatment
12/41(29%) 3/45(7%) 0.006 5.8(1.5-22.4) 1.3(1.1-1.6)
Data presented as numbers (%). OR=odds ratio, 95%CI=95% confidence interval. RR= Relative risk.
LSC= laparoscopic sacral colpopexy. TVM= total vaginal mesh.
$ chi-square test and the Fisher exact test in case of small numbers
*=including 1 re-sacrocolpopexy and 1 anterior colporrhaphy within 6 months
^=including 1 anterior colporrhaphy within 6 months; #=including 1 sacrocolpopexy within 6 months
in better overall results in the LSC group. After evaluation of these results this has 
now become the standard procedure in LSC.  
Our overall success rate of the TVM was high compared to the results of Maher et 
al, but in that study the follow-up was 1.5 years longer and 12 out of the 55 patients 
with TVM were considered as failures due to lost to follow-up in that study.11 Our 
success rate of the TVM was low compared to a previously published cohort by Milani 
et al.10 
In contrast with the results of the study by Maher, the symptom score of genital 
prolapse after 6 months was significantly lower (less complaints) in the TVM group, 
compared to the LSC group.11 Recurrent prolapse symptoms in the LSC group generally 
arose from the untreated anterior or posterior compartment. The application of mesh 
to the apex only in the LSC group might also explain this difference.
The types of complications were remarkably different between the two 
techniques. There was a high rate of temporary urinary retention in the TVM group. 
The complications with long lasting consequences were similar in both groups. Major 
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table 6. Effect of surgery on Symptoms and Health related quality of life scores.
domain
Baseline 6 months
P value  
within group*
P value 
between 
groups**
lsC  
(n=43)
tvM 
(n=46)
lsC
(n=40)
tvM
(n=49) (lsC / tvM)
lsC versus 
tvM 
baseline/6m
udi
Genital prolapse 67.9(30.2) 63.0(18.7) 11.3(22.5) 2.0(9.9) <0.001/<0.001 0.49/0.01
OAB 34.6(26.0) 32.2(26.8) 17.6(19.2) 15.4(19.7) <0.001/0.001 0.68/0.59
Incontinence 16.3(20.7) 24.2(26.8) 10.6(17.4) 15.9(21.8) 0.11/0.10 0.15/0.20
Obstructive micturition 34.5(24.8) 28.1(29.9) 15.4(21.8) 12.2(23.8) <0.001/<0.001 0.28/0.51
Pain 25.4(24.8) 27.7(27.6) 12.5(15.9) 10.1(16.8) 0.001/<0.001 0.69/0.49
ddi
Constipation 12.7(19.8) 14(18.7) 11.1(20.4) 8.2(15.1) 0.36/0.12 0.75/0.45
Obstructed defecation 13.4(14.6) 12.0(17.1) 7.5(11.1) 9.1(13.4) 0.003/0.10 0.69/0.56
Pain 6.2(15.9) 9.6(21.5) 6.7(15.5) 7.1(15.9) 0.99/0.56 0.40/0.89
Incontinence 4.4(11.7) 9.8(15.8) 5.0(10.1) 4.3(8.8) 0.99/0.03 0.07/0.72
iiQ
Physical functioning 20.8(26.9) 25.0(28.2) 14.1(24.0) 11.2(21.1) 0.17/0.004 0.50/0.56
Mobility 26.4(20.4) 32.0(24.6) 24.5(25.4) 15.7(19.5) 0.57/0.003 0.25/0.08
Social functioning 12.4(11.9) 15.9(18.1) 7.6(13.9) 6.7(10.6) 0.10/0.01 0.35/0.74
Embarrassment 12.6(20.7) 21.8(26.1) 7.2(13.9) 6.9(12.3) 0.15/0.002 0.09/0.92
Emotional health 21.4(21.4) 24.9(25.6) 15.7(21.1) 9.3(13.3) 0.51/0.002 0.51/0.10
UDI, DDI, IIQ data presented as mean (standard deviation); LSC= laparoscopic sacral colpopexy. TVM= 
total vaginal mesh.
Scores range between 0 (least bother) to 100 (maximum bother).
* paired t-test, **independent t-test
complications such as bowel injury, de novo dyspareunia, de novo pain and exposure 
did not differ between both groups in this study.  In comparison with earlier studies 
on these two techniques no major differences were found.7,10,11,20  In the RCT of 
Maher et al the reoperation rate in the LSC group was significantly lower, compared 
to the reoperation rate in the TVM group.11 This discrepancy between the results of 
these studies might be explained by the shorter follow-up as mentioned earlier.
Reports on major complications have recently been published on both techniques 
subject to this study.11,23-28 In the LSC group injury of the bowels, bowel herniation 
though a port site and lumber/sacral osteomyelitis with sepsis are possible life-
threatening complications that were described before.11,23,24,25 In this study one ileum 
injury occurred, that was recognized immediately and to treat this injury adequately, 
the surgeon choose to convert to a laparotomy. In the TVM group acute massive 
hemorrhage, retroperitoneal hematoma and infected pelvic hematoma have been 
reported, indicating major, possible life-threatening complications as well.11,27,28,29   A 
FDA Public Health Notification update informed the United States public that “surgical 
mesh for transvaginal repair of POP is an area of continuing serious concern” and 
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“serious complications associated with surgical mesh for transvaginal repair of POP 
are not rare”.30 A definition for a serious complications was not given. Severe/serious 
complications such as de novo dyspareunia, de novo pain and exposure did not differ 
between both groups in this study. 
The LSC and the TVM both involve a significant learning curve. Both techniques 
are associated with potential serious complications. The FDA promulgated a number 
of recommendations including proper training of the surgeon, certification and 
counseling of the patient. Therefore centralization of these procedures in the hands 
of surgeons with proven experience seems mandatory. 
Although either procedures (LSC or TVM) will be adequate in most patients with 
vault prolapse, specific indications for either technique may exist. For example, in 
elderly women with co-morbidity spinal analgesics and shorter duration of surgery 
as in TVM may be advantageous. Furthermore, in patients with known pelvic/
abdominal adhesions a TVM procedure could be preferable. In a young, healthy, 
sexually active women, the more superficial vaginal insertion of mesh maybe 
avoided when choosing LSC.
In order to make a deliberate choice between these two types of surgery and to 
improve the guidance to our patients, further evaluation with long-term follow-up 
of both procedures is required, preferably by well-designed RCT’s with a long-term 
follow-up of both procedures.
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absTracT 
introduction and hypothesis 
The objective of this study is to evaluate the complications and anatomical and 
functional outcomes of the surgical treatment of mesh-related complications. 
Methods 
A retrospective cohort study of patients who underwent complete or partial mesh 
excision to treat complications after prior mesh-augmented pelvic floor reconstructive 
surgery was conducted. 
results 
Seventy-three patients underwent 30 complete and 51 partial mesh excisions. 
Intraoperative complications occurred in 4 cases, postoperative complications in 13. 
Symptom relief was achieved in 92% of patients. Recurrence of pelvic organ prolapse 
(POP) occurred in 29% of complete and 5% of partial excisions of mesh used in POP 
surgery. De novo stress urinary incontinence (SUI) occurred in 36% of patients who 
underwent excision of a suburethral sling. 
Conclusions 
Mesh excision relieves mesh-related complications effectively, although with a 
substantial risk of serious complications and recurrence of POP or SUI. More complex 
excisions should be performed in skilled centers.
InTroducTIon
Pelvic organ prolapse (POP) with or without stress urinary incontinence (SUI) is a 
major health issue in older women. The prevalence of POP-Q stage 2 or more varies 
from 37% to 50%.1,2 A woman’s lifetime risk of undergoing surgery for POP or SUI 
is approximately 11%.3 Of those who undergo vaginal prolapse repair of the anterior 
vaginal wall, POP recurrence rates can reach 70%.4 Given this high recurrence rate 
after traditional vaginal prolapse surgery, many pelvic reconstructive surgeons began 
to use vaginal mesh to maintain the advantage of vaginal surgery and to obtain 
improved support. The use of synthetic mesh in procedures such as groin hernia 
surgery, abdominal sacrocolpopexy, and suburethral slings has been proven to be 
effective and is well established.5-7 However, current data suggest that the use of mesh 
in vaginal prolapse surgery is associated with both benefits and risks. Few randomized 
controlled trials have been published. They reveal improved anatomic outcomes and 
lower recurrence rates, but similar subjective outcomes and substantial mesh-related 
complications after vaginal mesh placement when compared to traditional vaginal 
prolapse repairs.8-11 
Mesh-related complications include mainly mesh exposure12  into the vagina or 
even the bladder or bowel, infection, granuloma, pain syndrome, dyspareunia, and 
voiding problems. Pelvic abscesses and rectovaginal or vesicovaginal fistula are also 
reported.13-17 These complications occur in approximately 10% of patients and may 
lead to a significant decrease in quality of life.8-11,18-20 The extent of impact of mesh-
related complications on quality of life has so far not been investigated thoroughly. 
Complications can be treated noninvasively in selected cases. However, with more 
severe mesh-related complications, partial or complete mesh excision is most of the 
time unavoidable. A recent review reported a higher rate of repeat surgery due to 
complications after vaginal mesh procedure compared to the rate of repeat surgery 
due to recurrent prolapse after conventional vaginal prolapse surgery.21 
The objective of this retrospective cohort study is to evaluate the surgical treatment 
of mesh-related complications with regard to complications and anatomical and 
functional outcomes. 
MaTerIals and MeThods
We conducted a retrospective cohort study including all patients who underwent 
surgical mesh excision, after prior POP and/or SUI surgery with mesh, between 
January 2005 and September 2010 in the Department of Obstetrics and Gynaecology 
of the Radboud University Nijmegen Medical Centre, a tertiary referral center in the 
Netherlands. In accordance with Dutch law, retrospective observational studies are 
exempt from submission for approval to a medical ethics review committee. Patients 
with mesh-related complications that were effectively managed on an outpatient 
basis were not included. Since we regarded voiding dysfunction after insertion of a 
suburethral sling a complication more specific for stress incontinence surgery than for 
vaginal mesh in general, we excluded these patients from further analysis (Figure 1). 
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Patient characteristics, characteristics of mesh insertion procedure, relevant surgical 
history, POP-Q stage,22 SUI and overactive bladder (OAB) complaints before mesh 
excision, symptoms and signs of mesh-related complications, and prior therapy were 
extracted from paper and electronic medical records. Operative reports and hospital 
discharge reports were used to collect characteristics of mesh excision, additional 
surgery, intraoperative complications, postoperative complications, and hospital 
stay. Outcomes after mesh excision including relief of mesh-related symptoms, mesh 
exposure, recurrence of POP, de novo SUI and OAB, and need of re-excision were 
collected at the latest available moment of follow-up. The extent of symptom relief 
was determined by patient history and categorized into complete relief when patients 
expressed no remaining symptoms, improvement when some symptoms persisted, 
and no improvement when symptoms had been unchanged. We defined recurrence 
of POP as the development of at least POP stage 2 after mesh excision or increase of 
POP with at least one stage when there was POP stage 2 before in the compartment 
where mesh was excised or occurring after apical mesh excision. 
Patients who underwent partial mesh excision, including section of mesh, were 
compared to patients who underwent complete mesh excision. Continuous variables 
were compared using the Mann–Whitney U test. Categorical variables were compared 
using the chi-square test and, in case of small numbers, with Fisher’s exact test. A P 
infection, granuloma, pain syndrome, dyspareunia, and
voiding problems. Pelvic abscesses and rectovaginal or
vesicovaginal fistula are also reported [13–17]. These
complications occur in approximately 10% of patients and
may lead to a significant decrease in quality of life [8–11,
18–20]. The extent of impact of mesh-related complications
on quality of life has so far not been investigated
thoroughly. Complications can be treated noninvasively in
selected cases. However, with more severe mesh-related
complications, partial or complete mesh excision is most of
the time unavoidable. A recent review reported a higher rate
of repeat surgery due to complications after vaginal mesh
procedure compared to the rate of repeat surgery due to
recurrent prolapse after conventional vaginal prolapse
surgery [21].
The objective of this retrospective cohort study is to
evaluate the surgical treatment of mesh-related complica-
tions with regard to complications and anatomical and
functional outcomes.
Materials and methods
We conducted a retrospective cohort study including all
patients who underwent surgical mesh excision, after prior
POP and/or SUI surgery with mesh, between January 2005
and September 2010 in the Department of Obstetrics and
Gynaecology of the Radboud University Nijmegen Medical
Centre, a tertiary referral center in the Netherlands. In
accordance with Dutch law, retrospective observational
studies are exempt from submission for approval to a
medical ethics review committee. Patients with mesh-
related complications that were effectively managed on an
outpatient basis were not included. Since we regarded
voiding dysfunction after insertion of a suburethral sling a
complication more specific for stress incontinence surgery
than for vaginal mesh in general, we excluded these
patients from further analysis (Fig. 1).
Patient characteristics, characteristics of mesh insertion
procedure, relevant surgical history, POP-Q stage [22], SUI
and overactive bladder (OAB) complaints before mesh
excision, symptoms and signs of mesh-related complica-
tions, and prior therapy were extracted from paper and
electronic medical records. Operative reports and hospital
discharge reports were used to collect characteristics of
mesh excision, additional surgery, intraoperative complica-
tions, postoperative complications, and hospital stay. Out-
comes after mesh excision including relief of mesh-related
symptoms, mesh exposure, recurrence of POP, de novo SUI
and OAB, and need of re-excision were collected at the
latest available moment of follow-up. The extent of
symptom relief was determined by patient history and
categorized into complete relief when patients expressed no
remaining symptoms, improvement when some symptoms
persisted, and no improvement when symptoms had been
unchanged. We defined recurrence of POP as the develop-
ment of at least POP stage 2 after mesh excision or increase
of POP with at least one stage when there was POP stage 2
before in the compartment where mesh was excised or
occurring after apical mesh excision.
Patients who underwent partial mesh excision, including
section of mesh, were compared to patients who underwent
complete mesh excision. Continuous variables were com-
pared using the Mann–Whitney U test. Categorical varia-
bles were compared using the chi-square test and, in case of
small numbers, with Fisher’s exact test. A P value of ≤0.05
Patients who underwent 
mesh excision 
N = 83 
Excluded: patients who had urinary 
retention after suburethral sling 
N = 10 
Patients who underwent 
mesh excision 
N = 73 
Patients who underwent 
mesh excision 
N = 75 
Patients who underwent 
second excision of other mesh 
N = 2 
Patients who underwent re-excision 
N = 6 
Procedures of 
mesh excision 
N = 81 
Complete excisions 
N = 30 
Partial excisions 
N = 49 
Sections 
N = 2 
Fig. 1 Flowchart of inclusion
of patients who underwent
excision of mesh
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figure 1. Flowchart of inclusion of patients who underwent excision of mesh.
CHAPTER 9122
value of ≤0.05 was considered statistically significant. Data were analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, IL, USA). 
surgical technique
An examination under anesthesia was performed and the problematic area of the 
mesh was identified. When there was suspicion of mesh exposure in the bladder or 
bowel, cystoscopy and/or rectal examination was used to identify the presence of 
exposed mesh in the bladder or rectum. 
Partial vaginal mesh excision
In case of a limited vaginal exposure with mild symptoms, the exposure site was 
circumcised and the edges of the vaginal epithelium were mobilized approximately 1 
cm around the exposure. The extruded part of the mesh was then removed and the 
edges of the vaginal epithelium trimmed, where appropriate, and reapproximated. 
Complete mesh excision via the vaginal approach
When there were larger exposures, severe symptoms, and/or involvement of the 
bladder or bowel (described in the “Results” section), the intention was to perform 
total mesh excision or to remove as much mesh as possible in case of mesh arms 
passing through the obturator space, ischiorectal fossa, or sacrum. The vaginal 
epithelium covering the mesh was injected with normal saline or 0.5% lidocaine 
with 1:200,000 epinephrine for hydrodissection. A midline or inverted U-shaped full-
thickness incision was performed over the palpable mesh and vaginal epithelium 
was sharply dissected from the mesh as far laterally as possible. The mesh, where 
necessary with a layer of interlaced fibrotic tissue, was carefully dissected from the 
bladder or rectum using both sharp and gentle blunt dissection. Sharp dissection of 
posterior mesh was performed over a finger placed into the rectum to avoid rectal 
injury. Once the body of the mesh was freed and the mesh arms were visualized, 
tension was applied to expose the maximum amount of mesh. The body of the mesh 
was then separated from the mesh arms at the most lateral position possible. In 
some cases of excision of sacrocolpopexy mesh, a hysteroscope was used to enable 
a higher and thus more complete mesh removal. When hemostasis was achieved, 
the vaginal epithelium was reapproximated. If necessary, concomitant procedures for 
prolapse repair or other gynecologic disorders were performed. 
When the tape was also exposed intravesically, firstly, two ureteral stents were 
inserted. The bladder was opened through the pubocervical fascia and the tape 
excised, taking utmost care of the ureters. The bladder was then closed in two layers, 
taking care to avoid the ureters. The ureteral stents were removed at the end of the 
procedure. The bladder was drained for 7–14 days with an indwelling catheter. An 
ultrasound control of the kidneys was performed after 1 day. 
Abdominal mesh excision
An abdominal approach was applied for the excision of mesh used in sacrocolpopexy 
or suburethral slings when previous vaginal approach has not been successful or in 
case of extensive bladder involvement. 
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In abdominal excision of sacrocolpopexy mesh, the abdominal cavity was accessed 
through a vertical midline incision. The intestines were packed out of the pelvis 
with moist laparotomy gauzes and held in place with a retractor. Adhesiolysis was 
performed as necessary to allow adequate visualization. The mesh was removed from 
the sacrum and apex of the vagina by both sharp and blunt dissection. The vaginal 
vault was closed, leaving a small opening for postoperative drainage. For abdominal 
excision of transvaginal tape (TVT) or excision of other intravesical localized mesh, 
a Pfannenstiel incision allowed entry to the Retzius space. After localizing the tape, it 
was dissected from the abdominal wall and bladder. 
In case of an intravesical exposure, dissection was continued down to the point 
of entry of the tape into the bladder, the bladder was opened, and the mesh was 
removed completely. The bladder was then closed in two layers, taking care to 
avoid the ureters. If necessary, any remaining mesh in the vagina was removed by a 
vaginal approach as described above. The bladder was drained for 7–14 days with an 
indwelling catheter. When the resection had to be done in proximity of the ureters, an 
ultrasound control of the kidneys was performed after the mesh excision procedure 
and after the removal of the ureteral stents. 
resulTs
Between January 2005 and September 2010, 83 patients underwent surgical excision 
of mesh used in POP or SUI surgery. Ten patients required excision of mesh because 
of urinary retention after insertion of a suburethral sling and were withdrawn from 
further analysis. Of the remaining 73 patients who underwent mesh excision, 2 
patients underwent a second excision for other mesh in another compartment. In 
further analysis, these 2 patients were considered as 4 individuals, resulting in 75 
patients. Six patients required a re-excision of the same mesh. Overall, there were 81 
operations for mesh excision, of which 30 (37%) were complete excisions, 49 (61%) 
partial excisions, and 2 (2%) sections of mesh (Figuur 1). In further analysis, sections 
of mesh were considered as partial mesh excisions. 
Patient demographics and characteristics before mesh excision are summarized 
in Table 1. A variety of mesh materials were excised in our population: Gynemesh™, 
Mersilene™, Prolift™, Ultrapro™, TVT™, TVT-O™ (Ethicon, Somerville, NJ, USA), IVS™ 
(Tyco Healthcare LP, Norwalk, CT, USA), Avaulta™ (CR Bard, Covington, GA, USA), 
Apogee™ (American Medical Systems, Minnetonka, MN, USA), EndoFast Reliant™ 
(Endogun Medical Systems, Kibbutz Haogen, Israel), Gore-Tex™, Mycromesh™ (WL 
Gore, Flagstaff, AZ, USA), Teflon™ (Davol/Bard, Cranston, RI, USA). Prolift™ was 
the most removed mesh material in our patients (40%). The mesh insertion surgery 
was performed at our center in 41% of patients; in 59%, mesh was inserted at 
other hospitals. 
Frequency of signs and symptoms and the distribution between different types 
of mesh insertion procedure are presented in Table 2. Fifty-seven (76%) patients had 
mesh exposure, of which most were localized in the vaginal wall (90%). Furthermore, 
four patients had an exposure in the bladder (three after TVT™, one after Prolift™), 
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two patients had a vesicovaginal fistula (after Prolift™), and one patient had a 
rectovaginal fistula (after sacrocolpopexy). Most women reported more than one 
mesh-related symptom. Only one patient did not report any symptoms, although she 
had a persistent, large exposure of the mesh. The primary complaint was pain in the 
majority of cases (77%), which consisted of dyspareunia, vaginal pain, chronic pain of 
the abdomen, back, buttock, or leg, or a combination of these. A distinct difference 
in frequency of mesh-related symptoms existed between the different types of mesh 
insertion procedure, especially in sacrocolpopexy compared to the other procedures 
(Table 2). Pain and dyspareunia are mainly seen after vaginal mesh insertion and 
vaginal bleeding and discharge after sacrocolpopexy. Patients with mesh exposure 
also presented differently than patients without exposure. They reported less pain 
symptoms (54% vs 94%, P=0.002) and more often vaginal bleeding and discharge 
(32% vs 6%, P=0.031 and 47% vs 6%, P=0.002).
table 1. Patient demographics and preoperative characteristics.
All, N=75 
(100%) 
Partial excision, 
n=48 (64%) 
Complete excision, 
n=27 (36%) P value 
Age (years) 56±11 54±10 59±10 0.034
BMIa 26±4 26± 4 26± 3 0.822
Smokingb 12 (16) 11 (23) 1 (4) 0.046
Comorbidity 49 (65) 33 (69) 16 (59) 0.407
History of POP/SUI surgery prior to 
mesh insertion
56 (75) 35 (73) 21 (78) 0.642
No. of previous POP/SUI surgeries 2 (0–7) 2 (0–7) 2 (0–4) 0.835
Previous hysterectomy 58 (77) 35 (73) 23 (85) 0.223
Procedure mesh insertion
-Anterior repair 14 (19) 7 (15) 7 (26) 0.226
-Posterior repair 15 (20) 13 (27) 2 (7) 0.041
-Total mesh/anterior–posterior repair 19 (25) 14 (29) 5 (19) 0.309
-Sacrocolpopexy 12 (16) 5 (10) 7 (26) 0.104
-Retro pubic incontinence sling 6 (8) 3 (6) 3 (11) 0.661
-Transobturator incontinence sling 9 (12) 6 (13) 3 (11) 1.000
POP-Q stage before mesh excisionc 
-POP-Q stage 0 31 (43) 18 (39) 13 (50) 0.371
-POP-Q stage I 11 (15) 10 (22) 1 (4) 0.048
-POP-Q stage II 25 (35) 16 (35) 9 (35) 0.989
-POP-Q stage III 5 (7) 2 (4) 3 (12) 0.344
Former mesh excision 22 (29) 6 (13) 16 (59) <0.001
No. of former mesh excisions 0 (0–4) 0 (0–1) 1 (0–4) <0.001
Values are presented as mean±SD, median (range), or number (%). P value represents a 
comparison between the groups “partial excision” and “complete excision” 
aMissing, n=4; partial excision, n=1; complete excision, n=3 
bMissing, n=1; partial excision, n=1 
cMissing, n=3; partial excision, n=2; complete excision, n=1
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Patients with severe mesh complications, patients with exposure in the bladder 
or fistula, and patients that have had a previous mesh excision underwent more 
often complete mesh excision compared to patients who did not have these severe 
complications (73% vs 27%, P=0.001, 83% vs 29%, P=0.017, and 73% vs 21%, 
P<0.001, respectively). 
Mesh-related complications were unsuccessfully treated conservatively with 
estrogen cream, antibiotics, and/or physiotherapy prior to mesh excision in 63% of 
patients. Previous mesh excision procedures were performed in 22 patients (29%). 
Five patients had two or more previous excisions. Three patients had undergone an 
earlier attempted complete excision. 
Characteristics of mesh excision surgery are presented in Table 3. Complete mesh 
excisions were frequently assisted by a urologist, especially in complex cases and with 
table 2. Presenting mesh-related symptoms and signs per type of mesh insertion procedure.
All, 
n= 75 
(100%) 
sacrocolpopexy, 
n= 12 (16%) 
vaginal PoP 
repair, n= 48 
(64%) 
suburethral 
slings, n= 15 
(20%) P value 
Exposure 57 (76) 11 (92) 34 (71) 12 (80) 0.294
-Vagina 51 (90) 10 (91) 31 (91) 10 (83) 0.737
-Bladder 3 (5) 0 (0) 1 (3) 2 (17) 0.128
-Vesicovaginal fistula 2 (4) 0 (0) 2 (6) 0 (0) 0.496
-Rectovaginal fistula 1 (2) 1 (9) 0 (0) 0 (0) 0.119
Symptoms
-Vaginal bleeding 19 (25) 9 (75) 8 (17) 2 (13) <0.001
-Vaginal discharge 28 (37) 10 (83) 16 (33) 2 (13) 0.001
-Dyspareunia 42 (56) 2 (17) 31 (65) 9 (60) 0.011
-Pain (vaginal pain and/or 
chronic pain)
48 (64) 3 (25) 34 (71) 11 (73) 0.009
-Vaginal pain 43 (57) 2 (17) 32 (67) 9 (60) 0.007
-Chronic pain 32 (43) 2 (17) 23 (48) 7 (47) 0.138
   -Abdomen 17 (53) 1 (50) 12 (52) 4 (57) 0.970
   -Back 3 (9) 0 (0) 3 (13) 0 (0) 0.523
   -Buttock 8 (25) 1 (50) 7 (30) 0 (0) 0.186
   -Leg 4 (13) 0 (0) 1 (4) 3 (43) 0.023
-Urinary tract infections 4 (5) 3 (25) 0 (0) 1(7) 0.003
-Defecation problems 8 (11) 2 (17) 6 (13) 0 (0) 0.299
-Dysfunctional voiding 3 (4) 1 (8) 1 (2) 1 (7) 0.516
Severe mesh complications 15 (20) 1 (8) 13 (27) 1 (7) 0.123
-Mesh shrinkage 8 (11) 0 (0) 8 (17) 0 (0) 0.081
-Mesh displacement 1 (1) 0 (0) 1 (2) 0 (0) 0.752
-Chronic inflammation 2 (3) 0 (0) 2 (4) 0 (0) 0.561
-Infection 1 (1) 0 (0) 1 (2) 0 (0) 0.752
-Granuloma 7 (9) 1 (8) 5 (10) 1 (7) 0.902
Values are presented as number (%). P value represents a comparison between the groups 
“sacrocolpopexy,” “vaginal POP repair,” and “suburethral slings”
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bladder involvement. Mesh was most often (89%) excised by a vaginal approach. In 
five cases, abdominal approach was combined with vaginal excision, and in one case, 
it was a laparoscopic approach. Additional POP repair surgery was performed in 14 
patients (17%). These were, except for one patient, classical repairs without mesh 
and in 10 out of 14 of another compartment then where the mesh was removed. 
Additional surgery led to a longer operation time (mean, 66±24 vs 35±31 min; 
P<0.001). 
Intraoperative complications occurred during four surgical procedures: three 
patients had a bowel lesion (one perforation of the sigmoid and two serosal lesions 
of the colon and small bowel), which occurred during abdominal mesh excision 
for previous sacrocolpopexy and were repaired during surgery. Postoperatively, 
one patient developed anuria as a consequence of lesions to both ureters, which 
table 3. Characteristics of mesh excision surgery.
All, N= 81 
(100%) 
Partial excision, 
n= 51 (63%) 
Complete excision, 
n= 30 (37%) P value 
Time between mesh insertion 
and recent excision (months)
16 (2–217) 11 (2–208) 26 (5–217) 0.001
Assistance of urologist 10 (12) 1 (2) 9 (30) <0.001
Operation time (min) 43± 29 34± 26 58± 28 <0.001
Blood loss (ml) 77± 147 52± 107 120± 193 0.066
Site of mesh excision
-Anterior vaginal wall 22 (27) 14 (27) 8 (27) 0.939
-Posterior vaginal wall 18 (22) 14 (27) 4 (13) 0.140
-Anterior and posterior vaginal 
wall
5 (6) 5 (10) 0 (0) 0.152
-Anterior and posterior vaginal 
wall and vaginal vault
2 (2) 0 (0) 2 (7) 0.134
-Vaginal vault 22 (27) 10 (20) 12 (40) 0.046
-Suburethral 19 (23) 11 (21) 8 (27) 0.601
Approach
-Vaginala 72 (89) 49 (96) 23 (77) 0.011
-Abdominalb 9 (11) 2 (4) 7 (23) 0.011
-Use of hysteroscope 2 (2) 0 (0) 2 (7) 0.134
-Use of laparoscope 1 (1) 1 (2) 0 (0) 1.000
Additional surgery 21 (26) 13 (25) 8 (27) 0.907
-POP 14 (17) 8 (16) 6 (20) 0.762
-SUI 3 (4) 2 (4) 1 (3) 1.000
-Other 4 (5) 3 (6) 1 (3) 0.609
Intraoperative complications 4 (5) 1 (2) 3 (10) 0.141
Postoperative complications 13 (16) 5 (10) 8 (27) 0.062
Hospital stay (days) 2± 2 1± 1 3± 2 <0.001
Values are presented as mean±SD, median (range), or number (%). P value represents a comparison 
between the groups “partial excision” and “complete excision” 
aTwo combined with hysteroscopy 
bFive combined with vaginal excision, one with laparoscope 
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had remained unnoticed during surgery. During this procedure of complete vaginal 
excision of mesh located at the anterior vaginal wall, dissection of the mesh from 
the bladder wall was difficult. However, at that moment, there was no suspicion 
of damage to the ureters. A bladder lesion was excluded by filling the bladder with 
methylene blue dye. Once this serious complication was identified, she was treated 
successfully with bilateral ureter reimplantation. 
Postoperative complications occurred after 13 surgical procedures, including 
hematoma (n=2), substantial bleeding (n=1), ileus (n=1), urinary tract infection (n=5), 
urinary retention (n=3), fever (n=2), wound infection (n=1), subcutaneous abscess 
(n=1), fistula from cervix to sigmoid (n=1), obstruction of a unilateral ureter and 
consequently blow-out of the kidney (n=1). The latter serious complication occurred 
in a patient who appeared to have a bilateral relative ureteropelvic junction stenosis, 
which probably was aggravated by the surgery. She was treated by temporary 
insertion of a nephrostomy catheter. Complications seemed to be more frequent in 
the group with complete mesh excision, although this difference was not statistically 
significant. 
Complications were more common in the group with former sacrocolpopexy; 
intraoperative complications in this group occurred in 23% (vs 1%, P=0.001) and, 
only during abdominal excision, postoperative complications in this group occurred 
in 46% (vs 12%, P=0.003). All patients recovered completely after treatment of their 
complications. 
Outcomes are shown in Table 4. The majority of patients had relief, either complete 
relief or improvement, of mesh-related symptoms (92%). No difference was found 
between groups with regard to symptom relief, although five of six patients with 
no relief of symptoms had undergone a partial excision. Nine patients (12%) had 
recurrence of POP, of which eight were in the anterior compartment. The recurrence 
rate of POP was significantly higher in patients who underwent complete excision 
of mesh used in POP surgery (29%) compared to patients who underwent partial 
excision (5%). De novo SUI after mesh excision was more frequent in the group of 
patients who underwent excision of suburethral slings (36%) compared to patients 
who underwent excision of mesh used in POP surgery (7%, P=0.010). 
Six patients (8%) needed re-excision of mesh; all had undergone a partial excision 
before. Four had persistent exposure of mesh in the vagina, one had a new exposure 
of mesh in the bladder, while she earlier had an exposure of mesh in the vagina, 
and one had persistent pain. Three patients underwent additional complete excision 
and three had partial excision. Eventually, after this re-excision, five patients had 
complete relief and one had improvement of symptoms, none had exposure, none 
had recurrence of POP, one had de novo SUI, and one had de novo OAB. 
The group of patients who underwent excision of mesh used in sacrocolpopexy 
was not different from the other groups concerning the outcomes. All had relief of 
symptoms (23% improvement and 77% complete relief of symptoms), none had 
exposure, three (25%) had recurrence of POP, one had SUI and one had OAB after 
mesh excision, and one patient needed re-excision of mesh. 
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dIscussIon
In this retrospective cohort study, we demonstrated that surgical mesh excision to treat 
complications after prior POP or SUI surgery with mesh was successful in the majority 
of cases, although with a substantial risk of serious complications and recurrence of 
POP or SUI. Only 8% of patients experienced no improvement of their symptoms. 
Main indications for mesh removal included pain (dyspareunia, vaginal pain, and/or 
pain in the lower abdomen, back, buttock, or leg), vaginal bleeding, and discharge, 
with or without evident mesh exposure. The frequency of these symptoms differed 
substantially between different types of mesh insertion procedure, but was similar to 
numbers found in other studies.14-17,23,24 Pain and dyspareunia are mainly seen after 
vaginal mesh insertion and vaginal discharge and bleeding after sacrocolpopexy. 
Mesh exposures are often reported as painless;8,9,16 however, pain is still found 
frequently together with exposures.14,15,17 In our study, pain and mesh exposure were 
both frequently reported; however, patients with mesh exposure reported less pain 
symptoms than patients without exposure. Still, 54% of patients with mesh exposure 
did report pain symptoms (excluding dyspareunia, which is often already present 
table 4. Outcomes of mesh excision.
All, 
N= 75 
(100%) 
Partial 
excision, n= 48 
(64%) 
Complete 
excision, n= 27 
(36%) P value 
Relief of mesh-related symptoms 69 (92) 43 (90) 26 (96) 0.410
-No improvement 6 (8) 5 (10) 1 (4) 0.410
-Improvement 21 (28) 14 (29) 7 (26) 0.764
-Complete relief 48 (64) 29 (60) 19 (70) 0.389
Persistent exposure after mesh excision 6 (8) 6 (13) 0 (0) 0.082
POP-Q stage after mesh excisiona 
-POP-Q stage 0 24 (35) 14 (32) 10 (42) 0.417
-POP-Q stage I 18 (27) 15 (34) 3 (13) 0.054
-POP-Q stage II 19 (28) 14 (32) 5 (21) 0.335
-POP-Q stage III 7 (10) 1 (2) 6 (25) 0.006
Recurrence of POPb 9 (12) 3 (6) 6 (23) 0.061
Recurrence of POP (POP mesh only, 
n=60)c 
8 (14) 2 (5) 6 (29) 0.019
De novo SUI after mesh excisiond 9 (12) 5 (11) 4 (15) 0.712
De novo OAB after mesh excisione 6 (8) 2 (4) 4 (15) 0.178
Follow-up (months) 6 (0–50) 5 (0–50) 7 (1–42) 0.557
Need of re-excision 6 (8) 6 (13) 0 (0) 0.082
Values are presented as median (range) or number (%). P value represents a comparison between 
the groups “partial excision” and “complete excision” 
aMissing, n=7; partial excision, n=4; complete excision, n=3 
bMissing, n=2; partial excision, n=1; complete excision, n=1 
cMissing, n=1; partial excision, n=1 
dMissing, n=2; partial excision, n=1; complete excision, n=1 
eMissing, n=2; partial excision, n=1; complete excision, n=1
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before mesh insertion).8,20 The exposure itself may not have been the cause of pain. 
Underlying mesh contraction, although less severe contraction may not always be 
recognized at physical examination, could actually have induced the pain symptoms.25 
It may also be possible that more complex cases of mesh exposures were seen at our 
tertiary referral center, in which pain may be more frequently present than in patients 
with less severe exposures. 
Most of the recent publications on vaginal mesh surgery report only short-term 
and medium-term follow-up results. Indeed, most of the mesh complications occur 
within the first postoperative year.9 However, late complications may arise after a 
long period of time. We found mesh-related complications even up to 18 years after 
mesh insertion and, in 36% of mesh excisions, the time between mesh insertion 
and removal was more than 2 years, mostly after sacrocolpopexy. Marcus-Braun et 
al. found mesh-related complications up to 8 years after mesh placement; in 56%, 
the delay from the primary operation was more than 2 years.13 Time between mesh 
insertion and excision was longer in the group of patients who underwent complete 
mesh excision, probably because they have undergone more minor interventions 
(former partial mesh excision) to treat their complications in this period. 
Not every mesh-related complication requires complete excision, although complete 
excision of mesh is sometimes advocated to avoid multiple procedures and to achieve 
optimal relief of symptoms.14,24,26 In our study, most patients (64%) underwent partial 
excision of mesh. Nevertheless, we found no difference in relief of symptoms between 
partial and complete excision. Ridgeway et al. described 19 cases of mesh removal in 
which the degree of mesh excision was tailored to the severity of the complications. 
This resulted also in great alleviation of symptoms in most cases.16 In our series, patients 
with more serious complaints indeed underwent more often a complete mesh excision. 
A substantial number of patients (36%) required multiple procedures, of which 
most had been performed in other centers before referral to our hospital. This 
corresponds with numbers of women requiring multiple procedures found by others 
ranging from 20% to 38%.13,15,26 This number may be overestimated in a tertiary 
referral center, as the more straightforward cases of mesh exposure that are recovered 
with a single (office) excision will not be referred. 
Recurrence of POP after excision of mesh used in POP surgery was more common 
with complete excision than with partial excision (29% vs 5%) and affected the 
anterior vaginal wall in 7 of 47 (15%) cases of mesh excision from the anterior vaginal 
wall or vaginal vault. Nevertheless, consistent with a previous study, the majority of 
patients (86%) did not have recurrence of POP after mesh excision.13 Possibly, the 
formation of scar tissue and fibrosis after mesh insertion surgery provides sufficient 
support to prevent the recurrence of POP in most patients who had mesh excision, 
even though in complete mesh excision the interlaced fibrotic tissue may be removed. 
De novo SUI after mesh excision occurred in 13% of all patients and reoccurred in 
36% after excision of a suburethral sling, which is consistent with recurrence rates of 
SUI up to 47% after suburethral sling excisions in other studies.13,27 The small amount 
of scar tissue around the suburethral tape is often not enough to remain supportive 
after mesh excision. 
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In two of our patients (who underwent surgery without the assistance of a 
urologist), very serious urologic complications occurred. Bilateral ureter lesion 
occurred in one of the first complete excisions of vaginal mesh performed at our 
center. This incident has led to a policy in which the urologist is being involved with 
the more extensive and complex surgeries. Also, the urologist is always involved in 
the treatment of patients with (suspected) mesh complications affecting the bladder. 
Furthermore, intraoperative and postoperative complications (5% and 16%, 
respectively) were found relatively frequent in our study compared to the study of 
Marcus-Braun et al.13 In their retrospective study of 104 cases of surgical vaginal mesh 
removal, intraoperative complications occurred only twice (2%) and postoperative 
complications in 10 operations (10%). However, they did not evaluate patients with 
mesh excision after sacrocolpopexy. Most complications in our patients occurred 
in the group of patients who underwent abdominal excision of mesh used in 
sacrocolpopexy. This is consistent with the findings of South et al. who described that 
abdominal excision of eroded vaginal mesh after prior abdominal sacrocolpopexy 
involves more serious complications compared to the vaginal route.26 
The impact of this study is limited by its retrospective design and descriptive nature. 
It is, therefore, susceptible to recall and interpretation bias. Moreover, since data 
were collected retrospectively, 32% of the patients had a follow-up of only 2 months. 
Therefore, the postoperative follow-up may have been too short to find recurrences 
of POP in some cases. Furthermore, 17% of patients underwent concomitant POP or 
SUI surgery, which may have reduced the rate of recurrence of POP and de novo SUI 
we found. 
Incidence figures are hard to reproduce in this heterogeneous population, in which 
patients were often referred by various other hospitals. We were able to estimate the 
incidence of mesh-related complications only for Prolift™ inserted at our center. Of 
the patients included in this study, 20 underwent insertion of Prolift™ at our hospital 
between halfway of 2005 and end of 2009. In this period, 180 Prolift™ meshes 
were inserted. So, 20 out of 180 (11%) patients with Prolift™ inserted at our center 
developed complications that required excision. All 20 patients initially underwent 
partial excision, of which 2 required a re-excision (1 partial and 1 complete). As these 
patients originated from our center, the excisions included both minor and major 
complications. It can be concluded that, after the insertion of Prolift™, 0.6% needs 
excision for severe mesh-related complications and 11% for minor complications. 
This incidence number is consistent with numbers found in other studies.9,13,21 
Prolift™ was the most removed mesh material in our patients (40%). This could 
be explained by the fact that, in this region, Prolift™ is the most used mesh material 
in prolapse repairs. Since it is impossible to generate a denominator for each mesh 
type and patients referred from other centers, no inference can be made on the 
overall incidence of mesh complications in the population or the relative complication 
rates related to individual mesh kits. Different types of mesh may be more likely to 
erode and others may be easier to excise. 
Despite these limitations, this study is strengthened by the relatively large number 
of patients, the fact that all operations were performed in one center using the 
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same surgical techniques, and the detailed data available from operative reports and 
medical records. Moreover, this study shows that mesh complications after abdominal 
sacrocolpopexy and transvaginal mesh present differently and that patients who 
undergo complete mesh excision have a higher recurrence rate of POP compared to 
those who required only partial mesh excision, observations that are relatively new 
to the literature. 
conclusIon
There is a great variety of mesh-related complications, which present differently after 
abdominal sacrocolpopexy and transvaginal mesh insertion. Excision of mesh to treat 
these complications is challenging. It often requires extensive dissection and careful 
operative technique. Relief of symptoms is achieved in the majority of patients. 
Although complications do not occur frequently, serious complications may 
be associated with more extensive or complex surgery. Therefore, we recommend 
centralization of complete mesh excision, especially when there is involvement of the 
bladder or rectum. In these cases, the role of the urologist or colorectal surgeon is 
important to avoid serious organ-specific complications. Checking the ureters after 
all cases involving any anterior vaginal wall or bladder dissection by cystoscopy to 
avoid reoperation for ureteric complications should be considered. Partial excision 
should be preferred in more straightforward cases of mesh exposure with relatively 
mild symptoms. Complete excision should be reserved for patients with more serious 
complaints and severe mesh-related complications because of the higher risk of 
surgical complications and recurrence of POP. The vaginal mesh excision procedure 
with or without hysteroscopy would be the preferred method to approach patients 
with symptoms of sacrocolpopexy mesh because it is less invasive and associated 
with less morbidity than the abdominal approach. Concomitant repair of POP or 
incontinence surgery should be considered given the rates of recurrence of POP and 
de novo SUI, especially after complete mesh excision. 
The increasing number of inserted meshes for SUI and POP raises concerns. Mesh 
is successfully used for repair of prolapse, but when complications arise, they may be 
severe in nature and result in a decrease in quality of life. New meshes are introduced 
into clinical practice despite the lack of proper studies showing their safety and 
effectiveness. Moreover, the use of easy-to-do mesh kits lowers the threshold for 
inexperienced surgeons to start operating with meshes. This can only lead to more 
complications, which is harmful for the patients. The Food and Drug Administration 
also has noticed this and has given a firm warning about the use of mesh and how to 
consult patients.28 This strengthens us in our opinion that insertion of mesh and the 
use of kits should be done with utmost skill and only by trained and very experienced 
surgeons. 
The precise impact of mesh-related complications on quality of life has not been 
researched yet. Therefore, we encourage a future study evaluating the impact of 
mesh-related complications on the quality of life of patients. 
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GenerAl disCussion
General dIscussIon
In the Netherlands, approximately 13.000 surgical procedures per year are performed 
for pelvic organ prolapse.1 The large variety of procedures available emphasizes that 
consensus on the best treatment for pelvic organ prolapse has not been reached. 
This thesis provides a contribution to the search for an effective and safe treatment 
of primary and recurrent pelvic organ prolapse. 
efficacy of trocar-guided tension free vaginal mesh surgery in pelvic organ 
prolapse
The treatment of recurrent pelvic organ prolapse is a challenge, since the recurrence 
rate after repeat surgery is higher than after primary pelvic organ prolapse surgery.2 
Our randomized controlled trial comparing  tension-free vaginal mesh insertion 
with vaginal native tissue repair in women with recurrent pelvic organ prolapse 
demonstrated significantly lower failure rates in the anterior as well as the posterior 
compartment after mesh insertion (Chapter 2). However, improvement of symptoms 
and quality of life were not significantly different between both groups after one 
year of follow-up (Chapter 2). These results are consistent with findings of other 
randomized controlled trials assessing the efficacy of this treatment on the anterior 
compartment.3,4,5 As anatomic deterioration may precede symptoms, longer follow-
up might reveal a difference in bulge symptoms between the two groups. 
Pelvic organ prolapse may recur in a previously treated compartment, but can also 
arise in an untreated, unaffected compartment. Tension-free vaginal mesh treatment 
of one vaginal compartment seems to provoke the development of vaginal prolapse 
in initially unaffected vaginal compartments (Chapter 3). Twelve months after surgery 
the rate of de novo pelvic organ prolapse stage >II in the untreated compartment was 
higher in patients treated with trocar-guided tension free vaginal mesh insertion (47%) 
compared to patients with vaginal native tissue repair (17%)(Chapter 4). Additional 
apical support to an anterior repair with mesh seemed to reduce the de novo prolapse 
rate (0%), although the number of patients was limited (n=6)(Chapter 4). 
Different definitions of failure and success of pelvic organ prolapse surgery exist. 
It is customary to address anatomic failure or success with the POPQ system.6 Pelvic 
organ prolapse stage >II is generally considered as a failure, whereas it is unclear 
whether or not to consider the treated compartment(s) alone or treated and untreated 
compartments together. Furthermore, some studies also consider any surgery related 
to the prolapse surgery during the follow-up period as a failure, including surgery 
for incontinence or excision of a mesh exposure.7 Moreover, the hymen, instead 
of POP stage II, is sometimes used as a “cut-off point” to define failure, whereas 
others include the presence of bulge symptoms as criterion of failure.8 A standardized 
terminology for the definitions of reporting the outcomes of surgical procedures for 
pelvic organ prolapse is unfortunately lacking. In Chapter 5, three different definitions 
of failure (1:POP stage in treated compartment > II, 2:POP stage in any compartment 
> II, 3:POP beyond the hymen with bulge symptoms) are compared. The composite 
outcome, beyond the hymen with bulge symptoms (definition 3), showed the lowest 
failure rate, but not significantly different from POP stage in treated compartment > II 
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(definition 1). Focusing on anatomic criteria alone does ignore the patient’s perception 
of symptoms, for which she primarily had sought relief. We therefore agree with 
Barber et al that their suggested composite outcome is the most realistic outcome for 
prolapse surgery and should be the outcome of choice in future studies (Chapter 5). 8
Complications of trocar-guided tension free vaginal mesh surgery in pelvic 
organ prolapse
Trocar guided tension free vaginal mesh treatment is associated with specific 
complications. The most frequently reported complications include mesh exposure 
through the vagina (also called erosion, extrusion or protrusion), haemorrhage, 
haematoma, pain, shrinkage, infection, dyspareunia, perforation of the rectum or 
bladder, voiding disorders and faecal outlet obstruction.  
Mesh exposure is the most frequently found complication associated with the 
use of mesh in prolapse surgery. Although exposures have been reported as early as 
6 weeks and as late as 4 years after vaginal mesh surgery, they are usually reported 
during the first year following insertion.9,10 Exposure rates vary between 0% and 30% 
in 110 different studies on 11,785 patients with an overall incidence of 10.3% (95% 
CI, 9.7 – 10.9%).11 In a prospective observational cohort study we demonstrated that 
smoking, total tension-free vaginal mesh and less clinical and surgical experience 
are independent risk factors for mesh exposure after a tension-free vaginal mesh 
procedure (Chapter 6). “Concomitant hysterectomy” is another important risk factor 
that had previously been identified.12 
Pain as a long-term complication of mesh surgery has not been addressed often in 
previously performed studies. We found that 13% of patients had pain in the lower 
abdomen or genital region at one year after surgery, of which 5% of patients had de 
novo pain. In order to select patients carefully and inform patients properly before 
surgery, it is important to identify possible risk factors associated with pain after 
surgery. We found an increased risk of pain after surgery in patients who already had 
pain in the lower abdomen or genital region before surgery. This was not unexpected, 
since pain is not necessarily related to prolapse. In such cases it is not likely that the 
pain will resolve after pelvic organ prolapse surgery (Chapter 6). 
Dyspareunia rates after vaginal mesh surgery for pelvic organ prolapse vary in 
70 studies on 5,638 women from 0% to 67% with an overall incidence of 9.1% 
(95% CI, 8.2–10.0%).11 This wide range is probably caused by the use of different 
definitions and populations. In our randomized controlled trial we found  dyspareunia 
in 17% of cases at one year after surgery in the vaginal mesh group (8% de novo) 
and in 24% of patients in the native tissue repair group (10% de novo). However, 
in our prospective observational cohort we found higher rates (45% dyspareunia; 
26% de novo) at one year after trocar-guided tension free vaginal mesh surgery. 
Multivariable analysis demonstrated the pre-operative dyspareunia increased the 
odds of post-operative dyspareunia (Chapter 6). Furthermore, the surgeon himself 
(herself) is another prognostic factor for higher dyspareunia rates. Unfortunately, we 
could not find a more specific factor that was related to dyspareunia, such as the 
number of procedures performed before. 
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efficacy of laparoscopic sacral colpopexy with bone anchor fixation in pelvic 
organ prolapse
Sacral colpopexy is another treatment modality for (recurrent) pelvic organ prolapse. 
Open sacral colpopexy was developed to treat vaginal vault prolapse and had success 
rates of 74–98%.13 The downsides of this treatment, such as a high morbidity rate and a 
long length of hospital stay, were improved by a laparoscopic approach.  Laparoscopic 
sacral colpopexy with bone anchor fixation provides excellent vault support in 98% of 
patients (Chapter 6). This high success rate for the apical compartment is comparable 
with results of other studies on laparoscopic sacral colpopexy.14,15,16 Fixation of the 
vault to the sacral segments 2-4 provides adequate level I support. However, fixation 
of the vault without concurrent anterior or posterior repairs (either with laparoscopic 
mesh placement or with vaginal colporrhaphia) is not sufficient to prevent anterior 
and posterior wall prolapse in 53% of cases (Chapter 6). 
In our study comparing laparoscopic sacral colpopexy with bone anchor fixation 
to trocar guided tension free vaginal mesh insertion the success rates were equal 
with respect to the apical compartment (Chapter 7). However, if success is defined 
as POPQ stage < II in all compartments, trocar guided tension free vaginal mesh was 
superior (success rate 79%) compared to laparoscopic sacral colpopexy (success rate 
49%)(Chapter 7). In contrast, the only randomized controlled trial comparing total 
tension free vaginal mesh to laparoscopic sacral colpopexy for vaginal vault prolapse7 
showed the opposite of our results, with success rates of 77% and 43% in the 
laparoscopic and vaginal mesh group, respectively. Comparison of the results of these 
two studies, however, should be done with caution as the definitions of success used 
were different. Moreover, Maher et al. placed the mesh during laparoscopic sacral 
colpopexy not only on the vaginal vault, but also in the vesicovaginal and rectovaginal 
space, addressing (hidden) cystoceles and rectoceles.
Complications of laparoscopic sacral colpopexy with bone anchor fixation in 
pelvic organ prolapse
Laparoscopic sacral colpopexy is associated with specific complications. The most 
frequently reported complications of laparoscopic sacral colpopexy are bladder 
perforation, bowel perforation, haematoma, mesh exposure and dyspareunia.15  
Mesh exposure seems a less frequently reported complication in laparoscopic 
sacral colpopexy (1%-9%) compared to the rate after tension free vaginal mesh 
treatment (0%-30%).7,11,14,15,16 However, in our study comparing laparoscopic sacral 
colpopexy with trocar guided tension free vaginal mesh we found mesh exposure in 
2% and 8% of patients, respectively (Chapter 8). This difference was not statistically 
significant, but the duration of follow-up was only 6 months. However, longer 
follow-up might reveal a significant difference. In the randomized controlled trial of 
Maher et al. the exposure rates were also not significantly different, implying that an 
eventual difference may be small.7 
A rare, possibly life-threatening complication of laparoscopic sacral colpopexy is 
a bowel lesion. It is important to discover this complication in an early stage, 
preferably during surgery. If the lesion is not detected in time, severe morbidity and 
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even mortality may occur.  In our cohort we encountered a bowel (ileum) lesion 
in 2% of cases, which was detected and repaired during surgery. Neither bladder 
nor rectum lesions were described in our cohort, due to the minimum dissection at 
the bladder and rectum site, since mesh was only used at the apex of the posterior 
vaginal wall (Chapter 7). Other studies described bladder and rectum lesions in 2% 
and 1% of patients, respectively.14,16  
Dyspareunia rates after laparoscopic sacral colpopexy are not described in each 
study. Higgs reported dyspareunia after laparoscopic sacral colpopexy in 44% 
of patients.15 We found a dyspareunia rate after surgery of 20% (15% de novo) 
(Chapter7). 
treatment of complications of mesh 
Specific long-term complications related to mesh surgery, such as exposure, shrinkage 
causing pain and dyspareunia, can be difficult to treat. If the patient is asymptomatic, 
not sexually active, and the exposure is very small (<3 mm) or if the use of vaginal 
estrogen is contraindicated, a conservative approach can be considered.17 Although 
the exposure will often not heal spontaneously, it rarely progresses. In most patients 
vaginal estrogen treatment is used. If the exposure is symptomatic and persists despite 
estrogen use, if the use of vaginal estrogen is contraindicated or if the exposure is 
3 mm or more, mesh excision will be the next step.17 When mesh excision fails, 
when the exposure is larger than 1 to 2 cm, or when infection, fistula, or chronic 
pain is present, surgical removal of a large part of the mesh is the next therapeutic 
option. This procedure is technically challenging (Chapter 9). If trocars have been 
used to place the mesh, as is the case with many commercially available mesh kits, 
it is often not possible to remove the arms of the mesh because they pass through 
the ischiorectal fossa and/or obturator space. After excision of the mesh, relief of 
symptoms is achieved in the majority of patients (Chapter 9). Although complications 
during excision of the mesh do not occur frequently, serious complications may 
be associated with more extensive or complex surgery. Therefore, we recommend 
centralization of large mesh excision, especially when there is involvement of the 
bladder or rectum. In these cases, involvement of an urologist or colorectal surgeon 
is important to avoid serious organ-specific complications (Chapter 9).
Conclusion
Since the duration of follow-up of published trials on vaginal mesh in pelvic organ 
prolapse does not exceed a 3 year period, one should be very careful with the use 
of vaginal mesh in pelvic organ prolapse surgery. When counseling a woman with 
(recurrent) pelvic organ prolapse for native tissue or vaginal mesh repair, the potential 
complications such as mesh exposure, pain, and dyspareunia should be mentioned 
along with the differences in anatomic success rates. When vaginal mesh will be 
inserted, patients should be advised to stop smoking before surgery. Furthermore, 
centralization of mesh surgery to experienced surgeons seems mandatory. Moreover, 
surgeons should reconsider the indication for each part of the pelvic organ prolapse 
surgery, such as total or partial (anterior or posterior) mesh or concomitant hysterectomy. 
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Laparoscopic sacral colpopexy is a very effective treatment for an apical compartment 
prolapse, however in case of anterior or posterior prolapse additional mesh insertion 
is indicated. One could consider to insert additional mesh always to prevent de novo 
prolapse in the anterior or posterior compartment. Laparoscopic sacral colpopexy 
should only be considered when the apical compartment is involved in the prolapse. 
Complications such as mesh exposure, dyspareunia and bowel lesions may also occur 
after laparoscopic sacral colpopexy and should be mentioned during counseling. 
The large variety of procedures available for pelvic organ prolapse gives us the 
opportunity to make an individual choice for each patient. If a certain type of surgical 
procedure seems the best treatment option, referral to an expert surgeon may 
be preferable. 
answers To The MaIn research quesTIons:
1. Is the anatomic failure rate in each treated compartment in women with recurrent 
pelvic organ prolapse lower in patients with a tension-free vaginal mesh insertion 
(Prolift) compared to conventional vaginal prolapse surgery? 
Yes, the overall risk of anatomic failure of the treated compartment with mesh is 
9.6% and the overall risk of anatomic failure of the treated compartment with native 
tissue is 45.2%. This difference is even higher if we only look at the treatment of 
the anterior compartment (7.8% versus 55.1%), but it is also significant for the 
treatment of the posterior compartment (4.1% versus 24.5%). There is no difference 
for the treatment of the apical compartment. (Chapter 2)
2. Is the subjective improvement rate higher in patients treated with a tension-free 
vaginal mesh insertion (Prolift) compared to conventional vaginal prolapse surgery 
in women with recurrent pelvic organ prolapse? 
No, the patient impression of improvement was equal in both groups. In the trocar-
guided tension free vaginal mesh group 81% of patients reported improvement at 
one year after surgery and 80% of the patients in the vaginal native tissue repair group 
reported improvement. (Chapter 2) Furthermore the Urogenital Distress Inventory 
score on the domain ‘genital prolapse’ improved significantly in both groups, but 
there was no difference between the groups. (chapter 2)
3. Does mesh treatment of only one vaginal compartment provoke development of 
pelvic organ prolapse in other initially unaffected and untreated compartments? 
Yes, 23% percent of a cohort of 124 patients with anterior, posterior or anterior 
and posterior mesh had developed a de novo pelvic organ prolapse stage ≥II in the 
untreated compartment one year after surgery (chapter 3). Furthermore,  mesh 
augmented prolapse repair in only one vaginal compartment is associated with a 
higher de novo prolapse rate in the untreated compartments (47%) compared to 
conventional vaginal native tissue repair (17%) in patients with recurrent pelvic organ 
prolapse. (chapter 4)
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4. Can we identify predictors of failure of trocar-guided tension-free vaginal mesh 
surgery? 
Yes, depending on the definitions of failure we can identify predictors of failure. 
Predictor of failure for all of the definitions of failure was the location of mesh 
insertion. Particularly a combined anterior/posterior mesh with the uterus or cervix in 
situ increased the risk of failure. (chapter 5)
5. Can we identify risk factors for complications of trocar-guided tension-free vaginal 
mesh surgery? 
Yes, smoking, total tension-free vaginal mesh, and less clinical and surgical experience 
were predictive factors for mesh exposure one year after insertion of a trocar-guided 
tension free vaginal mesh (chapter 6).
6. Is laparoscopic sacral colpopexy with bone anchor fixation an effective and safe 
treatment of pelvic organ prolapse? 
Yes, laparoscopic sacral colpopexy with bone anchor fixation is an efficacious 
treatment for apical compartment prolapse with an objective success rate in the 
apical compartment of 98% and a subjective success rate of 79%. Intra-operative 
complications were rare (1% conversion due to lesion of the ileum). After 6 months 
2% mesh exposure was found, no de novo pain and 15% de novo dyspareunia. 
(chapter 7)
7. Is trocar-guided tension-free vaginal mesh as effective as laparoscopic sacral 
colpopexy? 
Yes, trocar-guided tension-free vaginal mesh had similar short-term success rates 
in the apical compartment compared with laparoscopic sacral colpopexy with bone 
anchor fixation. However, the overall pelvic organ prolapse failure rate (symptomatic 
failure in any of the compartments) was significantly higher in the laparoscopic sacral 
colpopexy group compared with the total tension-free vaginal mesh group. (chapter 8)
8. How should we treat mesh-related complications? 
Partial excision should be preferred in more straightforward cases of mesh exposure 
with relatively mild symptoms. Complete excision should be reserved for patients 
with more serious complaints and severe mesh-related complications because of 
the higher risk of surgical complications and recurrence of pelvic organ prolapse. 
We recommend centralization of complete mesh excision, especially when there is 
involvement of the bladder or rectum. Good collaboration between gynecologist, 
urologist and/or colorectal surgeon is essential. (chapter 9)
fuTure
New, innovative surgical techniques for treatment of pelvic organ prolapse will 
continue to emerge. New kinds of mesh aiming at strong tissue support with lower 
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exposure and dyspareunia rates are already available on the market. However, these 
meshes have often not been tested yet in properly designed clinical trials. Since the use 
of mesh in pelvic organ prolapse surgery is associated with long-term complications 
it is mandatory that new meshes, new kits, new techniques are properly tested, 
preferably in randomized controlled trials with long-term follow-up. Standardized 
terminology for the definition of failure should be developed and used. Specific tools 
to measure chronic pain, dyspareunia and shrinkage of mesh are lacking or are not 
standardized and should therefore be developed. 
Promising developments are partially absorbable mesh, permanent mesh with 
absorbable arms or meshes without any arms at all. Recent research investigating 
utilization of stem cells for the prevention and treatment of stress urinary incontinence 
might be applicable in pelvic organ prolapse surgery.18 One could think of a completely 
absorbable mesh, with stem cells on it, to repair the defects with proper strong 
authentic tissue. 
The availability of a robot to perform a laparoscopic sacral colpopexy might make 
the procedure more feasible and reduce the long learning curve (60 procedures).19 A 
reduced learning curve may ensure that laparoscopic/robotic sacral colpopexy could 
be performed in more centers. This would create the conditions for more randomized 
controlled trials comparing laparoscopic sacral colpopexy with tension free vaginal 
mesh insertion. 
Another important area of research would be the genetics of pelvic organ 
prolapse. If we can reveal certain genes that increase the risk of pelvic organ prolapse 
one could create a prediction model with different risk factors and decide in every 
patient whether she would be a candidate for native tissue repair or repair with 
abdominal or vaginal mesh. One could even consider caesarean section for certain 
geno- and phenotypes. 
Whether we will implant mesh with or without stem cells, whether we will 
perform genetic profiling in every woman who wants to become pregnant, in the 
coming years exciting developments in pelvic organ prolapse research will occur. 
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Chapter 1 
This chapter reviews the definition, epidemiology, aetiology, clinical characteristics 
and treatment options of pelvic organ prolapse. Pelvic organ prolapse is a descent of 
female pelvic organs. Its aetiology is multifactorial. Many women with pelvic organ 
prolapse are asymptomatic and do not need treatment. Prolapse-related symptoms are 
vaginal bulging or pelvic pressure. Other frequently mentioned complaints are lower 
urinary tract dysfunction, bowel dysfunction and interference with sexual function. A 
cross-sectional Dutch study demonstrates a prevalence of symptomatic pelvic organ 
prolapse of 11.4% in women aged 45-85 years. In case of a symptomatic  pelvic 
organ prolapse, the therapeutic options are  pelvic floor muscle training, pessary 
use, or surgery. Surgery can be done by either an abdominal, laparoscopic or vaginal 
approach. Recurrence rates of pelvic organ prolapse after vaginal surgery with native 
tissue are high (20%-60%). This high failure rate after traditional vaginal prolapse 
surgery has led to the introduction of mesh materials in vaginal prolapse surgery 
to obtain improved support.  This thesis studies two types of pelvic organ prolapse 
surgery with mesh as a possible solution for the high recurrence rates after vaginal 
pelvic organ prolapse surgery with native tissue.
Chapter 2
In Chapter 2, the results of a randomized controlled trial, comparing efficacy and 
safety of trocar-guided tension-free vaginal mesh insertion with conventional vaginal 
prolapse repair in 190 patients with recurrent pelvic organ prolapse are described. 
The primary outcome was anatomic failure (pelvic organ prolapse stage II or higher) 
in the treated vaginal compartments. At 12 months, the number of anatomic 
failures observed after tension-free vaginal mesh insertion (9.6%) was less than after 
conventional vaginal prolapse repair (45.2%). Symptom decrease and improvement 
of quality of life were not significantly different between both groups. Mesh exposure 
was detected in 16.9% of patients after trocar-guided tension-free vaginal mesh 
insertion. Other complications, such as de novo pain, de novo dyspareunia and de 
novo stress urinary incontinence did not occur frequently and were equally distributed 
among both groups. 
Chapter 3
In Chapter 3, a cohort of 150 patients who underwent a trocar-guided tension-free 
vaginal mesh insertion is described to assess the effect of the tension-free vaginal 
mesh procedure on the non-treated and initially unaffected vaginal compartments. 
Twenty-three percent of all patients developed a de novo pelvic organ prolapse stage 
≥II in the untreated compartment; 46% after an isolated anterior mesh repair and 
25% after an isolated posterior mesh repair. Therefore, tension-free vaginal mesh 
treatment of one vaginal compartment seems to provoke the development of vaginal 
prolapse in initially unaffected vaginal compartments, particularly after an isolated 
anterior mesh repair.
CHAPTER 11148
Chapter 4
Chapter 4 provides a secondary analysis of the previously mentioned randomized 
controlled trial (Chapter 2) to compare the de novo prolapse rate in the untreated 
vaginal compartments following conventional vaginal prolapse repair with native 
tissue and tension free vaginal mesh repair. Mesh repair of pelvic organ prolapse in 
only one compartment led to a significantly higher percentage of de novo prolapse 
of the untreated vaginal compartment (47%), as compared to conventional vaginal 
prolapse surgery with native tissue in only one compartment (17%). The exact 
aetiology of the higher rate of de novo pelvic organ prolapse in women treated with 
vaginal mesh is not fully understood. We hypothesize that insertion of polypropylene 
mesh in one compartment of the vagina causes such a vigorous support that it may 
be responsible for a supraphysiological reduction of prolapse and causes elevation 
as seen after a colposuspension and after a sacrospinous fixation. As a result, the 
vaginal wall of the non-treated compartment becomes the least supported vaginal 
compartment and will then be the compartment most susceptible for prolapse.
Chapter 5
Outcome of surgery depends on the definition of failure. In Chapter 5, 3 different 
failure rates according to 3 different definitions of failure in a prospective cohort of 
433 patients who underwent a trocar-guided tension-free vaginal mesh insertion 
were described. Twelve months post-surgery pelvic organ prolapse beyond stage I 
in the mesh-treated compartment was found in 15% and did not significantly differ 
from a composite failure rate (pelvic organ prolapse in any compartment beyond the 
hymen with bulge symptoms or repeat surgery for pelvic organ prolapse) of 9%. 
Pelvic organ prolapse beyond stage I in any compartment was seen in 41%. Since the 
composite outcome included the prolapse symptoms of the patient, we advised to 
use this outcome measure for future research. 
The second objective of this study was to identify independent predictors of failure 
with the use of logistic regression analysis. The combination of an anterior/posterior 
mesh with the uterus or cervix in situ appeared to be independently related to failure 
in all outcomes. Alternative treatment for this simultaneous mesh insertion and 
fixation to the uterus could be a single anterior mesh combined with a sacrospinous 
hysteropexy.
Chapter 6
In this chapter we focused on complications of vaginal mesh surgery and tried to 
identify possible risk factors for exposure, dyspareunia, and pain. In a prospective 
observational cohort study, 294 consecutive women who underwent surgery with a 
trocar-guided tension-free vaginal mesh kit were included and evaluated at 6 weeks 
and at 6 and 12 months after surgery with respect to anatomy and complications. 
Mesh exposure was found in 12% of the patients. Pain in the lower abdomen and 
genital region was found in 13% of the patients, de novo pain was noted in 5% of 
the patients. Dyspareunia was found in 45% of the sexually active patients, de novo 
dyspareunia was noted in 26% of the sexually active patients. Logistic regression 
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analysis was performed to identify risk factors for exposure, dyspareunia, and pain. 
Smoking, total mesh placement and less clinical/surgical experience of the surgeon 
were risk factors for exposure.  Pain (OR 3.2, 95% CI 1.2– 8.4) and dyspareunia (OR 
4.7, 95% CI 1.7–12.8) before surgery were predictive for pain and dyspareunia after 
surgery, respectively.
Chapter 7
In chapter 7, the short-term anatomic and functional outcomes and safety of 
laparoscopic sacrocolpopexy with bone anchor fixation were evaluated. In a 
prospective cohort study of 49 consecutive women undergoing laparoscopic 
sacrocolpopexy for a symptomatic apical compartment prolapse the objective and 
subjective success rates in the apical compartment were 98% and  79%, respectively. 
One mesh exposure (2%) was found. One conversion to laparotomy was necessary 
due to injury to the ileum. Laparoscopic sacrocolpopexy with bone anchor fixation is a 
safe and efficacious treatment for apical compartment prolapse. It provides excellent 
apical support and good functional outcome 6 months postoperatively. For anterior 
and/or posterior compartment prolapse in the same patient, additional surgery (with 
laparoscopic mesh or vaginal colporrhaphy) should be considered.
Chapter 8
Chapter 8 provides a comparison of laparoscopic sacral colpopexy (LSC) and total 
vaginal mesh (TVM) for vaginal vault prolapse. In a comparison of two prospective 
cohorts including 45 LSC patients and 52 TVM patients we found a recurrence rate of 
symptomatic vault prolapse of 2% in each group. Since the LSC provided only apical 
support, instead of the anterior, apical and posterior support the TVM provided, the 
overall failure rate (pelvic organ prolapse stage > II) was higher in the LSC group 
(51%) compared to the failure rate in the TVM group (21%). Each technique had its 
own type of complications, however this study was too small and the follow-up was 
too short to identify significant differences in serious complications rates.
Chapter 9
Chapter 9 provides data on the surgical management of mesh-related complications 
after prior pelvic floor reconstructive surgery with mesh. In this retrospective cohort 
study 81 mesh excisions in 73 patients were described. Indications for the excision 
were exposure (in the vaginal wall or bladder), pain, dyspareunia and fistula. Symptom 
relief was achieved in 92% of patients. Recurrence of pelvic organ prolapse occurred 
in 29% of complete and in 5% of the partial excisions of mesh used in pelvic organ 
prolapse surgery. Stress urinary incontinence occurred in 36% of patients who 
underwent excision of a suburethral sling. Intraoperative complications occurred 
in 4 cases (3 bowel and 1 bilateral ureteral lesion), postoperative complications 
occurred in 13 cases. Mesh excision relieves mesh-related complications effectively, 
although with a substantial risk of serious complications and recurrence of pelvic 
organ prolapse and stress urinary incontinence. More complex excisions should be 
performed in experienced centers.
CHAPTER 11150
Chapter 10
Chapter 10 is a general discussion on the findings of this thesis. Furthermore,  some 
challenging aspects of future research to improve the treatment of pelvic organ 
prolapse or even gain more insight on the development and prevention of pelvic 
organ prolapse are discussed. 
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saMenvaTTInG
hoofdstuk 1 
Dit hoofdstuk geeft een overzicht van de definitie, epidemiologie, etiologie, 
pathofysiologie, symptomen en behandelings mogelijkheden van genitale prolaps. 
Genitale prolaps is een verzakking van de bekkenorganen.  De etiologie is 
multifactorieel. Veel vrouwen met een prolaps zijn asymptomatisch en hebben geen 
behandeling nodig. Prolaps-gerelateerde symptomen bestaan uit een balgevoel of 
een drukkend gevoel in de vagina. Andere veelvoorkomende klachten zijn mictie 
en defecatie problemen en seksuele klachten. De prevalentie van symptomatische 
prolaps is 11.4% bij Nederlandse vrouwen van 45-85 jaar.  Een symptomatische 
prolaps kan behandeld worden met bekkenfysiotherapie, pessaria of een operatie. 
Een operatie kan abdominaal, laparoscopisch of vaginaal worden uitgevoerd. Een 
recidief prolaps na een vaginale prolaps operatie met eigen weefsel komt veel voor 
(20%-60%). Deze hoge recidiefpercentages na vaginale prolaps chirurgie hebben tot 
de introductie van mesh materiaal in de vaginale prolapse chirurgie geleid. Vaginale 
operatie met mesh wordt gezien als mogelijke oplossing voor de hoge recidiefkansen 
na vaginale prolaps chirurgie met eigen weefsel. 
hoofdstuk 2
In hoofdstuk 2 worden de resultaten beschreven van een gerandomiseerd 
gecontroleerd vergelijkend onderzoek tussen trocar geleide spanningsvrije vaginale 
mesh en conventionele vaginale prolaps plastiek met betrekking tot effectiviteit en 
veiligheid bij 190 patiënten met een recidief prolaps. De primaire uitkomst maat 
betrof anatomisch falen (gedefinieerd als POPQ stadium II of hoger) in het behandelde 
compartiment. Het aantal patiënten met anatomisch falen na spanningsvrije mesh 
(9.6%) 12 maanden na de operatie was lager dan na conventionele vaginale prolaps 
plastiek (45.2%). Vermindering van de klachten en verbetering van de kwaliteit van 
leven was niet significant verschillend tussen beide groepen. Mesh exposure (het 
zichtbaar worden van mesh door de vagina) werd gezien in 16.9% van de patiënten 
met de spanningsvrije mesh. Andere complicaties, zoals de novo pijn, de novo 
dyspareunie en de novo stress incontinentie voor urine kwamen niet veel voor en de 
frequentie was niet verschillend tussen de twee groepen. 
hoofdstuk 3
In hoofdstuk 3 wordt een cohort van 150 patiënten beschreven die een trocar geleide 
vaginale plaatsing van een spanningsvrije mesh ondergingen om het effect van de 
spanningsvrije mesh op het onbehandelde en initieel niet-aangedane compartiment 
te bepalen. 23% van alle patiënten ontwikkelde een de novo prolaps POPQ stadium 
II of hoger in het onbehandelde compartiment; 46% na een geïsoleerde anterieure 
mesh en 25% na een geïsoleerde posterieure mesh. Spanningsvrije vaginale mesh 
behandeling in slechts één compartiment lijkt de ontwikkeling van een prolaps in een 
ander, initieel niet-aangedaan compartiment uit te lokken, vooral na plaatsing van 
een geïsoleerde anterieure mesh.
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hoofdstuk 4
Hoofdstuk 4 beschrijft een secundaire analyse van de eerder genoemde 
gerandomiseerde gecontroleerde studie (hoofdstuk 2),waarbij het aantal patiënten 
met de novo prolaps in het onbehandelde vaginale compartiment wordt vergeleken 
tussen vaginale prolaps chirurgie met eigen weefsel en met spanningsvrije mesh. 
Spanningsvrije mesh in slechts één compartiment zorgde voor een significant hoger 
percentage de novo prolaps van het onbehandelde compartiment (47%) vergeleken 
met vaginale prolaps plastiek met eigen weefsel in slechts één compartiment 
(17%). De etiologie van het hogere percentage de novo prolaps na vaginale mesh 
is nog niet volledig bekend. Het inbrengen van polypropyleen mesh in één vaginaal 
compartiment zorgt voor een zeer stevige ondersteuning, zodanig dat het mogelijk 
een suprafysiologische reductie van de prolaps en elevatie veroorzaakt, zoals na 
een colposuspensie of sacrospinale fixatie. Hierdoor zal de vaginawand van het 
onbehandelde compartiment het minst gesteunde vaginale compartiment worden 
en derhalve het meest gevoelig voor prolaps.  
hoofdstuk 5
Resultaten van operaties zijn afhankelijk van de gebruikte definitie van falen. In 
hoofdstuk 5 worden 3 verschillende resultaten beschreven op basis van 3 verschillende 
definities van falen in een prospectief cohort van 433 patiënten die een prolaps 
operatie ondergingen met een trocar-geleide spanningsvrije mesh. Twaalf maanden 
na de operatie werd in 15% een prolaps POPQ stadium II of hoger in het met mesh 
behandelde compartiment gevonden en dat was niet significant verschillend van 
de 9% falen bij gebruik van een samengestelde uitkomstmaat (prolaps voorbij het 
hymen met de aanwezigheid van een "bal" gevoel of opnieuw een prolaps operatie). 
Prolaps in enig compartiment werd gezien in 41% van de patiënten. Aangezien de 
samengestelde uitkomstmaat ook de prolaps klachten van de patiënt meeneemt, 
adviseren we het gebruik van deze uitkomstmaat in toekomstig onderzoek. 
Het tweede doel van de studie was het identificeren van onafhankelijke 
voorspellende factoren voor falen met behulp van logistische regressie analyse. De 
combinatie van een anterieure met posterieure mesh en een uterus of cervix in situ 
bleek onafhankelijk gerelateerd aan falen voor alle uitkomstmaten. Een alternatieve 
behandeling voor deze simultane insertie van anterieure en posterieure mesh met 
fixatie aan de uterus zou een solitaire anterieure mesh gecombineerd met een 
sacrospinale hysteropexie kunnen zijn. 
hoofdstuk 6
In dit hoofdstuk worden de complicaties van vaginale mesh chirurgie beschreven en 
proberen we mogelijke risicofactoren te identificeren voor exposure, dyspareunie en 
pijn. In deze prospectieve cohort studie, ondergingen 294 opeenvolgende vrouwen 
die een trocar geleide spanningsvrije mesh operatie en werden na 6 weken, 6 
maanden en 12 maanden geëvalueerd met betrekking tot anatomie en complicaties. 
Mesh exposure werd in 12% van de patiënten aangetoond. Pijn onder in de buik of 
vagina werd in 13% van de patiënten aangetoond, het betrof in 5% de novo pijn. 
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Dyspareunie werd in 45% van de seksueel actieve patiënten aangetoond, het betrof 
de novo dyspareunie in 26% van de seksueel actieve patiënten. Om risicofactoren 
voor exposure, dyspareunie en pijn te identificeren werd een logistische regressie 
analyse uitgevoerd. Roken, plaatsing van een totale mesh en minder klinische/
chirurgische ervaring van de chirurg waren risicofactoren voor exposure. Pijn (Odss 
Ratio 3.2, 95% betrouwbaarheidsinterval 1.2-8.4) en dyspareunie (Odss Ratio 4.7, 
95% betrouwbaarheidsinterval 1.7-12.8) voorafgaand aan de prolaps operatie waren 
voorspellende factoren voor respectievelijk pijn en dyspareunia na de operatie.
hoofdstuk 7
In hoofdstuk 7 werden de korte termijn resultaten (anatomische en functioneel) en 
de veiligheid van laparoscopische sacrocolpopexie met bot anker fixatie geëvalueerd. 
In een prospectieve cohort studie, waarin 49 opeenvolgende vrouwen een 
laparoscopische sacrocolpopexie voor een symptomatische top prolaps ondergingen 
waren de objectieve en subjectieve succespercentages in het apicale compartiment 
respectievelijk 98% en 79%. Eén patiënt ontwikkelde een mesh exposure (2%) 
en één conversie tot laparotomie was nodig voor het herstel van een ileum letsel. 
Laparoscopische sacrocolpopexie met bot anker fixatie is een veilige en effectieve 
behandeling voor een prolaps van het apicale compartiment. Het zorgt voor 
uitstekende apicale ondersteuning en goede functionele resultaten 6 maanden na 
de operatie. Als een patiënt naast de top prolaps een prolaps van het voorste of 
achterste compartiment heeft, dan zal een aanvullende operatie (met laparoscopisch 
aangebrachte mesh of een vaginale plastiek) overwogen moeten worden. 
hoofdstuk 8
In hoofdstuk 8 wordt de laparoscopische sacrocolpopexie (LSC) met de totale 
vaginale spanningsvrije mesh (TVSM) voor een vagina top prolaps vergeleken. In een 
vergelijking tussen 2 prospectieve cohorten van respectievelijk 45 LSC patiënten en 
52 TVSM patiënten werd in 2% een symptomatisch recidief  van een top prolaps 
gevonden in elke groep. Aangezien de LSC, zoals in dit onderzoek uitgevoerd, 
alleen ondersteuning op de top geeft, in tegenstelling tot de anterieure, apicale en 
posterieure ondersteuning van de TVSM, was het algeheel falen (POPQ stadium II of 
hoger in één van de compartimenten) hoger in de LSC groep (51%) vergeleken met 
de TVSM groep (21%). Elke techniek had zijn eigen soort complicaties, maar deze 
studie was te klein en de follow-up was te kort om significante verschillen tussen de 
ernstige complicaties aan te tonen. 
hoofdstuk 9
Hoofdstuk 9 toont de resultaten na chirurgische therapie voor mesh-gerelateerde 
complicaties na eerdere prolaps chirurgie met mesh. In dit retrospectieve cohort 
werden 81 mesh excisies bij 73 patiënten beschreven. De indicaties voor de mesh 
excisies waren exposure (in de vagina of in de blaas), pijn, dyspareunie en fistels. 
Verbetering van de klachten werd bereikt in 92%. Recidief prolaps ontstond in 29% na 
een complete excisie en in 5% na een gedeeltelijke excisie van de mesh die ingebracht 
was wegens prolaps.  Stress incontinentie voor urine ontstond in 36% na excisie van 
CHAPTER 11154
een suburethrale sling. Intra-operatieve complicaties traden op in 4 patiënten (3 maal 
een darm lesie en 1 bilateraal ureter letsel), postoperatieve complicaties traden in 13 
patiënten op. Excisie van de mesh verbetert mesh-gerelateerde complicaties effectief, 
maar de ingreep gaat gepaard met substantiële risico's op ernstige complicaties en 
recidief prolaps of stress incontinentie. Complexere excisies zouden in centra met veel 
ervaring moeten worden uitgevoerd. 
hoofdstuk 10
Hoofdstuk 10 is de algemene discussie over de bevindingen in dit proefschrift. Tevens 
worden uitdagende aspecten van toekomstig onderzoek om de behandeling van 
prolaps te verbeteren of om meer inzicht te krijgen in de ontwikkeling van en de 
preventie van prolaps beschreven.   
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dankwoord
Hoewel ik zelf nooit zoveel haast had met het afronden van dit proefschrift, begon 
men om mij heen toch steeds vaker te vragen: “Hoe zit het nou met je proefschrift? 
Wanneer is het af?” Beste familie, vrienden en collegae……. het is af! Dat was 
uiteraard niet gelukt zonder hulp van velen, waarbij ieder op zijn eigen manier heeft 
bijgedragen aan dit proefschrift.
Professor Vierhout, beste Mark. Nadat ik je vanuit Rotterdam gevolgd was naar 
Nijmegen, begon ik eind 2005 aan het protocol dat de basis vormt van dit proefschrift. 
Met weinig woorden en in alle rust wist jij me altijd weer bij te sturen, te motiveren en 
op koers te houden. Dit gold niet alleen voor mijn wetenschappelijke zoektocht, maar 
ook voor de kliniek. Wat was ik, destijds als jonge klare, blij dat ik onder jouw hoede/
vleugels mocht groeien en nog steeds vind ik het fijn om samen op de operatiekamer 
een ingewikkelde recidief, recidief, recidief prolaps te opereren. Dank dat je ook altijd 
oog had voor mijn privé situatie. Ik kon me geen fijnere promotor wensen.
Doctor van der Weiden, beste Robin. In Rotterdam is het allemaal begonnen. En 
hoewel de afstand groter werd, ging de inclusie gestaag door. Ik vond het lastig 
om aan twee onderzoekslijnen tegelijk te werken, maar jouw enthousiasme en 
gedrevenheid stimuleerden mij altijd weer.
De manuscriptcommissie wil ik bedanken voor het lezen en beoordelen van mijn 
manuscript. Professor van Laarhoven, beste Kees. Wie had gedacht dat onze wegen 
op deze manier nogmaals zouden kruisen? Fijn dat je ondanks al je drukke taken, toch 
voorzitter wilde zijn van mijn manuscriptcommissie. Doctor Heesakkers, beste John. Ik 
hoop dat onze samenwerking in de kliniek met de Isabella-poli en op wetenschappelijk 
gebied nog maar aan het begin staat en we nog een lange samenwerking tegemoet 
gaan. Professor Brölmann, beste Hans, we zien elkaar meestal alleen maar in de pre-
view ruimte van congressen waar we dan onze presentatie nog even controleren en 
vervolgens ieder vaak naar een andere sessie gaan. Bedankt dat je mijn manuscript 
wilde beoordelen.
Doctor Vervest, beste Harry. Het idee van de multicenter RCT mesh versus klassieke 
prolaps repair kwam van Mark en jou. Ik heb dankbaar gebruik gemaakt van jouw 
wetenschappelijke ervaring bij het schrijven van het studieprotocol van de VROUW 
studie. Je vlotte correcties en adequate aanvullingen waren meer dan welkom. Dank 
voor je altijd oprechte interesse in de wetenschappelijke vorderingen en mijn gezin.
Zonder alle deelnemende patiënten was dit proefschrift er nooit geweest. Alle 
gynaecologen uit de deelnemende centra (Alysis Arnhem, Groene Hart Gouda, 
Ikazia Rotterdam, Isala Zwolle, Medisch Spectrum Twente Enschede, Nij Smellinghe 
Drachten, Refaja Stadskanaal, Reinier de Graaf Groep Delft, St Antonius Nieuwegein, 
St Elisabeth Tilburg, Twee Steden Tilburg, UMC St Radboud Nijmegen, Zaans Medisch 
Centrum Zaandam) wil ik bedanken voor hun inzet.
&
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Beste (ex-)pijlergenoten, dank voor jullie geduld en het inspringen bij mijn klinische 
taken op de momenten dat ik echt even moest schrijven.
Beste Robbert Thijssen. Het Engels in mijn eerste abstracts werd door jou 
gecorrigeerd en bij discussies over de woordkeus tussen de verschillende auteurs, 
kon jij het verlossende woord brengen.
Beste Wim Willemsen. Ruim 6,5 jaar was jij mijn kamergenoot. Met lastige 
(klinische) vragen kon ik altijd bij jou terecht. Nooit heb je geklaagd over mijn rotzooi 
en mijn gekwebbel, terwijl je zelf zo geordend, netjes en rustig bent. Ik heb je de 
laatste maanden erg gemist.
Beste Lenno Dukel. Bij lastig te interpreteren echobeelden ben ik blij dat ik mijn 
patiënten altijd naar de “echo-koning” kan sturen. Tijdens onze “dinerdates” als ik 
dienst heb, kletsen we weer even bij over ons Rotterdams verleden.
Beste Kirsten Kluivers. Als twee jonge vrouwelijke gynaecologen begonnen we 
samen bij de pijler gynaecologie. Door mijn verlof kwam ik wat later en had jij de 
eerste hobbels al genomen. De etentjes bij jou en Harry thuis maakten dat ik me al 
snel welkom voelde. Dank voor je inzet en steun bij de studies, je collegialiteit en 
je sterke wetenschappelijke blik bij het schrijven van de artikelen. Onze gezellige 
“woensdag-lunch” is sinds jou taak bij de NVOG helaas geannuleerd, maar dat halen 
we wel weer in.
Beste Bertho Nieboer (of moet ik @DokterBertho zeggen). Wat ben ik blij met jou 
als jonge enthousiaste collega in onze pijler. Nog even en dan sta je zelf je manuscript 
te verdedigen!
Beste collegae van de andere pijlers. Dank voor jullie interesse, steun, collegialiteit en 
gezelligheid. 
Beste arts-assistenten gynaecologie. Het was opvallend hoeveel van jullie altijd 
weer informeerden naar mijn vorderingen met het proefschrift. Dat maakte het 
makkelijker om tijdens de diensten weer achter mijn bureau te gaan zitten en door te 
analyseren/schrijven. Nu is er weer meer tijd voor gezelligheid in de dienst (en OSATS, 
KKB’s, ect). 
Beste “bewoners van de kantoortuin”, dank voor jullie morele support en 
interesse. Fijn dat jullie vaak mijn onnozele vragen konden beantwoorden. Sabine 
van de Akker, dank voor het versturen en invoeren van vragenlijsten en crf’s.
Bedankt medewerkers van de afdelingen (Q10, A20 of moet ik zeggen C5, SSU). 
Het dedicated ok-team (Iesje, Wendy, Corina en Anita) wil ik bedanken voor de fijne 
samenwerking. Mesh-chirurgie zonder gespecialiseerd team is niet mogelijk!
Alle poli-medewerkers bedankt, bij de volgende studies heb ik jullie ook weer 
hard nodig. Nu het proefschrift af is, staat mijn deur weer wat vaker open. Beste 
Dori-Anne van der Ligt en Ans Bakker. Dank voor jullie hulp bij het onderzoek en/of 
de organisatie van de promotie-dag.
Drs. Milani (nog even dan, want over een paar uur is het toch echt dr. Milani), beste 
Fred. Waar moet ik beginnen? Onze samenwerking begon in Delft/Voorburg, waar 
je mij de kneepjes van de urogynaecologie bijbracht in het laatste (differentiatie) jaar 
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van mijn opleiding. We schreven een artikel samen en kregen de smaak te pakken. 
Ondanks mijn verhuizing naar het Nijmeegse ging onze samenwerking voort op het 
wetenschappelijke, klinische en persoonlijke vlak. Bij jou kan ik altijd terecht om “effe 
te sparren”, motivatie op te doen of uit te huilen. Artikelen worden door jou altijd 
per ommegaande gecorrigeerd. Het kon je nooit snel genoeg gaan, ik was altijd 
de vertragende factor. Het liefst had jij dit feestje al in 2010 gevierd! Fred, wat mij 
betreft komt aan onze samenwerking nooit een einde, ik ben blij dat jij vandaag aan 
mijn zijde staat als paranimf.
Beste Caroline Vleggaar en Job de Ruiter. Dank je wel voor jullie steun en belangstelling. 
Inmiddels wonen we niet zo ver meer uit elkaar en nu het proefschrift af is, is er weer 
meer tijd om gezellig met elkaar te eten.
Beste Anneke en Johan Vleggaar. Wat fijn dat u elke dinsdag voor dag en dauw naar 
Bennekom komt om op de kinderen te passen (en al die andere dingen die u er dan 
nog even bij doet). Op dinsdag is er voor mij even geen stress om op tijd thuis te 
zijn. Daarnaast heeft u een grote interesse in mijn werkzaamheden en bent u altijd 
opvallend goed op de hoogte (“Prof. Braat was gister nog op tv”, “In de Volkskrant 
staat een stukje over de matjes” en ga zo maar door). Dank voor uw stimulerende 
vragen en uw steun op alle fronten. 
Beste Jos. Waar is de tijd dat je als jongetje van 8 bij me kwam logeren in Rotterdam? 
De tijd vliegt. Je bent een man van weinig woorden, dus bellen doen we niet veel en 
ook lopen we de deur bij elkaar niet plat. Maar als het er op aankomt, dan zijn we er 
voor elkaar. Ik ben trots dat jij mijn paranimf wilt zijn. 
Lieve mama en papa. Woorden schieten te kort om te beschrijven wat ik aan 
jullie te danken heb. Zo is ‘opgroeien in een liefdevol gezin’ de beste basis die 
iedereen zich kan wensen. Jullie leerden me bovendien dat je met hard werken en 
doorzettingsvermogen veel kan bereiken. Altijd staan jullie voor ons klaar en de 
afstand Ossendrecht-Bennekom vormt daarbij nooit een belemmering.  
Lieve Fleur. Jij leerde mij dat je met hard werken toch niet alles kan bereiken, soms 
zijn er grenzen. Maar met jouw rake opmerkingen, humor en stralende lach weet jij 
altijd weer een glimlach op mijn gezicht te toveren. Lieve Madelief. Met je bruisende 
enthousiasme maak je van elke dag een feestje. Meiden, de mama-maandag is weer 
voor jullie!
Lieve Frank. Wat ben ik gelukkig met jou! Zonder jou was me dit nooit gelukt. 
&
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currIculuM vITae
Mariëlla Isabella Johanna Withagen werd op 25 november 1971 in Ossendrecht 
geboren. In 1990 behaalde zij het gymnasium diploma aan het gymnasium Juvenaat ’t 
Heilig Hart te Bergen op Zoom. In datzelfde jaar begon zij met de studie geneeskunde 
aan de Erasmus Universiteit te Rotterdam. Tijdens de co-schappen ontstond de 
interesse in de gynaecologie/verloskunde en derhalve werden de co-schappen 
afgerond met een keuze-onderzoek bij Dr. W. Visser en Prof. H.C.S. Wallenburg naar 
de gevolgen van het verlengen van de zwangerschap bij vroege pre-eclampsie voor 
neonaten. 
Na het behalen van haar artsexamen (1996) werkte zij 2 jaar als AGNIO gynaecologie 
in het St. Clara Ziekenhuis te Rotterdam. Haar opleiding tot gynaecoloog vond plaats 
in het Erasmus Medisch Centrum te Rotterdam met Prof. Th.J.M. Helmerhorst als 
opleider en in het Sint Franciscus Gasthuis te Rotterdam met Dr. A.Th. Alberda als 
opleider. In het Sint Franciscus Gasthuis werd het eerste protocol dat onderdeel 
uitmaakt van dit proefschrift geschreven. Het laatste jaar van de opleiding betrof 
een differentiatie jaar in de bekkenbodem, deels in het Erasmus Medisch Centrum 
en deels in het Reinier de Graaf Gasthuis te Delft met Dr. J.C. Kuijpers als opleider. 
Alhier werd de basis gelegd voor de verdere (wetenschappelijke) samenwerking met 
dr(s). A.L. Milani. 
Sinds september 2005 werkt zij als gynaecoloog in het Universitair Medisch 
Centrum St. Radboud te Nijmegen, bij de pijler algemene gynaecologie onder leiding 
van Prof. M.E. Vierhout. Hier kwam dit proefschrift tot stand. Zij is bestuurslid van 
de werkgroep ‘Bekkenbodem’ van de Nederlandse Vereniging voor Obstetrie en 
Gynaecologie en sinds december 2011 subspecialist urogynaeocologie. 
Op 14 september 2002 is zij getrouwd met Frank Vleggaar. Zij hebben samen 2 
dochters, Fleur en Madelief.
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